CONTRIBUTION OF INTERLEUKIN 6 TRANS SIGNALING  IN PULMONARY FIBROSIS by Le, Thuy T
Texas Medical Center Library
DigitalCommons@The Texas Medical Center
UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences
5-2014
CONTRIBUTION OF INTERLEUKIN 6
TRANS SIGNALING IN PULMONARY
FIBROSIS
Thuy T. Le
Follow this and additional works at: http://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medicine and Health Sciences Commons
This Dissertation (PhD) is brought to you for free and open access by the
Graduate School of Biomedical Sciences at DigitalCommons@The Texas
Medical Center. It has been accepted for inclusion in UT GSBS
Dissertations and Theses (Open Access) by an authorized administrator of
DigitalCommons@The Texas Medical Center. For more information,
please contact laurel.sanders@library.tmc.edu.
Recommended Citation
Le, Thuy T., "CONTRIBUTION OF INTERLEUKIN 6 TRANS SIGNALING IN PULMONARY FIBROSIS" (2014). UT GSBS
Dissertations and Theses (Open Access). Paper 469.
i 
CONTRIBUTION OF INTERLEUKIN 6 TRANS SIGNALING  
IN PULMONARY FIBROSIS 
By 
THUY THANH LE, B.A. 
APPROVED: 
 
Michael R. Blackburn, Ph.D. 
Supervisory Professor 
 
Russell Broaddus, M.D., Ph.D. 
 
Yang Xia, M.D., Ph.D. 
 
Sandeep Agarwal, M.D., Ph.D. 
 
Richard Johnston, Ph.D. 
APPROVED: 
 
_______________________________        _______________________________ 
Michael R. Blackburn, Ph.D.          Michelle Craig Barton, Ph.D. 
Deans, The University of Texas 
Graduate School of Biomedical Sciences at Houston 
ii 
CONTRIBUTION OF INTERLEUKIN 6 TRANS SIGNALING  
IN PULMONARY FIBROSIS 
A 
DISSERTATION 
Presented to the Faculty of  
The University of Texas Health Science Center at Houston  
and  
The University of Texas M. D. Anderson Cancer Center 
Graduate School of Biomedical Sciences  
in Partial Fulfillment 
 
of the Requirements 
 
for the Degree of 
 
DOCTOR OF PHILOSOPHY 
 
By 
 
THUY THANH LE, B.A. 
Houston, Texas 
May 2014 
 
 3 
DEDICATION 
 
This thesis is dedicated in loving gratitude to… 
 
The best parents I could have ever asked for –  
 
My father Mr. MINH THANH LE  
and 
My mother Mrs. THACH KIM LE 
  
 4 
ACKNOWLEDGEMENTS 
 I would like to thank my supervisory professor, Dean Michael R. Blackburn, for taking 
on the difficult task of training me the last few years. His vast knowledge and many talents, 
along with an endless supply of patience, made him the perfect mentor. I cannot imagine a better 
person to guide me, professionally and personally. I am forever indebted to him for helping mold 
me into the person I am today.  
Thank you to the faculty mentors on my advisory, examining and supervisory committees 
– Drs. Russell Broaddus, Sandeep Agarwal, Yang Xia, Richard Johnston, Joe Alcorn and Chris 
Evans – as well as other mentors within the MD/PhD Program, Drs. Dianna Milewicz, Dennis 
Hughes, and Vicki Knutson. I am so appreciative of their invaluable time and efforts spent in 
training me to become a physician-scientist.  
Thank you to the Blackburn lab members, past and present, and the BMB Department 
faculty, staff and students for their support and friendships, which have made being in the lab 
and the department such a joy. Thank you to the MD-PhD program coordinators Doris Thornton 
and Jo Cheatwood as well as past and present students in the program. I want to acknowledge the 
UT-Houston MD-PhD Program and the Burroughs Wellcome Fund Training Program in Gene-
Environment Interactions for their financial support during my training. 
Finally, I have been extremely loved and spoiled by my family. My older sister Thao and 
my brother-in-law Nghi have been like a second set of parents to me. Thank you for always 
thinking about my needs, for your constant advice and for providing the financial means for me 
to further my education and pursue my dreams. Bao, what an amazing man you’ve grown up to 
be! You make me aspire to be more like you, which is highly unusual since you’re younger than 
me. Truc, my favorite little sister and best pal, what can I say? So much beauty, intelligence and 
 5 
love wrapped up in that tiny little body of yours. You could always cheer me up, even on the 
worst days. I owe you for life and you know why! Vinh Nguyen, love of my life, light of my life, 
thank you for all the joy you bring into my life. I look forward to being loved and spoiled even 
more by you in the coming years and to whatever life brings with you by my side.  
Saving the best for last, though there are few words that could fully describe my gratitude 
to my parents, I will try. Dad, the strongest man I know, your strength of character, perseverance 
through hardships and steadfast faith have inspired me to push through all obstacles and reach 
for the stars. Mom, your love and tender care have supported me throughout my whole life. You 
are the epitomy of a model wife and mother, and I hope I can be just half as wonderful as you.   
Mom and Dad, you are exemplars of faith, fidelity and unconditional love. You are the 
reasons I am here today. I could never thank you enough or repay all you have done for me, but I 
hope I have, in some small way, made you proud and shown you that the love and sacrifices 
you’ve made for me were not in vain.  
 
 
 
 
 
 
 
 
 
 
 6 
CONTRIBUTION OF INTERLEUKIN 6 TRANS SIGNALING  
IN PULMONARY FIBROSIS 
THUY THANH LE, B.A. 
Supervisory Professor: MICHAEL R. BLACKBURN, Ph.D. 
 
Idiopathic Pulmonary Fibrosis (IPF) is a lethal lung disease with progressive fibrosis and 
death within 2-3 years of diagnosis. IPF incidence and prevalence rates are increasing annually, 
and because the pathogenesis is unknown, there are no effective treatments available. Inhibition 
of interleukin 6 (IL-6) results in the attenuation of pulmonary fibrosis in mice. It is unclear 
whether this is due to blockade of classical signaling, mediated by membrane-bound IL-6 
receptor alpha (mIL-6Rα), or trans signaling, mediated by soluble IL-6Rα (sIL-6Rα). Our study 
assessed the role of sL-6Rα in IPF. We demonstrated elevations of sIL-6Rα in IPF patients and 
in mice during the onset and progression of fibrosis and showed that protease-mediated cleavage 
was important in production of sL-6Rα in fibrotic lungs. In vivo neutralization of sIL-6Rα, and 
resulting antagonism of IL-6 trans signaling, attenuated pulmonary fibrosis in mice. Decreases in 
sIL-6Rα were associated with reductions in myofibroblasts, fibronectin and collagen. In vitro 
activation of IL-6 trans signaling enhanced fibroblast proliferation and extracellular matrix 
protein production, effects relevant in the progression of pulmonary fibrosis. These findings 
suggest that IL-6 trans signaling influences events crucial in pulmonary fibrosis in vivo. 
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IDIOPATHIC PULMONARY FIBROSIS 
Definition and Epidemiology 
Idiopathic Pulmonary Fibrosis (IPF) is a lethal lung disease of unknown etiology and 
defined by chronic, progressive, irreversible interstitial fibrosis limited to the lungs(1, 2). It is the 
most common form of idiopathic interstitial pneumonia (IIP), affecting older adults, with age at 
diagnosis ranging from 55-75 years-old, median age of 66 years-old(2). Incidence increases with 
increasing age, and a diagnosis in adults less than 50-years old is uncommon. IPF is more 
prevalent in males than females (1.5-1.7:1)(1, 2). Recent estimates place the number of affected 
individuals around 128,000 (with some reports of prevalence as high as 200,000) in the USA and 
around 8 million worldwide. It is expected that 50,000 new IPF cases will be diagnosed each 
year, with that number rising annually(1-3). Over the last two decades, there has been an upward 
trend in incidence rates(3), emphasizing the increasing impact of this disease on the general 
population.  
 
Presentation & Diagnosis: 
Patients commonly present clinically with progressive dyspnea on exertion and a chronic, 
non-productive cough(1, 2). Other symptoms can include digit clubbing and bibasilar inspiratory 
crackles. Diagnosis is made based on presenting symptoms, evidence of a usual interstitial 
pneumonia (UIP) pattern on histology and imaging, and exclusion of other interstitial lung 
diseases(1, 2). UIP pattern on histology includes: a spatial and temporal heterogeneity in 
parenchymal involvement, appearance of fibrosis and honeycombing that is mainly subpleural 
and paraseptal, presence of fibroblastic foci, and absence of features suggesting other 
conditions(1, 2). UIP pattern on imaging includes: subpleural and basal involvement, 
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honeycombing with or without traction bronchiectasis, and reticular abnormalities(1, 2). 
Honeycombing refers to presence of airspaces that are cystic in appearance, lined with 
bronchiolar epithelium and may contain inflammatory cells and mucin. 
IPF can be broken up into sporadic and familial forms. Familial IPF, which accounts for 
<5% (0.5-3.7%) of IPF cases, is indistinguishable clinically and histologically from sporadic 
IPF, though they may have different genetic patterns and can present at a younger age(1, 2). The 
genetic mode of transmission of familial IPF is most likely autosomal dominant with variable or 
reduced penetrance(1, 2). 
 
Cause(s) and Risk Factors: 
As its name indicates, the cause or causes of IPF remain unidentified, though potential 
risk factors include genetics, lifestyle choices, environmental or occupational exposures and co-
morbid diseases.2-3  
Genetic factors: Studies have suggested that the gene ELMOD2 (located on chromosome 
4q31), which has unknown functions, may confer susceptibility to familial IPF(1). Mutations in 
human telomerase reverse transcriptase (hTERT) and human telomerase RNA (hTR), leading to 
telomere shortening and cellular apoptosis, have been linked to familial and sporadic IPF 
cases(1, 4). Mutations in surfactant protein C and A2 (SFTPC and SFTPA2) have been 
associated with familial IPF(1, 4). Mutations in SFTPC have not been found in sporadic IPF. 
SFTPA2 mutations are also associated with lung cancer(1).  
Quite a number of genetic polymorphisms has been reported to be increased in sporadic 
IPF and suggested to be involved in disease progression. The polymorphisms occurred in genes 
encoding enzymes (α1-antitrypsin, angiotensin converting enzyme), cytokines (interleukins 1α, 4, 
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6, 8, 10 and 12, tumor necrosis factor α, lymphotoxin α), fibrotic mediators (transforming growth 
factor β1), immune modulators (complement receptor 1, NOD2/CARD15), coagulation pathway 
elements (plasminogen activator inhibitors 1 & 2), matrix metalloproteinase 1 (MMP-1), and 
surfactant proteins A and B (SFTPA, SFTPB)(1). Associations have also been made between 
human leukocyte antigen class I and II (HLA-I, HLA-II) haplotypes and MHC class I chain-
related gene A (MICA) and IPF(1). A polymorphism in the promoter of the mucin gene MUC5B 
has been associated with familial and sporadic IPF(5).  
Lifestyle choices: Cigarette smoking is a significant risk factor in both familial and 
sporadic IPF. There is a strong association between moking history of >20 pack-years and 
development of IPF(1).  
Environmental factors: Exposures to wood dust, like pine, and metal dusts, like lead, 
steel and brass, significantly elevates risk of IPF(1). Hairdressers, farmers, and stone cutters also 
experience increased risk, as does anyone with exposure to birds, livestock, animal dust and 
vegetable dust(1).  
Co-morbid conditions: Investigations into the involvement of viral infections as risk 
factors revealed associations between IPF and Epstein-Barr virus, hepatitis C, and a few herpes 
viruses(1). There were positive and negative associations studies reported with Epstein-Barr 
virus (EBV), cytomegalovirus (CMV), and human herpesvirus 7 and 8 (HHV-7 & HHV-8). 
Hepatitis C had variable associations, and elevated CMV antibodies have been reported in 
IPF(1).  
 Gastroesophageal reflux (GER) abnormalities is common in IPF patients and has long 
been thought to be a risk factor. Erosive esophagitis from GER was associated with development 
of pulmonary fibrosis(1). Diabetes mellitus, obesity, obstructive sleep apnea, and coronary artery 
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disease may play a role in IPF risk but that still remains to be determined(1, 2). There are many 
confounding factors involved in reports of risk factors, so interpretation must be taken 
cautiously(1). 
 
Natural history & Clinical Phenotypes in IPF 
The natural history of IPF is highly variable and unpredictable(1, 2). IPF was once 
thought to simply be a slowly progressive disease, but over the years, there is increasing 
awareness of the heterogeneity of the disease and discussion has revolved around possible 
distinct IPF phenotypes that have may have genotypic associations and clinical features that 
affect prognosis in terms of disease progression and mortality risks(2, 6).  
Some patients with IPF have stable disease. Some have rapidly progressive disease. 
Others exhibit gradual decline in pulmonary function over time(1, 2, 6). Some have co-morbid 
conditions, including pulmonary hypertension and emphysema. All are at risk of possible 
episodes of acute respiratory worsening, known as acute exacerbations(1, 2).  
Subclinical IPF: Ley et al have defined various categories of disease in IPF, including 
subclinical IPF, which refers to the period before diagnosis(7). Patients with IPF will typically 
have symptoms prior to diagnosis for a median of 1-2 years. Prior to symptoms, however, there 
may also be radiographic evidence of disease(7). These patients can progress from asymptomatic 
to symptomatic disease over years or decades. This period of subclinical disease is not well 
understood(7). Asymptomatic pulmonary fibrosis is now better reported because it has been 
identified in family members of IPF patients, particularly individuals with smoking history. The 
lungs of these individuals show histologic evidence of various subtypes of interstitial lung 
disease (ILD)(7). High-resolution CT (HRCT) is the best modality to identify asymptomatic, 
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subclinical IPF, though it is not yet known how to manage subclinical individuals(7). They may 
be at higher risk for developing acute exacerbations after procedures(7).  
Stable or slowly progressive IPF: Once diagnosed, some IPF patients will have stable or 
slowly progressing disease(1, 2). These patients have usually presented with progressive dyspnea 
on exertion and cough associated with decreased lung capacities and volumes(1, 2). The rate of 
decline in these patients is 0.13-0.21 L in forced vital capacity (FVC)(2, 7).  
Rapidly progressive IPF: IPF that is rapidly progressing typically occurs in males who 
are smokers(2, 6, 8). At diagnosis, these patients have similar lung capacities and volumes, and 
similar imaging and histological findings to stable or slowly progressive IPF patients(2). Despite 
the similarities, rapidly progressive IPF differ in clinical course and transcriptional profile. This 
accelerated version of IPF is associated with shortened survival(2, 6, 8). There is evidence of 
transcriptional upregulation in pathways that affect alveolar epithelial and mesenchymal 
functions(2). Boon et al reported upregulation in genes involved in the MAPK-EGR1-HSP70 
pathway, a pathway known to regulate inflammation induced by smoking(9). Selman et al 
reported overexpression of genes involved in migration/proliferation, oxidative stress, 
morphogenesis, and fibroblast and smooth muscle cell genes along(8).  
Acute Exacerbations: Acute exacerbations (AE) are defined by several measures. There 
must be an abrupt decline in respiratory function, as evident by worsening dyspnea (in a matter 
of days or weeks and less than 1 month) and worsening hypoxemia (decrease in arterial blood 
PaO2)(1, 2). This rapid deterioration is associated with new radiologic findings of diffuse alveolar 
damage (bilateral alveolar infiltrates and ground-glass opacities) on top of previous parenchymal 
involved(1, 2). Importantly, there is an absence of identifiable precipitating triggers. Other 
observed symptoms include fever, increased cough and increased production of sputum(1).  
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Acute exacerbations occur in about 5-20% of patients(1, 2). Prognosis is grim and 
mortality exceeds 60% with hospitalization(2). Survivors of AE have a greater than 90% 
mortality risk within 6 months. In about 27% of IPF AE cases, torque teno virus was detected. 
Pathogenesis of AE episodes are not known but excessive epithelial apoptosis and increased 
circulating fibrocytes have been reported(2). It is unclear whether these episodes of acute 
exacerbations had precipitating causes that were missed in diagnosis or if it is a reflection of 
progression in the inherent IPF disease processes(1).  
Combined pulmonary fibrosis and hypertension: Pulmonary hypertension (PH) is a 
recognized complication of IPF(1). Though PH is typically seen in severe IPF, it is observed in 
some patients with earlier stages of IPF(6).  It is defined as mean pulmonary artery pressure 
(mPAP) ≥25 mmHg at rest and ≥30 mmHg with exertion(6, 10, 11). Retrospective studies show 
prevalence of IPF patients with PH to be between 31-85%(6, 12-14). The wide range may be due 
to the fact that occurrence and severity of PH increases with time(15), so the number varies 
depending on the timing of analysis and the patient population.  
A number of studies have shown associations between PH and increased mortality risk in 
IPF patients. Lettieri et al reported a correlation between PH (indicated by mPAP) and mortality 
risk(12). Higher mPAP was associated with increased mortality risk(12). Hamada et al indicated 
specifically that mPAP above 17 mmHg best indicates increased 5-year mortality rates(16). 
Nadrous et al reported an inverse correlation between PH and diffusing capacity of carbon 
monoxide (DLCO) in IPF patients(13). They also showed that estimated systolic pulmonary artery 
pressure (sPAP) had a negative impact on survival, especially when higher than 50 mgHg(13). 
Mortality rates increase in more in the presence of pulmonary fibrosis, emphysema and 
pulmonary hypertension(6, 17).  
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Combined pulmonary fibrosis and emphysema: Recent retrospective studies place the 
prevalence of co-existing pulmonary fibrosis and emphysema in IPF patients around 28-55%, 
depending on the study population(6, 17, 18). Cottin et al first coined the name Combined 
Pulmonary Fibrosis and Emphysema (CPFE) in 2005 when they formally described clinical 
characteristics comprising this syndrome(18). Those characteristics included findings of dyspnea 
on exertion, basal crackles, finger clubbing, upper lobe emphysema and lower lobe pulmonary 
fibrosis on CT, abnormal spirometry, severe gas exchange impairment, and high prevalence of 
pulmonary hypertension(18).  
Mejia et al also reported an association between CPFE and pulmonary arterial 
hypertension(17). In fact, they stratified pulmonary hypertension and further showed a positive 
correlation between PH and extent of emphysema in their study population(17). The presence of 
both pulmonary fibrosis and emphysema carries a poorer prognosis than IPF alone and mortality 
is even worse if pulmonary hypertension is also present(6, 17, 18). The prognosis is dismal with 
the combination of CPFE, severe pulmonary hypertension and severe pulmonary restriction(17). 
Severe PH was defined as estimated systolic pulmonary artery pressure (eSPAP) greater than 75 
mmHg. Severe pulmonary restriction was defined as forced vital capacity (FVC) below 50%. 
Mejia et al reported that CPFE is associated with male gender and smoking(17). Though 
the pathogenesis of CPFE is unclear, smoking appears to be a trigger(6, 18). Exposure to 
agrochemical compounds has also been suggested to be environmental risk factors(6, 19). As for 
genetic risk factors, it is not known if susceptibility to IPF and COPD may lead to CPFE or if 
CPFE may have its own distinct genetic variations(6).  
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Treatment of IPF 
The latest published global recommendations regarding management of IPF was a joint 
statement released by the American, European, Japanese, and Latin American thoracic and 
respiratory societies in 2011. At the time, there was little evidence of effective pharmacologic 
therapies for IPF(1). The statement did report strong recommendations against use of: 
corticosteroids alone and in combination with immune modulators, colchicine, cyclosporine A, 
interferon γ 1b, bosentan, and etanercept(1). Therapies that received weak recommendations 
against (meaning it may be suitable in some patients) include: triple therapy (N-acetylcysteine, 
azathioprine, and prednisone), N-acetylecysteine (NAC) alone, anticoagulants and pirfenidone. 
Other recommendations included interventions to relieve symptoms in management of acute 
exacerbations and chronic disease, with treatment of pulmonary hypertension, use of long-term 
oxygen therapy and referral for lung transplantation in appropriate patients(1).  
Pharmacologic options: Since the release of the joint statement, published outcomes 
from various clinical trials have raised a need to modify treatment recommendations(20, 21). 
Recommendations regarding the use of N-acetylcysteine monotherapy are expected to be 
updated in 2014, pending report of results from the PANTHER-IPF randomized controlled trial 
(RCT). NAC monotherapy was initially studied in the IPHIGENIA RCT. Results of 
IPHIGENIA, released in 2005, demonstrated a significant reduction in decline of forced vital 
capacity (FVC) and diffusion capacity with high-dose NAC(20, 21). The trial did not show 
survival benefit and was criticized for various reasons, so NAC monotherapy was further studied 
in the PANTHER-IPF RCT. The trial has concluded and final report is expected in 2014. In the 
meantime, because NAC therapy is relatively well tolerated, it is widely used for IPF(20, 21).  
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The PANTHER-IPF trial also tested efficacy of triple therapy (NAC, azathioprine, and 
prednisone) in IPF as one of the treatment groups. In October 2011, the trial terminated its triple 
therapy arm early when it became evident that triple therapy increased mortality, hospitalizations 
and adverse effects. Reports of the detrimental effects have since shifted IPF treatment emphasis 
away from immunosuppressants(20, 21). Another treatment option that also led to harmful 
effects in IPF patients is warfarin. The ACE-IPF RCT, looking at warfarin therapy in IPF, was 
terminated prematurely due to increased mortality. Most of the deaths in the warfarin group was 
attributed to disease progression and acute exacerbations, not to complications of warfarin, like 
bleeding(20). Ambrisentan, a type A endothelin receptor antagonist, was tested in the phase III 
RCT ARTEMIS. ARTEMIS was terminated prematurely due to increased disease progression 
and increased hospitalizations(21). Phase II testing of the efficacy of everolimus (MTOR 
inhibitor) was discontinued due to increased disease progression and increased acute 
exacerbations(21).  
Therapies that have yielded no benefits in phase II RCT were imatinib mesylate (inhibitor 
of PDGF receptors, c-kit and c-ABL tyrosine kinases), macitentan (dual endothelin receptor 
antagonist) and tumor necrosis factor-α (TNF-α) antagonists(20, 21).  
The good news, on the other hand, is that the pyridone analogue pirfenidone has been 
gaining recognition as a novel, effective therapy for IPF. Pirfenidone is thought to have anti-
inflammatory, anti-fibrotic, and antioxidant effects(20-22). It is the first agent approved for 
treatment of mild to moderate IPF, currently available in Japan, Europe, Canada and India(20-
22). It has not yet been approved in the USA despite a number of clinical trials showing efficacy 
and improvement in IPF patients. The first phase II RCT of pirfenidone was conducted in Japan 
and reported in 2005 by Azuma et al(20-22). The study was stopped early due to high numbers 
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of acute exacerbations in the placebo group, but they did show significant reduction in decline of 
FVC. Since then, three phase III RCT evaluating efficacy of pirfenidone have been completed 
and two were able to show significant reduction in FVC decline(20-22). The first phase III RCT, 
conducted in Japan, showed significant reduction in FVC decline at 52 weeks and improvement 
in progression-free survival with high-dose pirfenidone therapy(20-22). This led to approval of 
pirfenidone for use in Japan in 2008.  
After that, two other phase III RCT trials, CAPACITY 1 and 2, were carried out 
concurrently in North America, Europe and Australia. CAPACITY 1 met its primary end-point 
of reduction in FVC decline at 72 weeks while CAPACITY 2 did not(20-22). However, 
CAPACITY 2 did show improvement in 6MWT decline as a secondary endpoint. When the data 
from both CAPACITY trials were pooled, there were significant differences in primary and 
secondary endpoints. Pirfenidone therapy resulted in significant reduction in FVC decline, mean 
decline in 6-minute walk test distance, and progression-free survival(20-22). When all four 
pirfenidone clinical trials were analyzed by Cochrane meta-analysis, it was evident that 
pirfenidone reduced disease progression risk by 30% in comparison to placebo(20-22). Based on 
that evidence, in 2011, Europe approved the use of pirfenidone for mild to moderate IPF.  
In the USA, however, the FDA decided in 2010 to withhold approval of pirfenidone until 
more clinical trial data was obtained. They cited failure of CAPACITY 2 to replicate the 
improvement in FVC decline seen in CAPACITY 1 as the reason. ASCEND, another phase III 
RCT designed to test efficacy of pirfenidone in IPF, was initiated in 2011 and is currently in 
progress in North America, South America and Australia. The primary endpoint for ASCEND is 
FVC decline at 52 weeks(20, 21). Reassessment of FDA approval in the USA is expected to 
come in the future, pending results of the ASCEND trial. In the meantime, investigations of 
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high-dose pirfenidone side effects indicate long-term therapy is generally safe and well 
tolerated(20-22). Pirfenidone represents a promising therapeutic option for IPF.  
Sildenafil (phosphodiesterase inhibitor 5) was tested in phase III trial STEP-IPF. No 
significant difference was observed in primary endpoint of ≥20% increase in 6MWT distance at 
12 weeks, but secondary endpoints (quality of life and carbon monoxide diffusing capacity) 
showed significant improvements(21).  
An option that is currently in phase III RCT testing is treatment with a nintedanib or 
BIBF 1120 (triple inhibitor of tyrosine kinases receptors). Nintedanib has been evaluated in the 
phase II RCT TOMORROW, which showed improvement in FVC decline and fewer acute 
exacerbation events(20). The targets of nintedanib are platelet derived growth factor (PDGF), 
fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) receptors. The 
results from TOMORROW led to two phase III RCT currently in progress(20, 21). 
 Current ongoing phase II clinical trials involve targeting: interleukin 13 with 
lebrikizumab (QAX576, human anti-IL-13 monoclonal antibody), chemokine (C-C motif) ligand 
2 or monocyte chemoattractant-1 with CNTO 888 (monoclonal antibody against CCL2), 
connective tissue growth factor with FG-3019 (monoclonal antibody to CTGF), transforming 
growth factor beta with GC1008 (antibody against TGF-β)(20, 21).  
 Other ideas currently in phase I testing include targeting lysyl oxidase and lysyl oxidase-
like enzymes with simtuzumab (AB0024, monoclonal antibody against LOXL2) and 
administration of mesenchymal stem cells for treatment of IPF(20, 21).  
Lung Transplantation: Lung transplantation is effective at reducing risk of death and 
prolonging survival in advanced IPF disease(1, 2). However, 5-year survival post-transplant is 
still only about 44-56%(1, 2). It is unclear whether single versus double lung transplantation 
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confers different survival benefits. Discussion of transplantation is appropriate at diagnosis and 
referral of patients for transplant evaluation is recommended at first sign of deterioration(1, 2).  
Treatment of Co-Existing PH and Emphysema: Regarding the treatment of pulmonary 
hypertension in IPF, the joint committee gave a weak recommendation for a trial of vasodilator 
therapy in IPF patients with moderate to severe PH that has been confirmed by right heart 
catheterization(1, 2). Sildenafil, a phosphodiesterase 5 inhibitor, has been shown to improve 
quality of life and dyspnea in cases of IPF patients with advanced PH(1, 2).  
Treatment of combined pulmonary fibrosis and emphysema has not been clearly defined. 
Cessation of smoking is advised and supplemental oxygen should be provided as needed for 
hypoxemia(6). The use of sildenafil to treat pulmonary hypertension in this group has not been 
evaluated(6).  
 
Prognosis & Mortality 
IPF prognosis is grim. Mortality in IPF patients is expected within 2-3 years of 
diagnosis(1, 2). Mortality rate is about 40,000 deaths annually(1-3). Of increasing concern is the 
upward trend in mortality rates for IPF over the past two decades(3). Particularly, from 1992 to 
2003, the number of deaths secondary to IPF in the USA increased by 50%, a mortality rate 
similar to and surpassing those of many cancers, emphasizing the devastating nature of this 
disease(23, 24). 
 
Pathogenesis of IPF  
The dismal prognosis and paucity of effective treatment modalities in IPF is secondary to 
inadequate knowledge of the pathways and factors that govern the development and progression 
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of this complex disease. IPF was originally considered to be an inflammatory condition(1, 2). 
However, when anti-inflammatory therapies failed to achieve an effect in IPF patients, the focus 
shifted away from inflammation and towards an epithelium-centered disease model(1, 2).  
Evidence to date indicates that epithelial injury and activation plays an important role in 
IPF pathogenesis. Involvement of local mesenchymal cells and circulating fibrocytes, in this 
process, leads to expansion of the fibroblast and myofibroblast populations that are responsible 
for the exaggerated deposition of extracellular matrix and resulting destruction of pulmonary 
architecture evident in IPF(2). Thus, of particular importance are efforts to understand the 
contribution of factors generated during tissue injury and how those factors impact development 
of fibrosis.  
 
ADENOSINE IN CHRONIC LUNG DISEASES 
One of the factors that has emerged as being central to injury response in the lung is the 
signaling nucleoside adenosine. During times of tissue stress and damage, cells will release 
adenosine triphosphate (ATP) into the extracellular space(25). There, ATP is rapidly 
dephosphorylated and converted to AMP and then adenosine(25). Adenosine can then engage its 
cell surface G-protein-coupled receptors (A1, A2A, A2B, and A3 adenosine receptors) to exert 
various effects on inflammation, repair and remodeling processes(26), producing either tissue-
protective or tissue-destructive results(25, 27). 
Adenosine has been shown, in humans and mouse models, to be elevated in and 
contribute to chronic lung disorders, including asthma, COPD, and pulmonary fibrosis(25). 
Recent publications have reported, specifically, that it is the activation of the A2B receptor by 
adenosine that mediates production of pro-fibrotic molecules, like interleukin-6, leading to 
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chronic lung diseases(25, 28-31). Adenosine regulates production and release of IL-6 from 
various cell types, including from lung epithelial cells(32), macrophages(33), smooth muscle 
cells(34) and fibroblasts(35). 
 
INTERLEUKIN 6 (IL-6) 
Interleukin 6 (IL-6) is a pleiotropic cytokine first identified as a secretory product of 
fibroblasts(36) and later recognized for the ability to stimulate the differentiation of activated B 
cells into immunoglobulin-producing plasma cells(37). Since then, studies have reported 
extensive effects in various systems, particularly the immune and hematopoietic systems. Aside 
from mediating the differentiation of activated B cells, IL-6 induces growth and activation of T 
lymphocytes and regulation of cytotoxic T cell differentiation(38, 39). With regards to 
hematopoiesis, IL-6 mediates the expansion of hematopoietic progenitors(40), promotes 
proliferation and differentiation of megakaryocytes, and regulates macrophage and neutrophil 
differentiation(38). IL-6 acts in the liver as a hepatocyte stimulatory factor, regulating the 
production of acute phase proteins like C-reactive protein (CRP) and fibrinogen, driving the 
acute phase response(38, 41). In the musculoskeletal system, IL-6 is important for bone health 
and remodeling. It acts to promote osteoclast differentiation, leading to bone resorption(42, 43). 
IL-6 also mediates neural cell differentiation and homeostatic activities related to fatigue, mood 
and pain through poorly understood mechanisms(43, 44). 
 
INTERLEUKIN 6 SIGNALING PATHWAYS 
IL-6 signals through a receptor complex consisting of two distinct glycoprotein chains – 
the ligand-binding interleukin 6 receptor alpha (CD126, IL-6Rα) and the non-ligand binding, 
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signal-transducing receptor gp130 (CD130)(38, 43, 44). While gp130 is expressed constitutively 
as a membrane-bound receptor on most cells in the body, expression of IL-6Rα is more 
limited(38, 43, 44). Membrane-bound IL-6Rα is present only on certain cells in the body, 
primarily hepatocytes and leukocyte subpopulations – B and T cells, monocytes, and 
neutrophils(45, 46). However, the presence of a natural, soluble form of the IL-6Rα (produced 
through alternative splicing and proteolytic cleavage) drastically widens the range of cellular 
targets and allows IL-6 to signal via two pathways(38, 43, 44, 47).  
The first pathway is known as classical signaling and occurs on cells that co-express 
membrane-bound IL-6Rα and gp130. Here, IL-6 binds a membrane-bound IL-6Rα, and this IL-
6/mIL-6Rα complex then triggers the association with two molecules of gp130 to initate the 
signaling cascade (Figure 1.1A). In the alternative pathway, known as trans signaling, IL-6 
complexes with a soluble form of IL-6Rα in order to associate with gp130 and initiate signaling 
(Figure 1.1B)(38, 43, 44). In both pathways, binding of IL-6 to IL-6Rα causes association with 
two gp130(48). This dimerization of gp130 in turn activates associated Janus tyrosine kinases 
(JAK), leading to phosphorylation of gp130(49, 50). Activated gp130 then facilitates the 
phosphorylation of signal transducer and activator of transcription 3 (STAT3)(51). Phospho-
STAT3 dimerizes and translocates to the nucleus, where it acts as a transcription factor to 
regulate target genes(52).  
 
GENERATION OF SOLUBLE IL-6R ALPHA 
Soluble receptors for cytokines can be generated in two ways: 1) shedding (where limited 
proteolysis of the membrane-bound receptor produces a soluble form of the receptor) and 2) 
alternative splicing (where soluble receptors are produced via translation of differentially spliced 
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mRNAs exhibiting deletions of transmembrane and cytoplasmic domains). Many soluble 
receptors retain their ligand-binding capacity and have been characterized in biological 
fluids(53). 
 
Figure 1.1. Interleukin 6 (IL-6) classical and trans signaling pathways. (A) Classical 
signaling occurs on cells that co-express membrane-bound gp130 and membrane-bound IL-6Rα 
(mIL-6Rα). There, IL-6 binds mIL-6Rα to form the IL-6/mIL-6Rα complex to initiate signaling. 
(B) Cells that express membrane-bound gp130 but lack mIL-6Rα can still be activated in the 
presence of the soluble IL-6Rα. Activation in this manner is known as trans signaling. There, IL-
6 binds a soluble version of IL-6Rα to form the IL-6/mIL-6Rα complex. (C) In both pathways, 
binding of IL-6 to either mIL-6Rα or sIL-6Rα leads to association with 2 membrane-bound 
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gp130 molecules, which activates Janus kinases (JAK), which in turn phosphorylates gp130, 
leading to phosphorylation of Signal Transducer and Activator of Transcription 3 (STAT3). 
Phospho-STAT3 dimerizes and translocates to the nucleus, where it acts as a transcription factor 
to facilitate transcription of target genes.  
 
Figure 1.2. Mechanisms of generation of soluble IL-6Rα (sIL-6Rα). Soluble IL-6Rα (sIL-
6Rα) can be generated via (A) translation of alternatively spliced mRNA or (B) by proteolytic 
cleavage of the membrane-bound receptor by metalloproteases such as ADAM17. Soluble IL-
6Rα retains its ability to bind IL-6 and has a binding affinity for IL-6 similar to the membrane-
bound version. The complex of IL-6/sIL-6Rα can activate cells in an autocrine (1) or paracrine 
(2) manner.  
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Soluble IL-6Rα can be generated via translation of alternatively spliced mRNA but 
mainly through proteolytic cleavage(44). Different studies have identified IL-6Rα mRNA 
isoforms that, secondary to alternative splicing and resulting reading frame shift, encodes a 
receptor that lacks the transmembrane and cytosolic domains and possesses a novel carboxy-
terminal protein sequence(54-56). Most of the focus, however, has been on unraveling the 
mechanism of protease-mediated cleavage of membrane-bound IL-6Rα to produce a soluble 
receptor. Mullberg et al demonstrated that a soluble form of the IL-6Rα is produced via shedding 
of membrane-bound receptor from human peripheral blood monocytes(57). Protein kinase C 
activity regulates this shedding process and the shed receptor retains IL-6 binding capacity(58). 
Studies in subsequent years supported a role for the metalloprotease ADAM17 in mediating IL-
6Rα shedding in response to various stimuli, including apoptosis(59), Ca2+ mobilization(60), 
cellular cholesterol depletion(61), leptin induction(62), TCR activation of CD4 T cells(63), and 
bacterial activation of bronchial epithelial cells(64). 
 
A DISINTEGRIN AND METALOPROTEASE 17 (ADAM17) 
 A Disintegrin and Metalloproteinase 17 (ADAM17) (previously known as TACE – tumor 
necrosis factor-alpha converting enzyme) is a membrane-bound metalloprotease belonging to the 
ADAM (a disintegrin and metalloproteinase) family that is responsible for cleaving cell surface 
proteins. The list of substrates for ADAM17 includes a number of cytokines and growth factors 
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(e.g. TNFα, TGFα, HB-EGF), cytokine receptors (e.g. IL-6Rα, TNFα-RI and RII), and adhesion 
molecules (e.g. L-selectin, ICAM-1)(65), among others. 
ADAM17 has been implicated as the main protease responsible for shedding IL-6Rα 
from cell membrane surfaces of hepatocytes, peripheral monocytes, neutrophils and T cells(38, 
59, 61-63). Increased levels of this protease have been found in association with diseases that 
have reported increased sIL-6Rα levels(66-69). A related protease, ADAM10, has been 
implicated in constitutive shedding of IL-6Rα, while ADAM17 is better known for rapid, 
inducible shedding(38, 61).  
 
INTERLEUKIN 6 TRANS SIGNALING AND DISEASE 
IL-6 has comparable binding affinity to soluble IL-6Rα as it does for membrane-bound 
IL-6Rα (mIL-6Rα). By binding IL-6 to form the IL-6/sIL-6Rα complex, soluble IL-6Rα 
prolongs the plasma half-life of IL-6(70). At the same time, IL-6/IL-6Rα complex acts 
agonistically, interacting with gp130 to initiate signaling, allowing for activation of cells not 
responsive to IL-6 alone. Thus, soluble IL-6Rα provides an alternative mechanism of gp130 
activation, which serves to widen the spectrum of IL-6-responsive cells and amplify IL-6 effects, 
leading to important roles in chronic pathological states(44, 71). 
IL-6 trans signaling has been implicated in the pathogenesis of a number of chronic 
diseases, including myocardial fibrosis(72), rheumatoid arthritis(73), asthma(74), inflammatory 
bowel disease (colitis) and colitis-associated cancer(38). IL-6 and sIL-6Rα levels are elevated in 
association with these diseases and reported to contribute to their pathogenesis. Effects in 
suppressing the generation of regulatory T cells (Treg) and promoting differentiation of T helper 2 
(Th2) and T helper 17 (Th17) cells are important in chronic inflammatory and autoimmune 
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diseases. By promoting osteoclast differentiation and angiogenesis via stimulation of synovial 
fibroblast cells to produce receptor activator of NF-κB ligand (RANKL) and vascular endothelial 
growth factor (VEGF), IL-6 is implicated in the pathogenesis of arthritic conditions, most 
prominently in rheumatoid arthritis. Its induction of cellular proliferation, like in lymphoid and 
epithelial cells, contributes to tumor growth and development and has significant ramifications 
on inflammation-associated cancer, multiple myeloma, and lymphomas(71, 75). Given this 
knowledge, studies have also been conducted to specifically block IL-6 trans signaling in vivo, 
with resulting amelioration of disease, in colitis, arthritis, sepsis, asthma, and cancer(76-80).  
 
INTERLEUKIN 6 SIGNALING AND FIBROSIS 
In terms of its role in fibrosis, levels of IL-6 and soluble IL-6Rα are elevated in chronic 
hepatitis and liver cirrhosis and correlate with disease severity, suggesting involvement of IL-6 
trans signaling(81). In the kidneys, adenosine A2B receptor-mediated induction of IL-6 leads to 
excessive pro-collagen production, resulting in renal fibrosis. Interleukin 6 is also said to 
stimulate mesangial cell proliferation(75, 82). In the heart, IL-6 mediates the differentiation of 
cardiac fibroblasts to myofibroblasts (the main effector cell of fibrosis) and contributes to cardiac 
hypertrophy and myocardial fibrosis(72). IL-6 has been reported to promote collagen production 
in dermal fibroblasts(75). Increased IL-6 levels correlated with extent of skin fibrosis in systemic 
sclerosis(83), and levels of sIL-6Rα are increased in cases of systemic sclerosis patients with 
pulmonary fibrosis(84).  
In the lungs, IL-6 is important in airway remodeling in asthma(85), induces the 
conversion of human lung fibroblasts to myofibroblasts(35), and promotes pancreatitis-
associated lung injury(86). However, the role of IL-6 in pulmonary fibrosis was not defined until 
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O’Donoghue et al. demonstrated that IL-6 ablation attenuated fibrosis in a bleomycin-induced 
murine model(87). Pedroza et al previously demonstrated that IL-6 contributes to pulmonary 
fibrosis when they reported that genetic or pharmacologic removal of IL-6 resulted in attenuation 
of fibrosis(29). What is not known from those studies, though, is the role of IL-6 trans signaling 
in pulmonary fibrosis.  
It is with the intention of mending this deficit in knowledge that we have designed a 
project to examine the role of IL-6 trans signaling in pulmonary fibrosis. We will be using IPF 
human samples obtained from Methodist Hospital as well as two murine models of pulmonary 
fibrosis to evaluate the role of this pathway in pulmonary fibrosis.  
 
INTRAPERITONEAL BLEOMYCIN (IPB) MODEL OF PULMONARY FIBROSIS 
The general consensus at this time is that there is no adequate model for IPF, though 
previous models have employed the use of bleomycin, silica, fluorescein isothiocyanate (FITC), 
irradiation, or other agents. The most frequently used model is one that involves exposure to 
bleomycin. Bleomycin is a chemo-therapeutic agent known to cause pulmonary fibrosis in a 
portion of patients exposed to it. This is secondary to the lower level of the enzyme bleomycin 
hydrolase (responsible for inactivating bleomycin) in the lungs(88). Models of repetitive 
bleomycin exposure have been demonstrated to better recapitulate features of IPF(89). Our lab 
currently uses the repetitive intraperitoneal bleomycin (IPB) model of pulmonary fibrosis (Figure 
1.3). In this model, mice are given intraperitoneal injections of bleomycin twice weekly for four 
weeks, which lead to progressive development of pulmonary fibrosis(33, 90, 91). This model of 
chronic bleomycin exposure has been demonstrated to recapitulate features of IPF, such as the 
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presence of hyperplastic airway epithelial cells and fibrosis that radiates inward from the pleural 
surfaces and is progressive, irreversible and lethal(92, 93).  
 
 
Figure 1.3. Intraperitoneal Bleomycin (IPB) mouse model of pulmonary fibrosis. Wildtype 
C57Blk6 male mice were injected intraperitoneally with saline or bleomycin twice weekly for 4 
weeks, resulting in progressive development of pulmonary fibrosis. Mice were sacrificed and 
samples collected on day 33.  
 
 
 
 
Figure 1.4. Adenosine deaminase (ADA)-deficient mouse model of pulmonary disease. 
ADA-deficient (ADA-/-) mice were identified at birth and maintained on PEG-ADA enzyme 
replacement therapy until postnatal day 25. Therapy is then discontinued and endogenous 
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adenosine allowed to accumulate in the lung. Mice were sacrificed and samples collected for 
analysis on postnatal day 42. 
 
ADENOSINE DEAMINASE (ADA)-DEFICIENT MODEL OF PULMONARY FIBROSIS 
Another mouse model of pulmonary disease typically used by our laboratory is the 
Adenosine Deaminase (ADA)-deficient model (Figure 1.4). The benefit of this model is that it 
allows for evaluation of the role of adenosine in lung disease that consists of pulmonary fibrosis 
and emphysema(28).  
Blackburn et al first reported the generation of a viable mouse with complete genetic 
deficiency in the enzyme ADA, an enzyme necessary to metabolize adenosine. ADA-deficient 
mice exhibited severe metabolic disturbances and pulmonary insufficiency resulting in mortality 
in the postnatal period(94). Specifically, ADA-deficient mice exhibited abnormal alveogenesis, 
pulmonary inflammation and airway obstruction(95). The use of ADA enzyme supplementation 
in these mice resulted in reduction of metabolic disturbances and survival of the animals(96).  
The model now employs the use of enzyme replacement therapy from postnatal day 1 to 
25 to allow normal pulmonary development in ADA-deficient mice. Discontinuation of therapy 
allows endogenous adenosine levels to rise, leading to increasing pulmonary inflammation, 
emphysematous distal airway enlargement and progressive development of pulmonary 
fibrosis(29, 97). These mice exhibited features similar to IPF, such as fibroblastic foci and 
hyperplastic airway epithelial cells (AEC)(29, 30).  
Use of the ADA-deficient model allowed for exploration of adenosine in regulating 
events pertinent in lung injury and fibrosis. Chunn et al revealed that chronic elevation of 
endogenous adenosine in ADA-deficient mice resulted in pulmonary inflammation, expression 
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of profibrotic mediators and collagen deposition, and that these effects were all reversible with 
therapeutic administration of the enzyme ADA to lower adenosine(28). Blackburn et al reported 
that the effects of IL-13 on pulmonary inflammation, remodeling and fibrosis are mediated 
through augmentation of adenosine and its receptors(98). The adenosine A1 receptor (A1AR) 
serves an anti-inflammatory, protective role in adenosine-mediated lung injury(99). ADA-
deficient mice lacking adenosine 2A receptor (A2AAR) experienced enhanced pulmonary 
inflammation, angiogenesis and mucin production(100). Antagonism of the adenosine 2B 
receptor (A2BAR) resulted in a reduction in pulmonary inflammation, fibrosis and alveolar 
airspace enlargement(97). Genetic removal of A2BAR in ADA-deficient mice, however, resulted 
in loss of barrier function and neutrophilia with resulting enhancement of inflammation and 
remodeling(101). This suggests a protective role for the A2BAR in acute stages. The adenosine 3 
receptor (A3AR) is important in regulating neutrophilia and mucus production in the lungs(102). 
Using this model, Schneider et al supported a role for osteopontin in mediating neutrophilia and 
alveolar airspace enlargement(30). Pedroza et al supported a role for interleukin 6 in promoting 
pulmonary inflammation and remodeling(29). 
 
DISSERTION OVERVIEW 
Idiopathic pulmonary fibrosis is a deadly lung disease that causes chronic, progressive, 
irreversible fibrosis. IPF has a highly variable and unpredictable natural history. Most patients 
experience respiratory decline with resulting respiratory failure and death within 2-3 years from 
diagnosis. There are no known causes for IPF, no cure, and at this time, no effective therapies 
available. The mortality rate for IPF is even worse than that of many malignancies. Of even 
greater concern is the fact that within the last two decades, there has been a trend for increasing 
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prevalence and incidence rates for IPF. There is an urgent need to better understand the pathways 
and events that govern the onset and progression of pulmonary fibrosis in order to remedy the 
lack of effective therapies. Production of the signaling nucleoside adenosine in response to lung 
injury is an important factor in the regulation of fibrosis. Adenosine, through activation of its 
adenosine 2B receptor (A2BR), initiates production and release of the cytokine interleukin 6 (IL-
6) in mice and humans with pulmonary fibrosis. Inhibition of IL-6, via pharmacologic blockade 
or genetic removal, resulted in attenuation of pulmonary fibrosis in mice. IL-6 can mediate 
tissue-protective effects via its membrane-bound receptor (mIL-6Rα) in a process termed 
classical signaling. However, when IL-6 signals through an alternative trans pathway, via the 
soluble form of its receptor (sIL-6Rα), the cytokine appears to exert a pro-fibrotic role. 
Preliminary data reveals increased levels of sIL-6Rα in the lungs of mice and patients with 
pulmonary fibrosis, suggesting involvement of IL-6 trans signaling. However, the role of IL-6 
trans signaling in pulmonary fibrosis has not been examined. Given the findings in our lab, along 
with published literature implicating IL-6 trans signaling in the pathogenesis of other chronic 
inflammatory and fibrotic disorders, we developed the following specific aims to test the 
HYPOTHESIS that: interleukin-6 trans signaling is critical for the development of 
pulmonary fibrosis and in vivo neutralization of this pathway will attenuate fibrosis.  
 
Specific Aim 1: To quantify levels of soluble IL-6Rα and characterize classical and trans 
signaling components during the development and progression of pulmonary fibrosis. 
We quantified soluble IL-6Rα levels in plasma and bronchoalveolar lavage fluid during 
disease progression in the intraperitoneal bleomycin model. We characterized and monitor 
changes in expression of membrane-bound IL-6Rα and soluble IL-6Rα over time. Utilizing dual 
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staining protocols, we identified the pulmonary cell types that are responsive to IL-6 and 
delineate those that exhibit classical signaling versus those responding to trans signaling. The 
findings were validated in explanted human IPF lung samples, and the results from this aim are 
presented in Chapter 3.  
 
Specific Aim 2: Assess the role of protease-mediated shedding in the production of soluble 
IL-6Rα during the development and progression of pulmonary fibrosis. 
We characterized ADAM17 expression during development of pulmonary fibrosis in the IPB 
model. To establish the role of ADAM17 as the main protease responsible for the generation of 
sIL-6Rα in pulmonary fibrosis, we conducted in vitro stimulation and neutralization experiments 
using bone marrow derived macrophages as well as primary alveolar macrophages. We 
conducted experiments to directly stimulate shedding of IL-6Rα from cultured macrophages via 
activation of ADAM 17 and to prevent IL-6Rα shedding using a pharmacologic inhibitor of 
ADAM17 and ADAM17 siRNA. The results from this aim are presented in Chapter 4.  
 
Specific Aim 3: Evaluate the therapeutic benefit of blocking IL-6 trans signaling in 
pulmonary fibrosis. 
In order to assess the impact of IL-6 trans signaling on the development of pulmonary 
fibrosis, we conducted in vivo neutralization experiments using the IPB model. We subjected 
mice to bleomycin exposure while also co-injecting them with either PBS alone (vehicle control) 
or mouse recombinant gp130Fc (to selectively inhibit trans signaling). We assessed pulmonary 
phenotypes, inflammation, various indexes of pulmonary fibrosis, and downstream mediators of 
IL-6 signaling to determine the contribution of trans signaling. We stimulated IL-6 trans 
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signaling in normal and IPF fibroblasts in vitro and assess changes to proliferation and 
extracellular matrix protein production. The results from this aim are presented in Chapter 5.  
 
Specific Aim 4: To characterize IL-6 trans signaling in a murine model of pulmonary 
fibrosis and emphysema, the ADA-deficient model, and assess the impact of trans signaling 
by neutralizing it in this model. 
We attempted to verify results obtained in the IPB model by repeating experiments in the 
above three aims but this time using the ADA-deficient model. We characterized changes in IL-6 
classical and trans signaling as well as ADAM17 expression during onset and progression of 
disease in the ADA-deficient model and conducted in vivo neutralization of IL-6 trans signaling 
in ADA-deficient mice and assess changes to pulmonary inflammation and pulmonary fibrosis. 
The results from this aim are presented in Chapter 6. 
 
By accomplishing the above aims, we sought to gain novel insights about the pathogenesis of 
IPF that will translate into more effective therapies for patients.      
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CHAPTER 2 
Experimental 
Procedures 
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HUMAN IPF SAMPLES 
Deidentified explanted lung samples from IPF patients were obtained from the Methodist 
Hospital J.C. Walter Jr. Transplant Center. Collection and use of these tissues for research were 
in accordance with the guidelines approved by the Methodist Hospital Institutional Review 
Board. Lung samples taken from unaffected lobes of IPF patients were used as controls. 
 
ANIMALS 
Mice used were ordered from Harlan Laboratories. They were inbred, male 
C57Bl/6NHsd mice, 4-5 weeks old. Once they arrive at our institution, mice were allowed a 
week to acclimate to their environment before the start of experiments. Maintenance and care of 
animals were in accordance with NIH guidelines and those set by the Animal Welfare 
Committee at the University of Texas Health Science Center at Houston. Mice were housed in 
ventilated cages equipped with microisolator lids and maintained under strict containment 
protocols. Housing conditions consisted of ambient temperature of 22°C and 12-hour light/dark 
cycles, and mice were provided with food and water ad libium. All study designs were reviewed 
and approved by the Animal Welfare Committee.  
 
INTRAPERITONEAL BLEOMYCIN (IPB) MODEL  
Male C57Bl/6 mice, 4-5 weeks old, were treated with intraperitoneal injections of saline 
or bleomycin (Teva Pharmaceutical, Petach Tikva, Israel) (0.035U/g) diluted in sterile 1X 
Phosphate Buffered Saline (PBS). A total of 8 injections were given twice a week for 4 weeks. 
Mice were sacrificed at the end of the model, on day 33, and samples were collected to assess 
pulmonary phenotype (Figure 1.3).  
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For the time course experiment, to evaluate pulmonary phenotype during development 
and progression of disease in the model, mice were sacrificed at various points in the model, on 
days 5, 10, 15, 20, 25, and 33. Day 0 mice are wildtype mice, who have not received any 
injections, saline or bleomycin.  
 
ADENOSINE DEAMINASE (ADA) DEFICIENT MODEL 
Adenosine deaminase heterozygous (ADA+/-) and homozygous (ADA-/-) mice were 
generated (on a C57Blk/6J background) and genotyped as described previously(96). Mice 
homozygous for the ADA-null allele were identified at birth and supported with polyethylene 
glycol modified ADA (PEG-ADA) enzyme therapy from postnatal day 1 to day 25 (Figure 1.4). 
Intramuscular injections were given on days 1, 5, 9, 13 and 17 (0.625, 1.25, 2.5, 2.5 and 2.5 units 
respectively). Intraperitoneal injections were given on days 21 and 25 (5 units each). Analysis of 
pulmonary phenotypes was performed on postnatal day 42. All comparisons were done among 
littermates of ADA-competent (ADA+/-) and ADA-deficient (ADA-/-) mice. 
 
SOLUBLE GP130 INHIBITION OF INTERLEUKIN-6 TRANS SIGNALING 
 In vivo neutralization of interleukin 6 trans signaling was performed using recombinant 
mouse gp130Fc chimera (R&D Systems) (Figure 5.1A). In the IPB model, male C57Bl/6 mice, 
4-5 weeks old, were treated with bleomycin or vehicle (saline) intraperitoneally twice a week for 
4 weeks. Beginning on day 19 and continuing daily until day 32, mice were treated with saline 
(200µl 1X sterile PBS) or gp130Fc (250ng-2µg/mouse reconstituted in 200µl sterile PBS) 
(Figure 5.1B). On treatment days that coincide with bleomycin injections, mice received 
gp130Fc injections 1-2 hours before bleomycin. On day 32, arterial oxygen saturation levels 
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were measured. On day 33, animals were sacrificed and samples collected to assess changes to 
pulmonary phenotype.  
In the ADA-deficient model, starting on postnatal day 30, mice were treated with saline 
(200µl 1X sterile PBS) or gp130Fc (1µg/mouse reconstituted in 200µl sterile PBS) until day 41 
(Figure 6.4A). On day 42, animals were sacrificed and samples collected to assess changes to 
pulmonary phenotype.  
The dosage and schedule of administration of soluble gp130 are adapted from previous 
published studies that have shown effectiveness of this reagent in vivo(76-80, 103). The decision 
of when to begin treatment with soluble gp130 was based on preliminary data regarding the 
temporal course of disease development in both models (Figure 3.3 & 6.1).  
 
ASSESSMENT OF ARTERIAL OXYGEN SATURATION 
Assessment of arterial oxygen saturation was performed on conscious mice on day 32 
using the pulse MouseOx software analysis (STARR Life Sciences Corp, Oakmont, PA). Mice 
were shaved on day 31 to remove the hair around the neck to allow proper measurements by 
collar clip light sensor. The MouseOx utilizes pulse oximetry measurements of light absorption 
from the red and infrared LEDs (Light Emitting Diodes) to determine real-time percent oxygen 
saturation of functional arterial hemoglobin.  
 
MEASUREMENT OF RIGHT VENTRICULAR SYSTOLIC PRESSURE (RVSP) 
Protocol for measurement of right ventricular systolic pressure (RVSP) is as previously 
published(91). Briefly, mice were anesthetized with avertin and placed on heated pad 
(Deltaphase Isothermal model 39; Braintree Scientific, Braintree, MA). Tracheostomy was 
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performed and mice were connected to a ventilator (MiniVent, Hugo-Sachs Elektronik, March-
Hugstetten, Germany) via a 19-gauge blunt needle (Brico, Dayton, NJ). Mice were maintained 
on volume of 250µl and rate of 100/minute. Using a surgical microscope (SMZ-2B, Nikon, 
Tokyo, Japan), the abdomen was accessed through an incision made below the xiphoid process. 
A retractor (ALM-112, Braintree Scientific) was used to visualize abdominal contents. The heart 
was exposed through an incision in the diaphragm and pericardium was removed. The right 
ventricle (RV) was punctured with 27-gauge needle and catheterized with a 1-french pressure 
catheter (SPR-1000, Millar Instruments, Houston, TX). RVSP was recorded using Chart5.3 
software (AD Instruments).  
 
COLLECTION OF BLOOD AND ISOLATION OF PLASMA 
Mice were anesthetized with avertin and blood was collected via needle aspiration of the 
left ventricle. Plasma was isolated via centrifugation at 10,000xG for 10 minutes at 4°C and flash 
frozen for storage at -80°C for later use in ELISA analyses.  
 
BRONCHOALVEOLAR LAVAGE (BAL) FLUID COLLECTION, CELL COUNT AND 
DIFFERENTIALS 
After collection of blood, the mouse trachea was exposed and cannulated to perform 
bronchoalveolar lavage. Lungs were lavaged 4 times with 0.3 ml sterile PBS each; 
approximately 1ml of pooled lavage fluid per mouse was recovered. An aliquot was sampled to 
determine total BAL cells using a hemocytometer. The rest of the BAL fluid was spun at 1200 
rpm for 5 minutes at 4°C. The supernatant was removed, aliquoted and flash frozen. Cell pellets 
were resuspended in 100µl sterile PBS and aliquots were spun onto microscope slides (50µl for 
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PBS samples, 10-20µl for bleomycin samples). The slides were stained with Diff-Quick (Dade 
Behring, Deerfield, IL) and cellular differentials were performed. Remaining cells were pelleted 
once again at 10,000xG for 5 minutes at 4°C and supernatant was removed. Cell pellets were 
flash frozen. BAL fluid supernatant aliquots and cell pellets were stored at -80°C for later use in 
protein quantification, ELISA and western blot analyses.  
 
HISTOLOGY  
After lavage was performed, mouse lungs were inflated with 10% phosphate buffered 
formalin at 25 cm of pressure and fixed at 4°C overnight. Formalin-fixed lungs were dehydrated 
through an ethanol gradient and paraffin-embedded. 5µm sections were cut and collected on 
microscope slides for use in fibrosis assessment and immunohistochemistry staining.  
 
IMMUNOSTAINING OF PARAFFIN-EMBEDDED LUNG SECTIONS 
Lung sections were rehydrated through an ethanol gradient to water. Rehydrated sections 
were incubated in 10% hydrogen peroxide to quench endogenous peroxidases. Antigen retrieval 
(Dako Corp.) was performed at 95°C for 20 minutes and slides were allowed to cool to room 
temperature for 20 minutes. Endogenous avidin and biotin were blocked using the Biotin 
Blocking System (Dako Corp., Carpinteria, CA). Slides were blocked in 3% blocking solution 
(goat or rabbit serum in PBS) for 1 hour at room temperature then incubated at 4°C overnight in: 
anti-STAT3 (phospho S727) antibody (rabbit polyclonal, 1:100 dilution, Abcam, Cambridge, 
MA), anti-prosurfactant protein C (proSP-C) (rabbit polyclonal, 1:1000 dilution, EMD Millipore, 
Billerica, MA), anti-human S100A4 (rabbit polyclonal, 1:200 dilution, Dako Corp.), arginase 1 
antibody (H-52) (rabbit polyclonal, 1:100 dilution, Santa Cruz Biotechnology, Dallas, TX), anti-
 47
ADAM17 (rabbit polyclonal, 1:100 dilution at 37°C for 1 hour, EMD Millipore). For alpha-
SMA staining, slides were processed with a Mouse on Mouse kit per manufacturer protocols 
(Vector Laboratories, Burlingame, CA). Slides were then incubated in anti-actin, α smooth 
muscle antibody (1:1000 dilution, 4°C overnight, mouse monoclonal clone 1A4, Sigma-Aldrich, 
St. Louis, MO).  
After incubation with primary antibodies, all sections were incubated at room 
temperature for 1 hour in appropriate biotinylated secondary antibodies. Vectastain ABC 
peroxidase rabbit IgG kit (Vector Laboratories) and 3,3’-diaminobenzidine (Sigma-Aldrich) 
were used to develop stains for P-STAT3 and ADAM17. Vectastain ABC Alkaline Phosphatase 
Standard Kit (Vector Laboratories) and Vector Alkaline Phosphatase substrate kit (Vector 
Laboratories) were used to develop stains for alpha-SMA, pro-SPC, S100A4, and arginase 1. All 
sections were counterstained with methyl green. Slides were mounted with cover slip and 
Vectashield (Vector Laboratories) mounting medium.  
 
 
IMMUNOFLUORESCENCE OF BAL CELLS 
Aliquots of resuspended BAL cell pellets were cytospun onto microscope slides, allowed 
to air-dry, then fixed in 3.7% paraformaldehyde in PBS for 10 minutes and permeabilized in cold 
methanol for 10 minutes. Slides were blocked in 1% bovine serum albumin in PBS for 1 hour at 
room temperature and then incubated in: anti-human CD126 (IL-6R) antibody (1:50 dilution, 
4°C overnight, mouse monoclonal, ABD Serotec, Raleigh, NC). Incubation in secondary 
antibody, Alexa Fluor 488 rabbit anti-mouse IgG (1:1000 dilution, Life Technologies, Grand 
Island, NY) occurred for 1 hour at room temperature, protected from light. Slides were mounted 
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with coverslip and Prolong Gold antifade medium with DAPI (Life Technologies) and let air dry, 
protected from light. 
 
DUAL IMMUNOFLUORESCENCE OF LUNG SECTIONS FOR P-STAT3 AND α-SMA 
Rehydrated sections were processed as in above section on immunostaining with regards 
to hydrogen peroxide quench, antigen retrieval, avidin/biotin block, and serum block. Slides 
were incubated in anti-STAT3 (phospho S727) antibody (1:100 dilution, O/N, 4°C) then in 
appropriate secondary antibody for one hour at room temperature. ABC Alkaline Phosphatase 
Standard Kit and Vector Alkaline Phosphatase Substrate Kit were used to develop P-STAT3 as a 
red fluorescence. From this point forward, all steps were performed in the dark and slides were 
protected from light. Slides were washed in PBS to remove excess substrate and then processed 
using the Mouse on Mouse Kit. Sections were incubated in blocking reagent for 1 hour at room 
temperature then reagent diluent for 5 minutes at room temperature and then incubated in anti-
actin, α smooth muscle antibody (1:500 dilution, 4°C overnight). Secondary antibody incubation 
in Alexa Fluor 488 rabbit anti-mouse IgG (1:1000 dilution) was performed for 1 hour to allow 
detection of alpha-SMA as a green fluorescence. Slides were mounted with coverslip and 
Prolong Gold antifade medium with DAPI and let air dry, protected from light. 
 
FIBROSIS ASSESSMENT 
Rehydrated lung sections were stained using a Masson’s trichrome protocol. Fibrosis was 
quantified using the Ashcroft method of scoring. Scoring was performed blinded with regards to 
animal treatment. All areas of the lung were scored and an overall average score was given per 
lung section.  
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The Sircol assay (Biocolor Ltd., Carrick, UK) was used to measure soluble collagen 
content in BAL fluid. Transcript levels of collagen isoforms were quantitated using whole lung 
mRNA. Fibronectin expression was determined using western blot analysis of lung lysates.  
 
WESTERN BLOT ANALYSES OF PROTEIN LYSATES AND BAL FLUID 
Protein lysates were prepared by homogenizing frozen lung tissue in cold protein lysis 
buffer (1M Tris pH 7.4, 1M NaCl, 1% Triton-X 100) containing 1X protease inhibitor cocktail 
(Thermo Scientific, Rockford, IL). Lysates were centrifuged at 14,000 rpm for 10 minutes at 
4°C, supernatant was removed and aliquoted for use in western blot analysis. Protein 
concentrations were determined using the Bradford assay (Bio-rad, Hercules, CA). Equal 
amounts of total protein per sample (25-50µg) were prepared in SDS-Sample Buffer (6X, 
reducing, Boston Bioproducts, Ashland, MA) and incubated at 95°C for 5 minutes. 
Electrophoresis was performed on 10-12% SDS-PAGE gels (Bio-rad). Transfer onto Immobilon-
P PVDF membranes (EMD Millipore) was conducted at 100V for 2 hours at 4°C. Membranes 
were allowed to air dry, were trimmed and blocked with 5% (w/v) non-fat, dehydrated milk in 
Tris-buffered saline-tween 20 (TBST) for 1 hour at room temperature. Membranes were then 
incubated with shaking at 4°C overnight in: anti-human CD126 (IL-6R (1:500 dilution, mouse 
monoclonal, ABD Serotec), anti-STAT3 (phospho S727) antibody (1:500 dilution, rabbit 
polyclonal, Abcam), anti-ADAM17 (1:2000, rabbit polyclonal, Millipore), anti-fibronectin, 
cellular antibody (1:2000, mouse monoclonal clone FN 3E2, Sigma-Aldrich) and anti-β-Actin 
antibody (1:5000, mouse monoclonal clone AC-74, Sigma-Aldrich). Membranes were rinsed in 
TBST and incubated with appropriate horseradish-conjugated secondary antibodies for 1 hour at 
room temperature with shaking. Secondary antibodies used were: anti-rabbit IgG HRP-linked 
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antibody (1:1000-4000 dilution, Cell Signaling, Danvers, MA) anti-mouse IgG HRP-linked 
antibody (1:1000-10,000 dilutions, Cell Signaling). Signal was developed using Thermo 
Scientific Chemiluminescent Substrate.  
For BAL fluid samples, equal volumes of samples were prepared in 6X SDS sample 
buffer and processed as detailed above.  
 
ANALYSIS OF WHOLE LUNG RNA 
Total RNA was isolated from frozen lung tissue using TRIzol reagent (Invitrogen) per 
manufacturer protocol. Samples were treated with RNAse-free DNAse 1 (Invitrogen) and used 
for quantitative real-time RT-PCR analysis. cDNA was made using Superscript II reverse 
transcriptase (Invitrogen). Equal amounts of cDNA were analyzed for transcript levels of 
COL1A2 and MCP-1 with normalization to beta actin and/or peptidylprolyl isomerase A (PPIA). 
Primer sets used were: COL1A2 – forward 5’-AAGGGTGCTACTGGACTCCC-3’ and reverse 
5’-TTGTTACCGGATTCTCCTTTGG-3’. Primers for MCP-1 were: forward 5’-
AGCATCCACGTGTTGGCTC-3’ and reverse 5’-TGGGATCATCTTGCTGGTG-3’. Data 
presented as mean normalized transcript levels using the comparative Ct method.  
 
ELISA ANALYSIS OF SOLUBLE INTERLEUKIN 6 RECEPTOR ALPHA (sIL-6Rα) IN 
PROTEIN LYSATES, BAL FLUID AND PLASMA 
 Soluble IL-6Rα was quantified in protein lysates made from COPD & IPF lungs using 
the Human IL-6R Alpha Duoset ELISA kit (R&D Systems). 10µl of lysate was diluted in 90µl 
reagent diluent and subjected to ELISA analysis per manufacturer protocol. Murine BAL fluid 
and plasma samples were processed using the Mouse IL-6R Alpha Duoset ELISA kit (R&D 
 51
Systems). For BAL fluid samples, 100µl was used. For plasma samples, 10µl of plasma was 
diluted in 90µl reagent diluent. 
 
BONE MARROW MACROPHAGE ISOLATION AND CULTURE 
 Male C57Bl/6 mice, 4-5 weeks old, were euthanized via cervical dislocation technique. 
Both femurs were isolated, removed and cleaned of surrounding muscles and tissues. The ends of 
each femur were carefully cut off and a 5ml syringe with 21-22G needle was used to flush the 
bone marrow cavity of the femur with complete macrophage medium, which is Dulbecco’s 
Modification of Eagle’s Medium (Fisher Scientific) supplemented with 10% fetal bovine serum 
and 20% L929 media supplement (see below for protocol for growing L929 cells and making 
L929 media supplement). Femur cavity was flushed with 2-5ml of media, until bone appears 
white. Flushed media was collected in a sterile 50ml conical tube and centrifuged at 500 X g for 
10 minutes at room temperature to pellet cells. Cells were resuspended in macrophage media, 
counted and plated in 100mm bacterial dishes (not tissue culture treated dishes). Plate cells to 
have a total of 3-5x106 cells in 7.5ml media per dish. A yield of approximately 10-15 dishes is 
typical per mouse. Cells were incubated at 37°C, 5% CO2 for 4 days, supplemented with an extra 
5ml of media per dish and cultured until day 7-8, by which time most adherent cells are 
macrophages. On day 7-8, culture media was discarded, fresh media was added (5ml per dish) 
and a cell scraper was used to dislodge adherent cells. Detached cells were collected in 50ml 
conical tube and centrifuged at 400 X g for 10 minutes at 4°C. Cells were then resuspended in 
macrophage media and seeded in tissue culture plates for experiments.  
 To make L929 media supplement, L929 cells were obtained from our collaborator, Dr. 
Sandeep Agarwal (Baylor College of Medicine, Department of Internal Medicine). Cells were 
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plated at a density of 5x105 cells per T75 flasks in 55ml of media consisting of DMEM with 1% 
HEPES, 1% penicillin-streptamycin, 1% L-glutamine and 10% fetal bovine serum. Cells were 
cultured for 7 days, then media was harvested and sterile filtered for addition to macrophage 
culture media.  
 
DIFFERENTIATION OF MACROPHAGES WITH IL-4 AND IL-13 
 Day 7-8 bone-marrow-derived macrophages were plated in 6-well plates at a density of 
1.5-2x106 cells/well and allowed to adhere 2-3 hours at 37°C, 5% CO2. Culture media and non-
adherent cells were removed after 3 hours. Cells were then incubated in macrophage media 
containing IL-4 (20 ng/ml) and IL-13 (10 ng/ml) (Peprotech, Rocky Hill, NJ) for 72 hours. Fresh 
reagents were added daily. After 72 hours, macrophages were washed with sterile PBS and used 
in TAPI-1 experiments. 
 
TAPI-1 INHIBITION OF ADAM17 IN MACROPHAGES 
 The reagent phorbol 12-myristate 13-acetate (PMA) is known to activate ADAM17 and 
induce receptor and substrate shedding. IL-4/IL-13-stimulated macrophages were incubated in 
serum-free media containing PMA (10µg/ml, Enzo Life Sciences, Farmingdale, NY) for 2-3 
hours at 37°C, 5% CO2, to activate ADAM17 and induce membrane IL-6Rα shedding. Inhibition 
of ADAM17 activity was carried out by pre-incubation of macrophages with TNFα protease 
inhibitor 1 (TAPI-1) (20µM) for 1 hour followed by PMA stimulation in the presence of TAPI-1. 
After 2-3 hours exposure to media alone, media and TAPI-1, PMA alone, or PMA and TAPI-1, 
culture media was collected and soluble IL-6Rα was quantified using ELISA. Macrophages were 
washed with PBS and lysed in RIPA lysis buffer containing protease inhibitors. 5-10µg of 
 53
protein per sample were subjected to western blot analysis to determine expression of arginase 1 
(rabbit polyclonal antibody, 1:200 dilution, O/N incubation, 4°C, Santa Cruz), IL-6R (anti-
human CD126 (IL-6R) antibody, mouse monoclonal, 1:500 dilution, 4°C overnight, ABD 
Serotec, 1:500 dilution, O/N, 4°C), and ADAM17 (rabbit polyclonal antibody, 1:500 dilution, 
O/N incubation, 4°C, EMD Millipore).  
 
ADAM17 SIRNA SILENCING IN MACROPHAGES 
 For siRNA silencing of ADAM17, day 7-8 bone-marrow-derived macrophages were 
resuspended in antibiotics-free macrophage media and seeded in 6-well plates and allowed to 
adhere for 2-3 hours. Cells were then incubated in antibiotics-free media containing IL-4, IL-13, 
Optimem (Invitrogen) with Lipofectamine RNAiMax (Invitrogen) and ADAM17 siRNA or 
scrambled control siRNA (Sigma-Aldrich) for 24 hours. Final concentration of siRNA was 
100nM. After 24 hours, media was changed and a second transfection was performed with fresh 
reagents. Macrophages were incubated in the second transfection media for 48 hours. Fresh IL-4 
and IL-13 were added to culture media daily. After 72 hours of stimulation and transfection, non-
transfection macrophages, macrophages transfected with control siRNA, and macrophages 
transfected with ADAM17 siRNA were stimulated with PMA in serum-free conditions for 2 
hours. Culture media were collected and soluble IL-6Rα levels were quantified using ELISA. 
Cells were washed with PBS and lysed in RIPA lysis buffer containing protease inhibitors. 5-
10µg of protein per sample were subjected to western blot analysis to determine expression of 
arginase 1 (rabbit polyclonal antibody, 1:200 dilution, O/N incubation, 4°C, Santa Cruz), IL-6R 
(anti-human CD126 (IL-6R) antibody, mouse monoclonal, 1:500 dilution, 4°C overnight, ABD 
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Serotec, 1:500 dilution, O/N, 4°C), and ADAM17 (rabbit polyclonal antibody, 1:500 dilution, 
O/N incubation, 4°C, EMD Millipore).  
 
SHEDDING OF MEMBRANE IL-6R ALPHA FROM PRIMARY LUNG 
MACROPHAGES 
 Bronchoalveolar lavage fluid was collected from Day 33 male C57Bl/6 mice treated with 
PBS or bleomycin. Lungs were lavaged 10 times with 0.5 ml sterile PBS each; approximately 
5ml of pooled lavage fluid per mouse was recovered. BAL fluid from all PBS mice or all 
bleomycin mice were pooled and spun at 1200 rpm for 5 minutes at 4°C. The supernatant was 
removed and cell pellets were resuspended in complete macrophage media (RPMI 1640 
containing 10% FBS and 1% penicillin-streptomycin). Cells were counted by hemocytometer, 
plated in 6-well plates at 1x106 cells/well and allowed to adhere 4 hours at 37°C, 5% CO2. 
Culture media and non-adherent cells were removed after 4 hours by washing with serum-free 
RPMI. Cells were then incubated in macrophage media containing PMA (10µg/ml, Enzo Life 
Sciences, Farmingdale, NY) for 2 hours at 37°C, 5% CO2, to activate ADAM17 and induce 
membrane IL-6Rα shedding. Inhibition of ADAM17 activity was carried out by pre-incubation 
of macrophages with TNFα protease inhibitor 1 (TAPI-1) (20µM) for 1 hour followed by PMA 
stimulation in the presence of TAPI-1. After 2 hours exposure to media alone, PMA alone, or 
PMA and TAPI-1, culture media was collected and soluble IL-6Rα was quantified using ELISA. 
 
CONTROL AND IPF FIBROBLAST CELL LINES 
CCD8Lu and LL97A (AlMy) are control and IPF fibroblast cell lines, respectively, 
purchased from American Type Culture Collection (ATCC, Manassas, VA). CCD8Lu was 
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cultured in ATCC-formulated Eagle’s Minimum Essential Medium (ATCC), supplemented with 
10% fetal bovine serum and 1% penicillin-streptomycin-amphotericin B mix. LL97A was 
cultured in Ham’s F12K medium (ATCC) supplemented with 15% fetal bovine serum and 1% 
penicillin-streptomycin-amphotericin B mix. Both cell lines were maintained in T75 flask with 
10ml medium, at 5% carbon dioxide atmosphere in a 37°C humidified incubator. Medium was 
changed every 3 days and cells were passaged using trypsin. For stimulation experiments, cells 
were used between passages 4-8. 
 
IN VITRO STIMULATION OF INTERLEUKIN 6 TRANS SIGNALING IN CCD8LU 
AND LL97A 
To assess the effects of IL-6 trans signaling on fibroblast proliferation, CCD8Lu and 
LL97A cells were plated in 96-well plates at a density of 3-5x103 cells/well. They were cultured 
until they reached 70-80% confluency, then washed with sterile PBS and serum starved for 24 
hours. After 24 hours in their respective serum-free media, cells were maintained in serum-free 
conditions and stimulated for 48 hours with: recombinant human TGF beta 1 (10ng/ml), 
recombinant human IL-6 (50ng/ml), or IL-6 (50ng/ml) + recombinant human IL-6R alpha 
(100ng/ml) (R&D Systems). Fresh reagents were added to culture media every 24 hours. Total 
volume per well was 100µl after 48 hours. Cells were then subjected to proliferation analysis 
using the Apo Tox-Glo Triplex Assay kit protocol (Promega, Madison, WI). Briefly, viability 
reagent was added per well and fluorescence was measured after 30 minutes incubation at 37°C.  
To assess effects of IL-6 trans signaling on extracellular matrix protein production, 
CCD8Lu and LL97A cells were seeded in 6-well plates at a density of 1x105 cells/well. They 
were allowed to reach 70-80% confluency, then washed with sterile PBS and serum starved and 
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stimulated as mentioned above. After 48 hours of stimulation, cells were washed with PBS and 
lysed in RIPA lysis buffer supplemented with protease inhibitor cocktail. Protein lysates were 
subjected to western blot analysis (as detailed above) to detect extracellular matrix protein 
production. Typically 5-10µg of protein per sample was loaded. Incubation was performed in 
primary antibodies for collagen 1 (rabbit polyclonal, Abcam, 1:500 dilution, 48 hours, 4°C) and 
fibronectin EDA (mouse monoclonal clone FN 3E2, Sigma-Aldrich, 1:4000 dilution, O/N, 4°C).  
 
STATISTICAL ANALYSIS: 
 Experimental results were reported as mean ± standard error of the mean. One-way 
ANOVA was used for comparisons among groups, and comparisons between groups were 
completed with two-tailed Student’s t-test. Statistical significance for all comparisons were 
presented as p-values. A p value less than 0.05 was considered to be significant.  
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CHAPTER 3 
Interleukin-6 (IL-6)  
Classical and Trans Signaling in  
Idiopathic Pulmonary Fibrosis (IPF) and 
a Chronic Bleomycin Mouse Model  
of Pulmonary Fibrosis 
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EXPERIMENTAL RATIONALE AND KEY QUESTIONS 
Idiopathic pulmonary fibrosis (IPF) is a deadly lung disease that causes chronic, 
progressive, and irreversible fibrosis. IPF is characterized by abnormal wound healing processes 
related to epithelial cell injury and turnover, fibroblast proliferation and differentiation, and 
matrix deposition(2, 104). Most patients experience respiratory decline with resulting respiratory 
failure and death within 2-3 years of diagnosis. There are no known causes for IPF and no cure. 
At this time, there is no consensus on effective therapies though the use of an antifibrotic 
pirfenidone is gaining support(1). The mortality rate for IPF currently surpasses that of many 
malignancies, and over the last 2 decades, prevalence and incidence rates have continued to 
increase(3, 23, 24). Thus, there is an urgent need to better understand the onset and progression 
of pulmonary fibrosis in order to develop effective therapies against IPF.  
The cytokine interleukin 6 (IL-6) is elevated in mice and humans with pulmonary 
fibrosis(29, 31). IL-6 signals through two pathways, classical and trans (Figure 1.1), via a 
receptor complex consisting of the ligand-binding interleukin 6 receptor alpha (IL-6Rα) and the 
non-ligand binding, signal-transducing receptor gp130. While gp130 is expressed constitutively 
as a membrane-bound receptor, membrane-bound IL-6Rα (mIL-6Rα) is expressed predominantly 
on hepatocytes and leukocytes(38, 43-46). IL-6 classical signaling occurs on cells that co-express 
mIL-6Rα and gp130, where IL-6 binds mIL-6Rα and associates with two molecules of gp130 to 
initiate the intracellular signaling cascade. In the alternative pathway, known as trans signaling, 
IL-6 complexes with a soluble form of IL-6Rα (sIL-6Rα) before it can associate with gp130 and 
initiate signaling(38, 43, 44, 48). Soluble IL-6Rα is generated via translation of alternatively 
spliced mRNA or by protease-mediated cleavage of membrane IL-6Rα to form the soluble 
receptor(44, 56-61, 63, 70). In both IL-6 classical and trans signaling, binding of IL-6/IL-6Rα 
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with gp130 activates associated Janus kinases and leads to phosphorylation of signal transducer 
and activator of transcription 3 (STAT3), which dimerizes and translocates to the nucleus where 
it acts as a transcription factor to regulate target genes(49-52). Thus, the presence of phospho-
STAT3 is used as an indication of IL-6-mediated cellular activation.  
Because of the limited expression of membrane IL-6Rα, the presence of soluble IL-6Rα, 
mediating IL-6 trans signaling, allows for activation of cells not inherently responsive to IL-6. 
Thus, soluble IL-6Rα widens the spectrum of IL-6-responsive cells and trans signaling amplifies 
IL-6 effects in the body, leading to important roles in chronic pathological states(44, 71). IL-6 
trans signaling has been implicated in the pathogenesis of rheumatoid arthritis(73), asthma(74), 
inflammatory bowel disease (colitis)(76) and colitis-associated cancer(78). IL-6 and sIL-6Rα 
levels are elevated in association with these diseases, and in vivo blockade of IL-6 trans 
signaling using the natural inhibitor soluble gp130(105, 106) has resulted in amelioration of 
disease(73, 74, 76, 78).  
Though the focus in published literature has been on the pathogenic role of IL-6 trans 
signaling, it must be noted that classical signaling can contribute to disease as well. As evident in 
studies in colitis, where it was demonstrated that IL-6 classical signaling was pathogenic but 
trans signaling amplified those effects and contribute to the propagation of disease(76). Using 
mouse models of arthritis, Lissilaa et al demonstrated that IL-6 trans signaling was responsible 
for local inflammatory reactions but that classical signaling is required to promote T-cell-
mediated autoimmune responses that result in systemic disease(107). In an allergic asthma 
model, Doganci et al demonstrated that sIL-6Rα mediates Th2 functions in T effector cells while 
mIL-6Rα regulates differentiation of naïve CD4+ cells towards Th2 phenotype and suppressing 
Treg development(108). On the other hand, IL-6 classical signaling has been shown to play 
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protective roles in certain human conditions. Hoge et al reported that classical signaling is 
responsible for the innate immunity response to and control of Listeria monocytogenes 
infection(109). The authors concluded that IL-6 trans signaling does not protect against certain 
bacterial infections. Therefore, its blockade may be of more benefit than global blockade of IL-6 
signaling in chronic inflammatory diseases.  
In terms of fibrosis, what is known is that levels of IL-6 and soluble IL-6Rα are elevated 
in systemic sclerosis(83, 110) and liver cirrhosis(81), correlating with disease severity and 
suggesting involvement of IL-6 trans signaling. In the kidneys, heart and skin, IL-6 induction 
promotes collagen production(72, 75, 82). In the lungs, IL-6 is important in airway remodeling in 
asthma(85), induces the conversion of human lung fibroblasts to myofibroblasts(35), and 
promotes pancreatitis-associated lung injury(86). However, the role of IL-6 in pulmonary 
fibrosis was not defined until O’Donoghue et al. demonstrated that IL-6 ablation attenuated 
fibrosis in a bleomycin-induced murine model(87). Pedroza et al demonstrated that IL-6 
contributes to pulmonary fibrosis when they reported that genetic or pharmacologic removal of 
IL-6 resulted in attenuation of fibrosis(29). What is unclear from those studies, however, is the 
differentiation of effects due to IL-6 classical signaling versus IL-6 trans signaling in the lungs.  
Whether fibrosis in IPF patients develops due to effects of IL-6 classical signaling alone 
or trans signaling alone or a mixture of both pathways is unclear. It is important to understand 
this differentiation in order to develop targeted therapies for IPF since current therapies with 
immunosuppressants carry with them many adverse side effects(1, 111, 112). Thus, to begin to 
determine if IL-6 classical and/or trans signaling may be important in the pathogenesis of IPF, it 
was necessary to first assess whether these pathways are enhanced in IPF lungs and characterize 
them more thoroughly by answering the following questions: 
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3.1  Is soluble IL-6Rα increased in patients with Idiopathic Pulmonary Fibrosis? 
3.2  Is soluble IL-6Rα increased in bleomycin-induced pulmonary fibrosis? 
3.3  What happens to soluble IL-6Rα levels as pulmonary fibrosis develops and 
progresses in this model? 
3.4  Is membrane IL-6Rα increased in patients with Idiopathic Pulmonary Fibrosis? 
Which pulmonary cell types exhibit classical signaling in humans? Which ones 
are susceptible to trans signaling?  
3.5 Is there enhanced activation of STAT3 in patients with Idiopathic Pulmonary 
Fibrosis? 
3.6  Is membrane IL-6Rα increased in bleomycin-induced pulmonary fibrosis and 
what happens as fibrosis develops and progresses? 
3.7  Is there enhanced activation of STAT3 in mouse fibrotic lungs? What 
pulmonary cell types exhibit classical signaling? Which ones are targets of 
trans signaling? 
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RESULTS 
3.1 - Soluble IL-6R alpha is elevated in Idiopathic Pulmonary Fibrosis.  
As an initial assessment of whether sIL-6Rα is elevated in fibrotic lungs, we measured its 
levels in the lungs of Idiopathic Pulmonary Fibrosis (IPF) patients, first in bronchoalveolar 
lavage (BAL) fluid, then in parenchymal lung samples. Bronchoalveolar lavage is a procedure 
that involves flushing saline down the airways of the lungs to wash out what is present in the 
airways. It is often performed in IPF patients for diagnostic purposes(1). Parenchymal lung 
samples were obtained from the diseased lungs of patients undergoing lung transplantation 
because of end-stage COPD or IPF.  
ELISA quantification of soluble IL-6Rα was performed in BAL fluid samples from 
different lobes of a single IPF lung. It revealed elevated sIL-6Rα in a fibrotic lobe (IPF LLL) but 
not a non-fibrotic lobe (IPF RML) (Figure 3.1A). Protein lysates were prepared from explanted 
COPD and IPF lung tissues, and ELISA measurement of sIL-6Rα in these samples revealed a 
significant, 4-fold increase in IPF lungs versus COPD lungs (Figure 3.1B). Secondary 
confirmation was achieved with western blot analysis of these samples, probing for expression of 
sIL-6Rα, which revealed increased sIL-6Rα in IPF lungs, visible as a 50 kDa band (Figure 3.1C). 
These findings demonstrate for the first time increased soluble IL-6Rα in IPF, specifically in 
regions of fibrosis, suggesting IL-6 trans signaling may play a role in this disease.  
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Figure 3.1. Soluble IL-6R alpha in Idiopathic Pulmonary Fibrosis (IPF). Soluble IL-6Rα 
expression was assessed in patients with Idiopathic Pulmonary Fibrosis. ELISA quantification of 
sIL-6Rα in (A) BAL fluid from non-fibrotic (RML) and fibrotic (LLL) lobes of an IPF patient, 
and (B) lung lysates from patients with COPD and IPF. (C) Western blot analysis of sIL-6Rα in 
lung lysates from patients with COPD and IPF. Results from A obtained by Mesias Pedroza, 
PhD. All data presented as mean ± SEM, n≥4 for B, n=1 for A. *significant difference from 
COPD; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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To further evaluate the role of soluble IL-6Rα in IPF, we turned to a chronic model of 
fibrosis, the Intraperitoneal Bleomycin (IPB) model (Figure 1.3). In this model, mice are given 
intraperitoneal injections of bleomycin twice weekly for four weeks, which lead to progressive 
development of pulmonary fibrosis(33, 90, 91). This model of chronic bleomycin exposure has 
been demonstrated to recapitulate features of IPF, such as the presence of hyperplastic airway 
epithelial cells and fibrosis that radiates inward from the pleural surfaces and is progressive, 
irreversible and lethal(92, 93).  
 
3.2 - Soluble IL-6R alpha is elevated in bleomycin-induced pulmonary fibrosis.  
To assess expression of sIL-6Rα in this model, protein lysates were made from day 33 
lungs and western blot performed. Soluble IL-6Rα was absent in PBS-injected, non-fibrotic 
lungs but present in bleomycin-exposed, fibrotic lungs (Figure 3.2A). Bands present at 55-65 
kDa represent glycosylated versions of the soluble receptor. BAL fluid samples (which reflect 
the local microenvironment of the bronchoalveolar compartment in the lung) were collected and 
analyzed for presence of the soluble receptor. ELISA measurement of sIL-6Rα in BAL fluid 
demonstrated a significant, 3-fold increase in bleomycin samples in comparison to PBS samples 
(Figure 3.2B). Western blot analysis of sIL-6Rα in BAL fluid confirmed this increase (Figure 
3.2C). ELISA measurement of sIL-6Rα in plasma (which reflects systemic conditions) from 
these mice demonstrated no significant difference between bleomycin and PBS samples (Figure 
3.2D), supporting the hypothesis that the increase in sIL-6Rα is a local occurrence in the lungs.  
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Figure 3.2. Soluble IL-6R alpha in bleomycin-induced pulmonary fibrosis. Soluble IL-6Rα 
expression was assessed in mice with pulmonary fibrosis. (A) Western blot analysis of sIL-6Rα 
in lung lysates, (B & C) ELISA measurement and western blot analysis of sIL-6Rα in 
bronchoalveolar lavage fluid (BAL fluid), and (D) ELISA measurement of sIL-6Rα in plasma 
from wildtype C57Blk/6 mice given saline or bleomycin, day 33. All data presented as mean ± 
SEM, n≥4. *significant difference from PBS-treated cohort; *= p<0.05, **= 0.001<p<0.01, ***= 
p<0.001. 
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Figure 3.3. Soluble IL-6R alpha as disease develops in bleomycin-induced pulmonary 
fibrosis. Soluble IL-6Rα expression was assessed in mice with pulmonary fibrosis. (A) Sircol 
analysis of soluble collagen in BAL fluid over time in a chronic bleomycin mouse model. (B) 
ELISA quantification and (C) western blot analysis of sIL-6Rα in BAL fluid and (D) ELISA 
measurement of sIL-6Rα in plasma during development and progression of pulmonary fibrosis in 
the model. Results from A obtained by Ernestina Melicoff, MD. All data presented as mean ± 
SEM, n≥4. *significant difference from PBS-treated cohort; *= p<0.05, **= 0.001<p<0.01, ***= 
p<0.001. 
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Figure 3.4. Membrane IL-6R alpha expression in human IPF lungs. (A) Western blot 
analysis of mIL-6Rα in lung lysates from explanted COPD and IPF samples. (B) Dual 
immunofluorescence to detect mIL-6Rα on macrophages isolated from IPF patients; CD-206 
(red) = marker of M2 macrophages, human IL-6Rα (green), dapi (blue). (C) Q-rtPCR 
measurement of IL-6Rα transcript in macrophages isolated from BAL fluid of IPF patients and 
in type II pneumocyte cell lines (A549 and MLE-12). (D) Western blot analysis of mIL-6Rα in 
protein lysates from control and IPF fibroblast cell lines (CCD8Lu and LL97A, +/- TGF-β) and 
type II pneumocyte cell lines. Results in B & C obtained by Yang Zhou, PhD. 
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3.3 - Soluble IL-6R alpha increases as pulmonary fibrosis develops and progresses.  
We next asked how sIL-6Rα levels change as pulmonary fibrosis develops and 
progresses. BAL fluid was collected at various time points during the course of the model (days 
5, 10, 15, 20, 25 and 33). Analysis of soluble collagen in BAL fluid revealed progressive 
development of fibrosis in the model, with significant increases in collagen already evident in 
bleomycin lungs by day 5 and the most prominent increase present by day 20 (Figure 3.3A). 
ELISA quantification of the samples showed a temporal increase in sIL-6Rα (Figure 3.3B) that 
mirrors the changes in collagen, which has never been shown before. This pattern was confirmed 
in a second manner by western blot analysis of sIL-6Rα in BAL fluid (Figure 3.3C). ELISA 
quantification of sIL-6Rα in plasma samples revealed no significant difference over the course of 
the model or between PBS and bleomycin samples (Figure 3.3D), again supporting the pattern 
seen in IPF samples of a local increase in sIL-6Rα in fibrotic areas. Collectively, the above 
findings demonstrate an association between increases in soluble IL-6Rα and increasing 
pulmonary fibrosis and suggest a role for the soluble receptor in disease onset and progression. 
 
3.4 – Membrane IL-6R alpha expression is elevated in alveolar macrophages and pulmonary 
fibroblasts from Idiopathic Pulmonary Fibrosis lungs. 
Recognizing that IL-6 classical signaling can play a pivotal role in disease pathogenesis, 
we asked whether the impact of this pathway is detrimental, neutral or protective in IPF. So, we 
proceeded to determine whether or not IL-6 classical signaling was elevated in IPF lungs.  
Protein lysates from explanted COPD and IPF lung tissues were subjected to western blot 
analysis to determine expression of membrane IL-6Rα. Western blotting revealed decreased or 
absent expression of mIL-6Rα in IPF lungs in comparison to COPD lungs (Figure 3.4A). In the 
 69
absence of normal lung lysates for a control, we had to use COPD lung samples as relative 
controls. As such, it is unclear whether this pattern of mIL-6Rα expression in IPF lungs 
represents a deviation from the norm or not. 
Examination of mIL-6Rα expression in specific cell types in the lung yielded more 
informative results. Bronchoalveolar lavage was performed on an IPF patient and alveolar 
macrophages were isolated from BAL fluid. These macrophages underwent immunofluorescence 
staining for detection of macrophage mannose receptor (CD206) and membrane IL-6Rα 
expression. CD206 is a marker of alternatively activated macrophages, or M2 macrophages. M2 
macrophages are found in the lungs of IPF patients and mice with bleomycin-induced pulmonary 
fibrosis and are reported to drive progression of disease(31, 33, 113-117). Immunofluorescence 
staining for CD206 in BAL cells from an IPF patient revealed that these cells were mainly M2 in 
phenotype. Immunofluorescence staining to detect membrane IL-6Rα on these cells 
demonstrated a significant proportion expressed membrane IL-6Rα (Figure 3.4B). Q-rtPCR 
analysis of the isolated macrophages was performed to assess expression of membrane IL-6Rα. 
IL-6Rα transcript was elevated in these macrophages (Figure 3.4C), confirming the increase in 
membrane protein. In comparison, type II airway epithelial cell lines, A549 and MLE-12, 
exhibited very low transcript levels of IL-6Rα  (Figure 3.4C). Western blot analysis of mIL-6Rα 
expression in protein lysates from these cells revealed absence of mIL-6Rα at baseline 
(Figure3.4D). Evaluation of control and IPF fibroblast cell lines (CCD8Lu and LL97A) revealed 
that fibroblasts express mIL-6Rα at baseline (Figure 3.4D). Stimulation of these fibroblasts with 
transforming growth factor beta (TGF-β) induced their differentiation into myofibroblasts, which 
enhanced expression of mIL-6Rα.  
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In all, these studies allowed us to draw 2 conclusions. The first is that M2 macrophages, 
fibroblasts and myofibroblasts are capable of IL-6 classical signaling while type II pneumocytes 
are not. All are still susceptible to trans signaling in the presence of the soluble receptor. The 
second conclusion is that M2 macrophages and fibroblasts and myofibroblasts from fibrotic lungs 
are all potential cellular sources of shedding of mIL-6Rα to produce sIL-6Rα. Though soluble 
IL-6Rα can be generated via translation of alternatively spliced mRNA, protease-mediated 
cleavage of membrane IL-6Rα is largely responsible for the generation of sIL-6Rα(44, 56-61, 63, 
70). Thus these potential cellular sources of sIL-6Rα may prove instrumental in the disease 
process.    
 
3.5 – STAT3 activation is increased in Idiopathic Pulmonary Fibrosis.  
Both IL-6 classical and trans signaling lead to phosphorylation and activation of STAT3, 
which acts as a transcription factor to regulate target genes(49-52). The presence of phospho-
STAT3 is used as an indication of IL-6-mediated cellular activation (Figure 1.1).  
As part of the attempt to further characterize IL-6 signaling in IPF, we assessed activation 
of STAT3 via immunostaining of lung sections from IPF patients and western blot analysis of 
protein lysates from explanted IPF lung samples. Both immunostaining and western blot 
revealed increased P-STAT3 in IPF samples (Figure 3.5A&B). Immunopositivity for P-STAT3 
(brown) was seen in various cell types in IPF lungs, including what appeared morphologically to 
be macrophages, fibroblasts/myofibroblasts and epithelial cells (Figure 3.5A). These results 
suggest that, in IPF lungs, macrophages and fibroblasts/myofibroblasts could have been activated 
either by IL-6 classical and/or trans signaling while type II pneumocytes appear to have been 
influenced by IL-6 trans signaling. 
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Figure 3.5. Activation of Signal Transducer and Activator of Transcription 3 (STAT3) in 
IPF lungs. (A) Immunostaining for phospho-STAT3 in lung sections from COPD and IPF 
patients. Scale bars: 50µm, 100x oil immersion. (B) Western blot analysis of phospho-STAT3 in 
lung lysates from explanted COPD and IPF samples.  
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Figure 3.6. Membrane IL-6R alpha in bleomycin-induced pulmonary fibrosis. Membrane 
IL-6Rα expression was assessed in mice with pulmonary fibrosis. Western blot analysis of mIL-
6Rα in (A) lung lysates, (B) BAL cell lysates and (C) BAL fluid from wildtype C57Bl/6 mice 
given saline or bleomycin, day 33. (D) Western blot analysis of mIL-6Rα in BAL fluid during 
development and progression of pulmonary fibrosis in a chronic bleomycin mouse model. 
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3.6 - Membrane IL-6R alpha is elevated in bleomycin-induced pulmonary fibrosis and 
increases as pulmonary fibrosis develops and progresses. 
Our evaluation of membrane IL-6Rα in IPF lungs indicated variable expression in 
parenchymal tissue but elevation of membrane IL-6Rα was seen in M2 alveolar macrophages. As 
such, we wanted to further understand classical signaling in our mouse model to better 
understand its role in IPF lungs. 
To determine if IL-6 classical signaling was elevated in mouse fibrotic lungs, we 
performed western blot analysis of membrane IL-6Rα was on protein lysates from day 33 PBS 
and bleomycin-exposed mouse lungs. Membrane IL-6Rα expression was present in PBS-
injected, non-fibrotic lungs and enhanced in bleomycin-exposed, fibrotic lungs (Figure 3.6A). 
Western blot analysis of mIL-6Rα in cells washed out of the lung during bronchoalveolar lavage 
revealed miniscule levels in PBS samples and visibly increased expression in bleomycin samples 
(Figure 3.6B). These cells have been shown to be primarily M2 activated macrophages from our 
analysis (Figure 3.4B) and previous studies(33),(31, 113-117). Bronchoalveolar lavage (BAL) 
fluid was collected and analyzed for presence of the membrane receptor in the airways and 
airspaces of the lung. Western blot analysis of mIL-6Rα in BAL fluid demonstrated a significant 
increase in day 33 bleomycin samples in comparison to PBS samples (Figure 3.6C). 
To better understand how mIL-6Rα levels changed over the course of development and 
progression of pulmonary fibrosis, BAL fluid was collected at various time points during the 
course of the model (days 5, 10, 15, 20, 25 and 33). Western blot analysis of the samples showed 
a temporal increase in mIL-6Rα (Figure 3.6D) that mirrors the changes in collagen and sIL-6Rα. 
Collectively, these findings demonstrate an association between increases in membrane IL-6Rα 
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and increasing pulmonary fibrosis and suggest a role for the membrane receptor in disease onset 
and progression in our bleomycin-induced model of pulmonary fibrosis.  
 
3.7 - STAT3 is activated in fibrotic lungs and fibroblasts, myofibroblasts and macrophages are 
capable of classical signaling while type II pneumocytes are not. 
To determine if there was increased IL-6 activity in fibrotic, bleomycin-exposed mouse 
lungs, western blot analysis for expression of phospho-STAT3 was performed in lung lysates 
from day 33 PBS-injected and bleomycin-treated mice. Results revealed an increase in P-STAT3 
in bleomycin lungs in comparison to PBS lungs (Figure 3.7A), suggesting increased IL-6 
signaling. 
To understand where this increased IL-6 signaling is occurring in fibrotic lungs, sections 
were cut from day 33 PBS and bleomycin lungs and immunostained for phospho-STAT3. Day 
33 lungs were positive for P-STAT3 in what appeared morphologically to be 
fibroblasts/myofibroblasts, macrophages and type II airway epithelial cells (AEC) (Figure 3.7B-
E). To confirm, we performed dual staining on these lung sections for co-localization of P-
STAT3 and cell-specific markers, including: arginase 1 (for activated macrophages), pro-
surfactant protein C (for type II pneumocytes), FSP1 (fibroblast specific protein 1 – to identify 
fibroblasts), and α-smooth muscle actin (marker of myofibroblasts). Dual staining revealed 
activation of STAT3 in fibroblasts, myofibroblasts, type II pneumocytes and activated 
macrophages in bleomycin lungs (Figure 3.7B-E). These findings validate what was observed in 
IPF samples, confirming that these cell types in fibrotic lungs are responsive to IL-6 signaling. 
Whether activation of STAT3 in these cells, in IPF lungs as well as bleomycin-exposed lungs, 
was due to IL-6 classical or trans signaling or both remain to be determined.  
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Figure 3.7. STAT3 activation and membrane IL-6R alpha expression in pulmonary cell 
types. (A) Western blot analysis of phospho-STAT3 in whole lung lysates from wildtype 
C57Blk/6 mice given saline or bleomycin, Day 33. (B-E) Day 33 lung sections from control and 
bleomycin-exposed mice were immunostained for P-STAT3 alone  and P-STAT3 dual stains 
with cell-specific markers for pulmonary myofibroblasts, fibroblasts, type II pneumocytes, and 
macrophages. Arrows denote dual-positive cells. Images are representative of n≥4 animals from 
each group. Scale bars: 50µm, 100x oil immersion.  
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Collectively, the experiments in sections 3.5-3.7 helped delineate cell types susceptible to 
classical versus trans signaling and identified potential cellular sources of generation of soluble 
IL-6Rα in the fibrotic lung, key processes that regulate pulmonary fibrosis. 
 
DISCUSSION 
The experiments presented in this chapter were designed to characterize IL-6 classical 
and trans signaling pathways and their activation during onset and progression of pulmonary 
fibrosis in order to assess the significance of each pathway, particularly trans pathway.  
Soluble IL-6Rα (sIL-6Rα) is a key feature of IL-6 signaling and a crucial component in 
the regulation of IL-6 responses. Soluble IL-6Rα acts agonistically in vivo to either enhance IL-6 
signaling on cells already expressing membrane IL-6Rα or render cells lacking mIL-6Rα 
susceptible to the effects of IL-6 signaling(44, 71). Elevations of sIL-6Rα have previously been 
demonstrated in a number of human diseases(73, 74, 76, 78) but not in IPF.  
A major observation in this study was that soluble IL-6Rα is elevated in IPF lungs and in 
mice with established pulmonary fibrosis (Figures 3.1&3.2), indicating its production and 
presence may play a role in the disease process. This is in agreement with previous studies that 
have demonstrated elevations in sIL-6Rα in established disease states(73, 74, 76, 78, 81, 110). 
Ours, however, is the first to show that sIL-6Rα levels in the lungs increased in a temporal 
pattern associated with the development and progression of pulmonary fibrosis in a mouse model 
(Figure 3.3). This suggests involvement of IL-6 trans signaling in onset and progression of 
pulmonary fibrosis. This knowledge raises the possibility of sIL-6Rα serving as a marker of 
staging disease severity and progression. It also supports the concept of sIL-6Rα as a potential 
target for therapeutic neutralization in pulmonary fibrosis. Interestingly, there is evidence that the 
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increase in soluble IL-6Rα in IPF is a local occurrence, only seen in a fibrotic area of the lung 
(Figure 3.1A). This data was supported by our mouse model findings and would suggest that 
sIL-6Rα could be used as a diagnostic marker, perhaps in localizing sites of active fibrosis. It 
may also serve prognostic values. Further investigation of soluble IL-6Rα in more IPF lavage 
and lung samples from fibrotic and non-fibrotic lobes is needed to validate these initial human 
sample findings. 
To thoroughly understand the molecular mechanisms involved in regulating pulmonary 
fibrosis, we also characterized the presence of IL-6 classical signaling in IPF lungs and 
bleomycin-exposed, fibrotic mouse lungs by evaluating mIL-6Rα expression. We have seen 
variable mIL-6Rα expression in IPF lung samples (Figure 3.4A). Due to lack of normal lung 
samples for negative controls, we have had to make our comparisons of IPF findings relative to 
those in COPD. As such, our conclusions with regards to mIL-6Rα expression in IPF lung 
lysates are reported cautiously and we are aware further evaluation is necessary. In the IPB 
mouse model, however, IL-6 classical signaling appears enhanced as evident by elevated 
membrane IL-6Rα expression in whole lung protein lysates in comparison to PBS lungs (Figure 
3.6). This begs the question of how much our findings about IL-6 classical signaling in the IPB 
model will translate to the human disease. We did, however, determine that there is increased 
STAT3 activation (indicative of increased IL-6 signaling) in both IPF and bleomycin-exposed 
lungs (Figures 3.5&3.7). Further analysis, with normal lung for negative controls, is needed in 
more whole lung human IPF samples to determine if mIL-6Rα is elevated or not in IPF.  
Despite tentative conclusions about mIL-6Rα expression in parenchymal IPF samples, 
examination of classical signaling in specific cell types revealed some interesting data. Our 
studies clearly indicate that IL-6 classical signaling is enhanced in the bronchoalveolar 
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compartment of IPF lungs, specifically in M2 alveolar macrophages. This finding is in agreement 
with Matsumoto et al, who reported increased mIL-6Rα expression in colonic macrophages in 
colitis-affected tissue (78). In our study, we were able to show augmented mIL-6Rα expression 
in macrophages collected via bronchoalveolar lavage of IPF lungs (Figure 3.4B). To our 
knowledge, this is the first study to illustrate elevations in mIL-6Rα in M2 alveolar macrophages 
from IPF patients. This observation of enhanced mIL-6Rα in M2 macrophages was confirmed in 
the IPB model, where membrane IL-6Rα expression was elevated in BAL cell lysates in 
comparison to PBS lungs (Figure 3.6). We know from the literature that M2 alveolar 
macrophages are implicated in pulmonary fibrosis(31, 113-117). Thus, it is of interest to assess 
what role, if any, membrane IL-6Rα (and therefore IL-6 classical signaling) plays in regulating 
the phenotype and actions of these macrophages. The finding of increased mIL-6Rα expression 
in M2 macrophages informs us that these cells are capable of classical and trans signaling and 
that they may serve as a potential source of shedding to produce the soluble IL-6Rα. Membrane 
IL-6Rα has been shown to be shed from cell surfaces of peripheral monocytes, bronchial 
epithelia cells, hepatocytes, neutrophils and T cells(38, 59, 61-64). Future experiments are 
needed to determine if M2 macrophages do shed their membrane IL-6Rα to generate soluble IL-
6Rα in fibrotic lungs. If they do, it would support a pathogenic role for these cells in pulmonary 
fibrosis. 
We also evaluated mIL-6Rα expression in fibroblasts, myofibroblasts and type II 
pneumocytes. Current understanding of the pathogenesis of IPF identifies two cellular targets as 
key players in disease initiation and progression – fibroblasts and epithelial cells(118, 119).  
Epithelial injury and dysregulated regeneration is thought to initiate disease(118) while aberrant 
fibroblast activation, differentiation into myofibroblasts, and excessive collagen and fibronectin 
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production and deposition in the lungs propagate the problem(2). Our study provides further 
insight into the characterization of these cells in disease. We found that fibroblasts and 
myofibroblasts are capable of IL-6 classical signaling while type II pneumocytes are not. All are 
still susceptible to trans signaling in the presence of the soluble receptor. Our data indicate that 
fibroblasts and myofibroblasts from fibrotic lungs express more mIL-6Rα than those from 
normal lungs, so they are also potential cellular sources of shedding of mIL-6Rα to produce sIL-
6Rα. Further examination is required to understand the impact of IL-6 classical and trans 
signaling in these individual cells. 
Collectively, the findings in this aim illustrate the existence of IL-6 trans signaling in IPF 
lungs and bleomycin-induced fibrotic mouse lungs. They demonstrate that soluble IL-6Rα is 
present and increases in association with pulmonary fibrosis and expression of membrane IL-
6Rα is elevated in fibrosis. This suggests that IL-6 classical signaling is enhanced and trans 
signaling is involved in the disease process in fibrotic lungs. Thus, there is a need to characterize 
the generation of soluble IL-6Rα in fibrotic lungs (Chapter 4) and to assess the role of IL-6 trans 
signaling in pulmonary fibrosis (Chapter 5). Chapter 4 will examine the role of protease-
mediated generation of sIL-6Rα and Chapter 5 will evaluate the effects of in vivo neutralization 
of IL-6 trans signaling.  
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CHAPTER 4 
ADAM17 Sheds Interleukin-6 Receptor 
Alpha (IL-6Rα) in a Chronic Bleomycin 
Murine Model of Pulmonary Fibrosis 
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EXPERIMENTAL RATIONALE AND KEY QUESTIONS 
From experiments presented in the last chapter characterizing IL-6 trans signaling in 
pulmonary fibrosis, we know that soluble IL-6Rα is expressed in fibrotic lungs and increases in 
association with increasing fibrosis. This points to a role for sIL-6Rα in pulmonary fibrosis and 
emphasizes a need to evaluate the mechanism of its generation. 
Soluble IL-6Rα is generated largely through protease-mediated cleavage of membrane-
bound IL-6Rα(44, 58, 70) (Figure 1.2). ADAM17 (A Disintegrin and Metaolloproteinase 17) is a 
membrane-bound metalloprotease belonging to the ADAM (a disintegrin and metalloproteinase) 
family that is responsible for cleaving cell surface proteins. ADAM17 has been implicated as the 
main protease responsible for shedding IL-6Rα from cell membrane surfaces of hepatocytes, 
peripheral monocytes, neutrophils and T cells(38, 59, 61-63). Increased levels of this protease 
have been found in association with diseases that have reported increased sIL-6Rα levels(66-69). 
A related protease, ADAM10, has been implicated in constitutive shedding of IL-6Rα, while 
ADAM17 is better known for rapid, inducible shedding(38, 61). The roles of both ADAM17 and 
ADAM10 in shedding IL-6Rα in fibrotic lungs have not been examined.  
In an initial attempt to determine whether or not the generation of soluble IL-6Rα in 
fibrotic lungs involves the actions of ADAM17 and ADAM10, transcript levels of these 
proteases were assessed in mice with adenosine-mediated (ADA-/-) or bleomycin-mediated 
pulmonary fibrosis. Microarray analysis of lungs from these mice was conducted, and results 
revealed a significant increase in ADAM17 and ADAM10 transcript in fibrotic lungs (Figure 
4.0). This data suggested that these proteases may mediate IL-6Rα shedding and prompted us to 
look more closely at this mechanism in pulmonary fibrosis.     
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Figure 4.0. ADAM10 and ADAM17 transcripts in murine models of pulmonary fibrosis. 
Microarray analysis of (A) ADAM10 and (B) ADAM17 transcripts using mRNA isolated from 
lungs of ADA+/- and ADA-/- mice (day 42) and wild type C57Blk6 mice after exposure to saline 
or bleomycin (day 21). Results presented as mean fold increases ± SEM, n=3. *significant 
difference from ADA+/- or saline. Data provided by Tingting Weng, PhD.  
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Given the preliminary microarray results, we set out to test the hypothesis that protease-
mediated shedding is the main mechanism of generation of soluble IL-6Rα in fibrotic lungs. In 
particular, we were interested in the role of ADAM17 in the process and wanted to answer the 
following questions: 
4.1  Is ADAM17 elevated in bleomycin-induced pulmonary fibrosis? 
4.2  What happens to ADAM17 expression as pulmonary fibrosis develops 
and progresses? 
4.3-4.4  Can ADAM17 shed IL-6Rα from membranes of bone-marrow-derived 
macrophages? Can this process be blocked by pharmacologic inhibitors 
or small interfering RNA? 
4.5  Can ADAM17 shed IL-6Rα from membranes of primary alveolar 
macrophages from fibrotic lungs? 
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RESULTS 
4.1 - ADAM17 is increased in bleomycin-induced pulmonary fibrosis.  
To assess the underlying mechanism of soluble IL-6Rα production in fibrotic lungs, we 
explored the role of the proteases ADAM 17 and ADAM 10 in cleaving membrane IL-6Rα to 
produce the soluble IL-6 receptor. To determine whether these proteases are elevated in 
pulmonary fibrosis, we evaluated their expression in the IPB model. Protein lysates were made 
from day 33 lungs, a stage when fibrosis was prominent, and western blotting was performed. 
Immature (130 kDa) and mature (93 kDa) forms of ADAM17 were increased in bleomycin-
exposed, fibrotic lungs in comparison to PBS-exposed, non-fibrotic lungs (Figure 4.1A). No 
difference in ADAM10 expression was observed between bleomycin and PBS lungs (Figure 
4.1B). Thus we focused our efforts on further characterizing ADAM17 expression.  
Bronchoaveolar lavage (BAL) was performed in day 33 PBS and bleomycin-exposed 
mice. BAL fluid was analyzed for presence of ADAM17 in the bronchoalveolar compartment of 
the lung. Western blot analysis detected an increase in mature ADAM17 in bleomycin samples 
(Figure 4.1C). Immature ADAM17 was absent in PBS samples but present in bleomycin 
samples, indicating increased production of ADAM17. Immunostaining of lung sections from 
day 33 lungs revealed the most prominent increase of ADAM17 was in alveolar macrophages of 
bleomycin-exposed lungs (Figure 4.1D). This observation, in combination with results presented 
in the last chapter on expression of membrane and soluble IL-6Rα in IPF and bleomycin-induced 
fibrotic lungs, further supports the hypothesis that ADAM17 is responsible for generating the 
soluble IL-6 receptor in fibrotic lungs.  
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Figure 4.1. ADAM17 expression in bleomycin-induced pulmonary fibrosis. Expression of 
the protease ADAM17 was evaluated in mice with pulmonary fibrosis. Western blot analysis of 
(A) immature (130 kDa) and mature (89 kDa) forms of ADAM17  and (B) ADAM10 in lung 
lysates from wildtype C57Bl/6 mice given saline or bleomycin, day 33. (C) Western blot 
analysis of bronchoalveolar lavage fluid from day 33 mice. (D) Immunostaining for ADAM17 
(brown) in the lungs of day 33 mice. Arrows denote positive cells. Images are representative of 
n≥4 animals from each group. Scale bars: 50µm, 100x oil immersion. (E) Immunofluorescence 
staining for membrane IL-6R alpha (green) and DAPI (blue) on BAL fluid cells. Arrows denote 
positive cells. Images are representative of n≥4 animals from each group, 20x magnification.  
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We know that macrophages isolated from IPF lungs expressed abundant mIL-6Rα 
(Figure 3.4B). We also saw that sIL-6Rα was increased in the bronchoalveolar compartment of 
fibrotic lungs (Figure 3.1 and 3.2B&C), suggesting that that might be where the soluble receptor 
was generated. In the last chapter, we reported increased expression of mIL-6Rα in BAL cells 
lavaged out of bleomycin-exposed lungs (Figure 3.6B). These cells are comprised mainly of 
alveolar macrophages but also include lymphocytes, neutrophils and eosinophils(33). The fact 
that there was an increase in ADAM17 in alveolar macrophages and these macrophages also 
expressed more membrane IL-6Rα than normal raise the possibility of ADAM17 acting in these 
cells to shed their membrane IL-6Rα to generate soluble IL-6Rα. 
To provide secondary confirmation of the increase in mIL-6Rα in BAL macrophages 
seen on western blot analysis (Figure 3.6B), we isolated alveolar macrophages from day 33 
bleomycin-exposed mouse lungs using bronchoalveolar lavage. The cells cytospun onto 
microscope slides and subjected to immunofluorescence staining for membrane IL-6Rα. It was 
evident that macrophages from day 33 bleomycin lungs had abundant expression of membrane 
IL-6Rα (Figure 4.1E). These findings confirm physical proximity of mature ADAM17 and 
membrane IL-6Rα to suggest a role for ADAM17 in shedding the membrane receptor.  
 
4.2 - ADAM17 is increased in association with increasing soluble IL-6R alpha and alveolar 
macrophages in fibrotic lungs.  
Further characterization of ADAM17 expression during the onset and development of 
fibrosis was achieved via western blot analysis of BAL fluid samples collected throughout the 
duration of the IPB model (days 5, 10, 15, 20, 25, and 33). Results indicated a temporal increase 
in ADAM17 expression (Figure 4.2A) that mirrored the increase in sIL-6Rα as pulmonary 
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fibrosis developed and progressed (Figure 3.3C). Specifically, just as sIL-6Rα became prominent 
in BAL fluid in day 20 samples, mature ADAM17 also started increasing with day 20 samples. 
Immature ADAM17 was absent in samples from the first 15 days of the model but appeared in 
BAL fluid samples from day 20. These results further strengthened our suspicions that ADAM17 
is involved in generation of the soluble IL-6 receptor in fibrotic lungs. 
Since our data had been pointing to the alveolar macrophage as the source of shedding, 
we wanted to determine if there was a temporal increase in alveolar macrophages in fibrotic 
lungs that would explain the temporal increase in ADAM17 in the bronchoalveolar 
compartment. Using BAL fluid samples collected throughout the duration of the IPB model from 
PBS and bleomycin mice, total BAL cell count was determined and cellular differentials 
performed. In comparison to total BAL cells from PBS-injected, non-fibrotic lungs, total cells 
from bleomycin-exposed, fibrotic lungs rose over time, starting with significant changes on day 
20 (Figure 4.2B). Total BAL cells in bleomycin-exposed lungs dropped between day 25 and 33 
but were still significantly different from those of PBS-exposed lungs. Analysis of cell 
differentials revealed that the number of BAL macrophages in these lungs also began increasing 
significantly on day 20, with maximum macrophage numbers in day 25 samples and a drop in 
numbers by day 33, though still significantly higher in comparison to controls (Figure 4.3C).  
Collectively, these findings demonstrate an association between increases in alveolar 
macrophages and ADAM17 and increases in soluble IL-6Rα in fibrotic lungs, suggesting that 
ADAM17 activation in alveolar macrophages of fibrotic lungs induces shedding of membrane 
IL-6Rα to produce soluble IL-6Rα. 
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Figure 4.2. ADAM17 expression and alveolar macrophage accumulation in bleomycin-
induced pulmonary fibrosis. (A) Western blot analysis of ADAM17 in BAL fluid samples over 
the course of the model, as pulmonary fibrosis develops and progresses secondary to chronic 
bleomycin exposure. (B&C) Total BAL cell and BAL macrophages in samples at various points 
during model. Data presented as mean ± SEM, n≥4. *significant difference from PBS-treated 
cohort. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. Data from B-C obtained by Tina Melicoff, 
MD, Tingting Weng, PhD and Harry Karmouty-Quintana, PhD.  
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4.3-4.5 – ADAM17 mediates shedding of IL-6R alpha from bone marrow derived M2 activated 
macrophage membranes.  
Given the previous data, we suspected that the generation of sIL-6Rα revolved around the 
alveolar macrophages in fibrotic lungs that co-express high levels of ADAM17 and mIL-6Rα. 
Alveolar macrophages found in the lungs of IPF patients and mice with bleomycin-induced 
pulmonary fibrosis are primarily M2 in phenotype and are reported to drive progression of 
disease(31, 113-117). We asked whether we could replicate the in vivo conditions using an in 
vitro cell system and show that activation of ADAM17 in M2 macrophages induces shedding of 
membrane IL-6Rα to increase production of soluble IL-6Rα.  
To generate M2 macrophages in vitro, we used the protocol detailed in Figure 4.3A 
(courtesy of Dr. Sandeep Agarwal’s laboratory). We isolated bone marrow cells from wild-type 
C57Blk6 mice and differentiated them into macrophages in culture. Macrophages were then 
stimulated with interleukin-4 (IL-4) and interleukin-13 (IL-13). These cytokines were reported to 
be important in the lung and their use in various studies has led to successful differentiation of 
macrophages to the M2 phenotype(120-123). Arginase 1 is a marker of M2 macrophages, and its 
expression after stimulation has been reported to be an indicator of successful 
differentiation(114, 120, 122, 123). Western blot analysis of protein lysates from IL-4/IL-13-
stimulated macrophages revealed more arginase 1 expression than in unstimulated macrophages 
(Figure 4.3B), suggesting they are M2 in phenotype.  
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Figure 4.3. In vitro culture and differentiation of bone marrow derived cells into M2 
macrophages. (A) Experimental protocol for generating bone marrow derived M2 macrophages. 
Bone marrow cells were isolated from the femurs of wild-type C57Blk6 mice and cultured in 
supplemented media for 1 week to induce macrophage development. After 1 week in culture, 
adherent macrophages were collected and replated then stimulated with IL-4 and IL-13 for 3 
days to polarize their differentiation into M2 macrophages. (B) Western blot analysis of 
membrane IL-6Rα and arginase 1 expression in bone marrow-derived macrophages stimulated 
with IL-4 and IL-13.  
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Figure 4.4. Generation of soluble IL-6Rα following pharmacologic neutralization of 
ADAM17 activity in bone marrow derived M2 macrophages. (A) Bone-marrow-derived M2 
macrophages were either stimulated with PMA alone or pre-incubated with TAPI-1 and 
stimulated with PMA in the presence of TAPI-1. Culture media and cell lysates were collected 
after 2 hours. (B) ELISA measurement of soluble IL-6Rα in culture media of macrophages 
stimulated with PMA, with and without TAPI-1. All data presented as mean ± SEM, n≥6. 
*significant difference from media only cohort; #significant difference from PMA-stimulated 
cohort;  *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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Figure 4.5. Generation of soluble IL-6Rα following siRNA-mediated silencing of ADAM17 
activity in bone marrow derived macrophages. (A) Bone-marrow-derived macrophages were 
stimulated with IL-4 and IL-13 and transfected with control or ADAM17 siRNA. Macrophages 
are then stimulated with PMA. Culture media and cell lysates were collected after 2 hours. (B) 
Western blot analysis of ADAM17 in protein lysates of transfected macrophages. (C) ELISA 
measurement of sIL-6Rα in culture media of macrophages transfected with control or ADAM17 
siRNA and then stimulated with PMA. All data presented as mean ± SEM, n≥6. *significant 
difference from media only cohort; #significant difference from PMA-stimulated cohort;  *= 
p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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Next, we evaluated mIL-6Rα expression in the M2 macrophages to see if the membrane 
receptor is present to be cleaved. Western blot analysis showed more mIL-6Rα in IL-4/IL-13 
stimulated macrophages than unstimulated macrophages (Figure 4.3B). The characteristics of 
augmented ADAM17 and mIL-6Rα expression in our bone marrow derived M2 macrophages 
mimicked those seen in alveolar macrophages isolated from IPF patients and fibrotic murine 
lungs (Figure 3.4B & 3.5B). Thus, we proceeded to use these cells in our shedding experiments.  
The experimental protocols are illustrated in Figures 4.4A and 4.5A. The experiments 
involved using a phorbol ester to activate ADAM17 in bone marrow derived M2 macrophages in 
order to induce shedding of IL-6R. Then, to support ADAM17’s role in shedding, we blocked 
ADAM17 activity in the cells using a pharmacologic inhibitor or siRNA and observed changes 
to sIL-6Rα generation in response to phorbol ester stimulation. 
The reagent phorbol 12-myrstate 13-acetate (PMA) is known to activate ADAM17-
mediated shedding of membrane IL-6Rα(65, 124). IL-4/IL-13-stimulated macrophages were 
incubated with PMA to activate ADAM17 and induce shedding. To assess shedding efficiency, 
culture media was collected and sIL-6Rα was quantified using ELISA. PMA activation of 
ADAM17 led to a significant, 4-fold increase in soluble IL-6Rα in the culture media (Figure 
4.4B), suggesting that ADAM17 is responsible for the increase in shedding.  
To further support the role of ADAM17 in this process, we assessed whether blocking 
ADAM17 would alter the extent of shedding. We first attempted to block ADAM17 activity 
pharmacologically using TAPI-1, a non-selective inhibitor of ADAM proteases(59, 124) (Figure 
4.4A). Addition of TAPI-1 to macrophages without PMA stimulation was able to significantly 
suppress baseline shedding; pre-incubation of macrophages with TAPI-1 resulted in inhibition of 
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sIL-6Rα release into the media with PMA stimulation (Figure 4.4B). These results demonstrated 
that ADAM17 mediated shedding of IL-6Rα from M2 macrophages to generate sIL-6Rα.  
We confirmed these results using a second, more specific method of neutralizing 
ADAM17 activity. Bone marrow derived M2 macrophages were transfected with ADAM17 
siRNA(69) to silence ADAM17 (Figure 4.5A). Successful silencing was confirmed by western 
blot analysis showing reduced expression of ADAM17 (Figure 4.5B). Macrophages were then 
stimulated with PMA. There was a 4-fold increase in release of sIL-6Rα from non-transfected 
macrophages and macrophages transfected with control siRNA. There was significant reduction 
in release of sIL-6Rα from macrophages transfected with ADAM17 siRNA (Figure 4.5B). 
Collectively, these findings support our hypothesis that ADAM17 activation in M2 macrophages 
induces shedding of membrane IL-6Rα to increase production of sIL-6Rα in pulmonary fibrosis.  
 
4.6 - ADAM17 promotes shedding of IL-6R alpha from alveolar macrophages collected from 
bleomycin-induced fibrotic lungs.  
To more accurately reflect what happens in active pulmonary fibrosis, we repeated the 
above experiments, this time using primary alveolar macrophages isolated from day 33 mice 
treated with PBS or bleomycin. Lungs were thoroughly lavaged (10-12 times) to ensure 
evacuation of the majority of alveolar macrophages present in the bronchoalveolar compartment. 
There were significantly more cells collected from bleomcyin-exposed lungs than PBS lungs, 
consistent with our previous characterization studies, which showed higher total cell counts in 
BAL fluid, indicative of enhanced levels of pulmonary inflammation in bleomycin-exposed mice 
(Figure 4.2B). Cells collected in BAL fluid were then cultured for 4 hours in tissue culture plates 
to allow for adherence of alveolar macrophages. All other non-adherent cells were washed away 
 95
at the end of the incubation period. Adherent macrophages were then used in shedding 
experiments.  
PMA-induced activation of ADAM17 in primary alveolar macrophages from PBS lungs 
induced an increase in soluble IL-6Rα in culture media (Figure 4.6). Pre-incubation with TAPI-1 
reduced levels of released sIL-6Rα to below detection threshold. PMA stimulation of ADAM17 
in macrophages from bleomycin lungs resulted in a 2-fold increase in sIL-6Rα in culture media 
(Figure 4.6). Pre-incubation with TAPI-1 reduced levels of released sIL-6Rα to baseline levels. 
This experiment validated findings from experiments with bone marrow derived M2 
macrophages and revealed that ADAM17 can shed IL-6R from primary alveolar macrophages. 
Overall, the results of our shedding experiments, both in bone marrow derived M2 
macrophages and in primary alveolar macrophages from fibrotic mouse lungs have supported a 
role for ADAM17 in shedding membrane IL-6Rα to generate soluble IL-6Rα in fibrotic lungs. 
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Figure 4.6. Generation of soluble IL-6Rα following pharmacologic inhibition of ADAM17 
activity in primary alveolar macrophages. Primary alveolar macrophages were isolated from 
the lungs of day 33 PBS and bleomycin-exposed mice. Macrophages were stimulated with PMA 
in the presence or absence of TAPI-1. ELISA measurement of soluble IL-6Rα in culture media 
was performed. All data presented as mean ± SEM, n=1 for PBS and n=3 for bleomycin. 
*significant difference from media only cohort; #significant difference from PMA-stimulated 
cohort;  *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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DISCUSSION 
The experimental results presented in this chapter suggest that generation of sIL-6Rα in 
pulmonary fibrosis is due to cleavage of membrane IL-6Rα from activated pulmonary 
macrophages via the action of the protease ADAM17.  
A major finding in this study is that ADAM17 expression was elevated in alveolar 
macrophages from bleomycin-induced, fibrotic mouse lungs (Figure 4.1). Lee et al have 
previously demonstrated increased ADAM17 expression in mice with acute lung injury in 
response to intratracheal bleomycin instillation(125). Our finding of increased ADAM17 in a 
chronic model of intraperitoneally-instilled bleomycin agrees with their results.  
To our knowledge, however, this is the first study to report a temporal increase in 
ADAM17 expression as pulmonary fibrosis develops and progresses. This pattern of increase in 
ADAM17 is associated with an increasing accumulation of alveolar macrophages in the lung 
(Figure 4.3) and a progressively increasing level of soluble IL-6Rα (Figure 3.3). The coordinated 
changes in ADAM17, alveolar macrophages and sIL-6Rα all support the hypothesis that 
increased activation of ADAM17 in alveolar macrophages of fibrotic lungs results in shedding of 
IL-6Rα to increase production of sIL-6Rα. Indeed, our in vitro experiments with bone marrow 
derived M2 macrophages and primary M2 alveolar macrophages confirmed the role of ADAM17. 
Activation of ADAM17 in these macrophages led to shedding and increases generation of sIL-
6Rα. Inhibition of ADAM17, both with a pharmacologic inhibitor and with ADAM17 siRNA, 
resulted in inhibition of shedding and a reduction in amounts of sIL-6Rα. 
As mentioned in Chapter 3, fibrosis is progressive in the IPB model (Figure 3.3A). Our 
findings presented in this chapter suggest a mechanism for the progressive nature of fibrosis in 
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the model. Augmented ADAM17-mediated generation of sIL-6Rα could be the mechanism by 
which sIL-6Rα accumulates in the lung over time, causing progressively increasing fibrosis.  
This finding is provocative in that it begs the question of ADAM17-targeted therapies in 
alleviating lung fibrosis. It also suggests a mechanism for the contribution of activated 
macrophages to pulmonary fibrosis and raises the possibility of targeting this potentially pivotal 
player in disease. ADAM17 could also be used as an important indicator of the progression of 
pulmonary fibrosis. It must be noted, however, that Garbers et al have argued that ADAM17 is 
the main protease responsible for cleavage of mIL-6Rα in humans, but that in mice, ADAM10 is 
primarily responsible(126). We do not deny that ADAM10 may be able to cleave mIL-6Rα; 
however, we have not been able to demonstrate an increase in ADAM10 in fibrotic murine lungs 
(Figure 4.1B). Our in vitro experiments with stimulation and neutralization of ADAM17 in 
macrophages have led us to conclude that ADAM17 is responsible for the generation of sIL-6Rα 
in our mouse model of chronic bleomycin exposure.  
In summary, the experiments conducted in this chapter demonstrated a temporal pattern 
of increasing ADAM17 expression in association with increasing pulmonary fibrosis and 
increasing levels of soluble IL-6Rα. Our stimulation and neutralization experiments supported a 
role for ADAM17 in shedding IL-6Rα from the membrane of activated pulmonary macrophages 
in order to increase production of soluble IL-6Rα in fibrotic lungs. The data presented in Chapter 
3 and this chapter have provided sufficient evidence and the rationale needed to propose in vivo 
neutralization of soluble IL-6Rα and resulting antagonism of IL-6 trans signaling in the IPB 
model to determine whether or not therapeutic benefits could be achieved. The results of in vivo 
neutralization of IL-6 trans signaling will be presented in the next chapter.  
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CHAPTER 5 
In Vivo Neutralization of  
Interleukin-6 (IL-6) Trans Signaling in a  
Chronic Bleomycin Murine Model  
of Pulmonary Fibrosis 
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EXPERIMENTAL RATIONALE AND KEY QUESTIONS 
In the previous two chapters, we have demonstrated that soluble IL-6Rα was elevated in 
association with pulmonary fibrosis as a result of ADAM17-mediated cleavage of the membrane 
receptor. We have also provided evidence to suggest that IL-6 trans signaling is associated with 
increasing severity of disease. The role of IL-6 trans signaling in Idiopathic Pulmonary Fibrosis, 
however, is unknown.  
IL-6 trans signaling via the soluble receptor has been implicated in the pathogenesis of 
rheumatoid arthritis(73), asthma(74), inflammatory bowel disease (colitis)(76) and colitis-
associated cancer(78). In pulmonary fibrosis, O’Donoghue et al. and Pedroza et al demonstrated 
that IL-6 ablation attenuated fibrosis in bleomycin-induced murine models(29, 87). What is not 
known from their work is the differentiation between the contribution of IL-6 classical versus 
trans signaling with regards to the development and progression of pulmonary fibrosis. It is with 
the intention of filling this gap in knowledge that the experiments in this chapter were designed. 
This chapter will emphasize the importance of IL-6 trans signaling by evaluating 
potential benefits of blocking this signaling pathway in vivo in a murine model of pulmonary 
fibrosis. So how is specific blockade of IL-6 trans signaling in vivo achieved? The answer lies 
with soluble gp130. As previously mentioned, the receptor protein gp130 is constitutively 
expressed in cell membranes and serves the function of signal transduction for various cytokines, 
including interleukin 6. Soluble forms of gp130 (sgp130) have been identified in human serum 
and urine(127, 128). Since the initial discovery, soluble gp130 has been shown to be a natural 
inhibitor of IL-6 trans signaling(105, 106) and a number of studies have employed its use as a 
mean of specifically blocking IL-6 trans signaling in vivo.  
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In various animal models of disease, the use of soluble gp130 has resulted in amelioration 
of disease states. In vivo neutralization of IL-6 trans signaling resulted in suppression of colitis in 
an experimental mouse model(76), lessened disease in a mouse experimental arthritis model(79), 
and resulted in clinical improvement in a systemic arthritis model(80). Blocking IL-6 trans 
signaling resulted in improvement in survival in a mouse sepsis model(77) and reduced colitis-
associated premalignant cancer (CApC) in a mouse model(78). Specifically targeting IL-6 trans 
signaling in vivo reduced ascites formation and enhanced the sensitivity of ovarian tumors to 
chemotherapy(103).  
Given the successful precedent of using soluble gp130 to neutralize IL-6 trans signaling 
in vivo in other disease models, we used a similar approach to assess the impact of IL-6 trans 
signaling in pulmonary fibrosis and answered the following key questions: 
5.1-5.2 Is recombinant gp130Fc able to neutralize IL-6 trans signaling in vivo? 
5.3-5.4 Does recombinant gp130Fc treatment attenuate pulmonary inflammation? 
5.5-5.8 Does recombinant gp130Fc treatment attenuate pulmonary fibrosis? 
5.9  Does recombinant gp130Fc treatment improve oxygen saturation? 
5.10 Does recombinant gp130Fc treatment reduce pulmonary hypertension? 
5.11 Does recombinant gp130Fc treatment decrease activation of STAT3? 
5.12-18 Does IL-6 trans signaling affect fibroblast proliferation, apoptosis and 
extracellular matrix protein production in vitro? If so, will recombinant 
gp130Fc inhibit the effects in vitro? 
5.19 Does recombinant gp130Fc administration affect in vivo IL-6 classical 
signaling? 
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Figure 5.1. In vivo neutralization of soluble IL-6Rα using mouse recombinant gp130Fc in a 
mouse model of chronic bleomycin exposure. (A) Illustration of the mechanism of action of 
mouse recombinant gp130Fc on neutralization of sIL-6Rα. (B) Experimental setup for in vivo 
neutralization of sIL-6Rα in the Intraperitoneal Bleomycin murine model of pulmonary fibrosis. 
Wildtype C57Blk6 male mice were injected intraperitoneally with saline or bleomycin twice 
weekly for 4 weeks. Beginning on day 19, when pulmonary fibrosis has been established, daily 
treatment with vehicle (saline) or recombinant gp130Fc was performed. Arterial oxygen 
saturation measurements were performed on live, shaved mice on day 32. Mice were sacrificed 
and samples collected on day 33.  
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Figure 5.2. Soluble IL-6Rα and IL-6 following chronic bleomycin exposure in mice treated 
with recombinant gp130Fc in a mouse model of chronic bleomycin exposure. Wildtype 
C57Blk6 male mice were injected intraperitoneally with saline or bleomycin twice weekly for 4 
weeks. Beginning on day 19, when pulmonary fibrosis has been established, daily treatment with 
vehicle (saline) or recombinant gp130Fc was performed. Mice were sacrificed and samples 
collected on day 33. (A) Western blot analysis and (B) ELISA measurement of sIL-6Rα levels in 
BAL fluid from day 33 lungs. (C) ELISA quantification of sIL-6Rα in plasma samples. (D) 
ELISA measurement of IL-6 protein in day 33 BAL fluid and (E) Q-rtPCR evaluation of IL-6 
transcript level in day 33 whole lung RNA. All data presented as mean ± SEM, n≥6 for B & C, 
n≥3 for D & E. *significant difference from PBS-treated cohort; #significant difference from 
bleomycin-exposed mice. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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RESULTS 
5.1 – Protocol for in vivo neutralization of IL-6 trans signaling using recombinant gp130Fc.  
In vivo neutralization of sIL-6Rα was performed in the IPB model using mouse 
recombinant gp130Fc, a commercially available reagent shown in previous studies to be an 
effective and selective inhibitor of IL-6 trans signaling(73, 74, 76, 78). Recombinant gp130Fc 
binds the only the complex of IL-6/sIL-6Rα, selectively inhibiting signaling through the trans 
pathway(44), as illustrated in Figure 5.1A. It does not bind IL-6 alone or sIL-6Rα alone, mIL-
6Rα, or the complex of IL-6/mIL-6Rα, thus leaving classical signaling intact.  
The neutralization treatment protocol was as illustrated in Figure 5.1B. The dosage and 
schedule for administration of recombinant gp130Fc are adapted from previous published studies 
that have shown effectiveness of soluble gp130 at blocking IL-6 trans signaling in vivo in 
various models(76-80, 103). Treatment with gp130Fc began late in the disease process, on day 
19 of the model, when pulmonary fibrosis was established. Treatment continued until day 32. 
Hypoxia was assessed in live mice on day 32 via measurement of arterial oxygen saturation. 
Mice were sacrificed on Day 33 and pulmonary phenotypes were assessed for changes to 
pulmonary inflammation and fibrosis. 
The decision of when to begin treatment with gp130Fc was based on preliminary data 
regarding the temporal course of disease development in the IPB model. Data from our 
characterization studies informed us that though collagen levels began rising as early as 5 days 
after the first dose of bleomycin, levels significantly jumped between day 15 to day 20 of the 
model, as does levels of soluble IL-6Rα (Figure 3.3A-B). This suggests that it is around this time 
in the model that fibrosis becomes much more robust and trans signaling takes a more prominent 
role in the disease process. This led us to choose day 19, coinciding with the 6th injection of 
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bleomycin, as the best time to initiate therapeutic blockade of the trans signaling pathway. In this 
way, we were able to determine the therapeutic rather than preventative benefits of antagonizing 
trans signaling. 
 
5.2 – Administration of recombinant gp130Fc reduced sIL-6Rα.  
To determine whether our neutralization protocol was sufficient to reduce levels of the 
soluble receptor and inhibit trans signaling, Day 33 BAL fluid samples were collected and 
subjected to ELISA analysis of sIL-6Rα. Bleomycin-treated mice exhibited a significant 
elevation in sIL-6Rα in BAL fluid (Figure 5.2A&B), similar to what was demonstrated in our 
earlier characterization studies (Figure 3.2B&C). Treatment with gp130Fc significantly lowered 
levels of sIL-6Rα in BAL fluid. Interestingly, levels of sIL-6Rα in plasma were not significantly 
different among the treatment groups (Figure 5.2C). This suggests that recombinant gp130Fc is 
able to alter levels of soluble IL-6Rα and antagonize IL-6 trans signaling in the lung 
microenvironment but not the systemic circulation. 
A consideration when using recombinant gp130Fc to inhibit trans signaling is whether it 
would inadvertently interact with IL-6 alone and thereby inhibit classical signaling. As previous 
studies have demonstrated, the inhibitory effects of gp130Fc are limited to trans signaling 
because it only binds IL-6/sIL-6Rα complexes(76-80, 103, 129). However, to confirm that 
gp130Fc administration in our mice did not have off-target effects, IL-6 transcript in whole lung 
RNA and protein levels in BAL fluid were determined. IL-6 protein and transcript levels were 
elevated in the lungs of bleomycin-treated mice in comparison to PBS-treated mice (Figure 
5.2D&E). No significant differences were seen in protein and transcript levels between 
bleomycin and bleomycin + gp130Fc groups, though there was a trend for decrease. These 
 106
results tell us that gp130Fc is not directly affecting IL-6 classical signaling since IL-6 protein 
levels were relatively unchanged. 
 
5.3 – Treatment with recombinant gp130Fc reduced inflammatory cells in the lungs.  
Once we confirmed neutralization of trans signaling in our experimental setup, we began 
evaluating changes to pulmonary phenotype. The histopathology of IPF lungs include presence 
of spatial and temporal heterogeneity in fibrosis, with regions of dense scarring and 
honeycombing alternating with less severe fibrosis or normal pulmonary architecture(1). Regions 
of fibrosis are usually packed with dense collagen and scattered fibroblastic foci (areas of 
proliferating fibroblasts and myofibroblasts). Areas of honeycombing (cystic fibrotic airspaces) 
consist of airspaces that are filled with inflammatory cells and mucus and lined with bronchiolar 
epithelium. When inflammation is present in the interstitium, it is typically mild, with 
lymphocytes and plasma cells making up a patchy infiltrate(1).  
To assess changes in pulmonary phenotype, we first examined the effects of recombinant 
gp130Fc administration on pulmonary inflammation. In the IPB model, mice develop extensive 
pulmonary fibrosis as well as pulmonary inflammation, consisting of an influx of inflammatory 
cells, including macrophages, lymphocytes and neutrophils(33, 91). Using a hemocytometer, 
total cell counts were performed on BAL fluid samples from day 33 mice. Mice treated with 
bleomycin exhibited increased inflammation, as evident by an increase in total inflammatory 
cells recovered in lavage fluid (Figure 5.3A). Treatment with gp130Fc was associated with 
decreased inflammation, as indicated by a significant reduction in total cell counts. Cell 
differential analysis of BAL fluid revealed a reduction in macrophages, lymphocytes, neutrophils 
and eosinophils (Figure 5.3B-D).  
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Figure 5.3. Pulmonary inflammation following chronic bleomycin exposure in mice treated 
with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected intraperitoneally with 
saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when pulmonary fibrosis 
has been established, daily treatment with vehicle (saline) or recombinant gp130Fc was 
performed. Mice were sacrificed and samples collected on day 33. (A-D) Total cell count and 
cell differential from bronchoalveolar lavage fluid (BAL fluid) of wild type C57Blk6 mice given 
saline or bleomycin, with and without gp130Fc. Data presented as mean ± SEM, n≥6. 
*significant difference from PBS-treated cohort; #significant difference from bleomycin-exposed 
mice. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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5.4 – Treatment with recombinant gp130Fc reduced inflammatory cytokines in the lungs.  
The ability of gp130Fc to dampen pulmonary inflammation led us to evaluate changes to 
relevant pro-inflammatory and IL-6 responsive mediators, including monocyte chemoattractant 
protein 1 (MCP-1), chemokine (C-X-C motif) ligand 1 (CXCL-1), interleukin 17 (IL-17), and 
tissue inhibitor of metalloproteinases (TIMP-1). Whole lung RNA analysis revealed a significant 
reduction in MCP-1, CXCL-1, IL-17 and TIMP-1 in mice treated with gp130Fc (Figure 5.4A-D). 
These findings demonstrate that gp130Fc-mediated neutralization of IL-6 trans signaling in the 
lungs can attenuate pulmonary inflammation and decrease pro-inflammatory and IL-6 responsive 
mediators in this model. 
 
5.5 – Treatment with recombinant gp130Fc reduced collagen transcript in the lungs.  
Having demonstrated attenuation of pulmonary inflammation with gp130Fc 
administration, we next determined the effects of gp130Fc on pulmonary fibrosis. Aberrant 
fibroblast activation, differentiation into myofibroblasts, and excessive collagen and fibronectin 
production and deposition in the lungs are hallmarks of pulmonary fibrosis(2). Therefore, we 
asked whether treatment with recombinant gp130Fc affected these indices.  
To assess collagen production, day 33 whole lung RNA samples were analyzed for 
transcript expression of collagen 1 isoforms. In comparison to levels of collagen transcript in the 
non-fibrotic lungs of PBS-treated mice, bleomycin-treated mice exhibited increased transcript 
levels of collagen 1A1 and collagen 1A2 (Figure 5.5A-B), consistent with the presence of 
pulmonary fibrosis in those lungs. Treatment with gp130Fc resulted in significant reductions in 
collagen 1A2 and and a trend for reduction in collagen 1A1.  
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Figure 5.4. Expression of pro-inflammatory and IL-6 responsive mediators following 
chronic bleomycin exposure in mice treated with recombinant gp130Fc. Wildtype C57Blk6 
male mice were injected intraperitoneally with saline or bleomycin twice weekly for 4 weeks. 
Beginning on day 19, when pulmonary fibrosis has been established, daily treatment with vehicle 
(saline) or recombinant gp130Fc was performed. Mice were sacrificed and samples collected on 
day 33. (A-D) Expression of MCP-1, CXCL-1, IL-17, and TIMP-1 transcript in whole lung 
RNA. Data presented as mean ± SEM, n≥3. *significant difference from PBS-treated cohort; 
#significant difference from bleomycin-exposed mice. *= p<0.05, **= 0.001<p<0.01, ***= 
p<0.001. 
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Figure 5.5. Changes in collagen transcript following chronic bleomycin exposure in mice 
treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected 
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when 
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant 
gp130Fc was performed. Mice were sacrificed and samples collected on day 33. (A-B) Whole 
lung RNA was prepared and subjected to q-rtPCR evaluation for analysis of transcript levels of 
collagen 1A1 and collagen 1A2. All data presented as mean ± SEM, n≥3. *significant difference 
from PBS-treated cohort; #significant difference from bleomycin-exposed mice. *= p<0.05, **= 
0.001<p<0.01, ***= p<0.001. 
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5.6 – Recombinant gp130Fc reduced collagen protein expression in the lungs. 
We validated the results of mRNA evaluation by measuring soluble collagen protein in 
BAL fluid using Sircol assay. Gp130Fc administration resulted in a significant reduction in 
collagen protein (Figure 5.6A). To see if this effect could be correlated to the decrease of soluble 
IL-6Rα in the lungs, we subjected matched data of soluble IL-6Rα level and soluble collagen in 
BAL fluid to correlation analysis. As seen in Figure 5.6B, when soluble IL-6Rα levels are 
displayed on the x-axis and corresponding levels of soluble collagen in each sample plotted on 
the y-axis, there is a significant correlation between receptor level and collagen level.   
 
5.7 – Recombinant gp130Fc reduced collagen deposition and attenuated pulmonary fibrosis.  
Changes in collagen transcripts and protein expression suggested gp130Fc mediated a 
reduction in collagen production, so we proceeded to evaluate whether it also led to a reduction 
in collagen deposition in the lungs. Day 33 lung sections were stained using Masson’s trichrome 
protocol to visualize collagen deposition (blue). Untreated bleomycin-exposed lungs were 
fibrotic and had extensive collagen deposition while gp130Fc-treated lungs had diminished 
collagen presence (Figure 5.7A). To assess how the reduction in collagen production and 
deposition affected pulmonary fibrosis in our mice, we performed Ashcroft scoring on the 
stained sections. This is a subjective method of quantifying morphologic fibrosis that has been 
used extensively(130). Bleomycin-treated lungs had mean scores of about 6 on a scale of 0-8, 
with 8 being the highest severity of fibrosis. Gp130Fc treatment improved overall scores by 
almost 50% (Figure 5.7B). These findings revealed that blockade of IL-6 trans signaling resulted 
in a significant reduction in collagen production and deposition in the lungs, resulting in 
attenuation of pulmonary fibrosis.  
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Figure 5.6. Changes in collagen protein expression following chronic bleomycin exposure in 
mice treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected 
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when 
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant 
gp130Fc was performed. Mice were sacrificed and samples collected on day 33. (A) Sircol 
measurement of soluble collagen in BAL fluid on day 33. (B) Matched results of soluble IL-6Rα 
level and corresponding soluble collagen level of each mouse subjected to correlation analysis; 
analysis representative of 2 independent experiments. All data presented as mean ± SEM, n≥6. 
*significant difference from PBS-treated cohort; #significant difference from bleomycin-exposed 
mice. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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Figure 5.7. Changes in collagen deposition following chronic bleomycin exposure in mice 
treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected 
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when 
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant 
gp130Fc was performed. Mice were sacrificed and samples collected on day 33. (A) Lung 
sections from day 33 mice were stained with Masson’s trichrome for visualization of collagen 
deposition (blue). Sections are representative of n≥6 mice from each group. Scale bars: 200µm. 
(B) Pulmonary fibrosis was quantified by Ashcroft method. All data presented as mean ± SEM, 
n≥6. *significant difference from PBS-treated cohort; #significant difference from bleomycin-
exposed mice. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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5.8 – Recombinant gp130Fc reduced myofibroblast accumulation and fibronectin expression. 
To better understand how in vivo neutralization of IL-6 trans signaling attenuated 
fibrosis, we assessed myofibroblast accumulation in gp130Fc-treated lungs. Myofibroblasts are a 
central cellular player in pulmonary fibrosis, the main collagen-producing culprit(131). Lung 
sections from day 33 mice were stained for alpha smooth muscle actin (α-SMA) for detection of 
myofibroblasts. Whereas fibrotic lungs exhibited prominent red α-SMA staining that is 
indicative of extensive myofibroblast accumulation, gp130Fc treated lungs presented with 
diminished myofibroblast accumulation (Figure 5.8A). Comparisons between bleomycin versus 
gp130Fc-treated lung sections visually emphasized the reduction in pulmonary fibrosis seen with 
gp130Fc treatment. We also analyzed the expression of fibronectin, an extracellular matrix 
protein found to be elevated in IPF lungs and is an additional indicator of fibrosis (132-135). 
Protein lysates were made from day 33 lungs and western blot analysis was performed to detect 
changes to fibronectin content. In comparison to bleomycin-exposed lungs, which have increased 
expression of fibronectin, lungs treated with gp130Fc exhibit less fibronectin (Figure 5.8B). 
PBS-injected mice treated with gp130Fc also experienced a reduction in fibronectin expression 
in the lungs.  
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Figure 5.8. Changes in myofibroblast presence and activity following chronic bleomycin 
exposure in mice treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were 
injected intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 
19, when pulmonary fibrosis has been established, daily treatment with vehicle (saline) or 
recombinant gp130Fc was performed. Mice were sacrificed and samples collected on day 33. 
Lung sections from day 33 mice were stained for: (A) alpha smooth muscle actin (α-SMA) for 
detection of myofibroblast accumulation (red). Sections are representative of n≥6 mice from 
each group. Scale bars: 1mm. (B) Western blot analysis of fibronectin expression in whole lung 
lysates.  
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5.9 – Recombinant gp130Fc administration improved oxygen saturation.  
Hypoxia is a feature of IPF and oxygen saturation measurements are often used clinically 
to evaluate presence and severity of hypoxia(1). We evaluated changes to hypoxia in mice 
treated with gp130Fc by measuring oxygen saturation. We observed a decrease in oxygen 
saturation in untreated, bleomycin-injected mice that was inhibited by gp130Fc treatment (Figure 
5.9). Collectively, these findings demonstrate that gp130Fc treatment attenuates pulmonary 
fibrosis, leading to physiologic improvement in mice.  
 
5.10 – Recombinant gp130Fc reduced pulmonary hypertension.  
Pulmonary hypertension (PH, mean pulmonary artery pressure > 25 mmHg at rest) 
occurs in 8.1-14.9% of IPF patients, with higher numbers seen in advanced (30-50%) and end-
stage (>60%) patients(136). Its presence in IPF patients is associated with increased mortality 
risk(1). Karmouty-Quintana et al recently presented data suggesting that adenosine receptor 2B-
mediated release of IL-6 from human pulmonary artery smooth muscle cells (PASMCs) is the 
mechanism via which PH develops secondary to pulmonary fibrosis(91). We wanted to know 
whether in vivo neutralization of sIL-6Rα affected development of PH in our mice. Right 
ventricular systolic pressure (RVSP) is commonly used to indicate presence of PH. Measurement 
of RVSP in mice administered bleomycin revealed significantly higher RVSP values in 
comparison to PBS-treated mice (Figure 5.10). This is consistent with previous published results 
demonstrating pulmonary hypertension secondary to bleomycin-induced pulmonary fibrosis(91). 
Gp130Fc treatment resulted in significant reduction in RVSP, demonstrating that neutralization 
of trans signaling led to improvement in pulmonary hypertension. 
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Figure 5.9. Changes in arterial oxygen saturation following chronic bleomycin exposure in 
mice treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected 
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when 
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant 
gp130Fc was performed. Pulse oximetry was conducted using neck collar on Day 32. All data 
presented as mean ± SEM, n≥4. *significant difference from PBS-treated cohort; #significant 
difference from bleomycin-exposed mice. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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Figure 5.10. Changes in pulmonary hypertension following chronic bleomycin exposure in 
mice treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected 
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when 
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant 
gp130Fc was performed. Right ventricular systolic pressure (RVSP) was measured on Day 33. 
All data presented as mean ± SEM, n≥4. *significant difference from PBS-treated cohort; 
#significant difference from bleomycin-exposed mice. *= p<0.05, **= 0.001<p<0.01, ***= 
p<0.001. Data obtained by Harry Karmouty-Quintana, PhD.  
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5.11. – Recombinant gp130Fc decreased STAT3 activation in lungs.  
In search of the mechanism behind the reduction in pulmonary fibrosis when IL-6 trans 
signaling is neutralized, we examined intracellular signaling effects of IL-6. IL-6 signaling 
phosphorylates and activates Signal Transducer and Activator of Transcription 3 (STAT3) 
(Figure 1.1), a transcription factor important in the pathogenesis of liver, skin and kidney 
fibrosis(137, 138). Increased STAT3 activation has been reported in IPF(87, 139). Its role in 
pulmonary fibrosis was evaluated by O’Donoghue et al., who demonstrated that IL-6-mediated 
STAT3 activation increased bleomycin-induced fibrosis in a mouse model(87). Thus, we 
evaluated changes to STAT3 activation in mice treated with gp130Fc. Western blot analysis of 
protein lysates made from day 33 lungs revealed that phospho-STAT3 was increased in 
bleomycin lungs compared to PBS lungs, and treatment with gp130Fc reduced STAT3 activation 
(Figure 5.11A). Co-staining of P-STAT3 and cell-specific markers allowed us to determine, 
more specifically, that there was a decrease in P-STAT3-positive myofibroblasts in gp130Fc-
treated lungs (Figure 5.11B). We confirmed this finding in human samples, where we saw an 
abundant presence of P-STAT3-positive myofibroblasts in IPF lung sections in comparison to 
control sections (Figure 5.11C). These results suggest that IL-6 trans signaling in this population 
of cells could be crucial to the fibrotic process. We therefore focused our efforts on examining 
IL-6 trans signaling in fibroblast biology to understand its contribution to pulmonary fibrosis. 
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Figure 5.11.  STAT3 activation following chronic bleomycin exposure in mice treated with 
mouse recombinant gp130Fc and in IPF lungs. Wildtype C57Blk6 male mice were injected 
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when 
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant 
gp130Fc was performed. Mice were sacrificed and samples collected on day 33. (A) Western 
blot analysis of phospho-STAT3 expression in lung lysates from C57Bl6 mice given saline or 
bleomycin with and without gp130Fc, Day 33. (B) P-STAT3 immunofluorescence (red) in 
myofibroblasts (green) in these lungs. (C) P-STAT3 immunopositivity (brown) in 
myofibroblasts (red) in IPF lungs. Arrows denote positive cells. Images are representative of n≥4 
animals from each group. Scale bars: 50µm, 100x oil immersion.  
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5.12-5.13 - IL-6 trans signaling promoted extracellular matrix protein production in vitro.  
Aberrant fibroblast activation, differentiation into myofibroblasts, and excessive collagen 
and fibronectin production and deposition in the lungs are hallmarks of pulmonary fibrosis(2). In 
an effort to better understand the effects of IL-6 trans signaling on fibroblast biology, we 
examined these endpoints in vitro, using normal and IPF fibroblast cell lines.  
To evaluate the effect of IL-6 trans signaling on production of extracellular matrix 
proteins, normal and IPF fibroblasts were serum-starved and stimulated with transforming 
growth factor β (TGF-β) or IL-6 and sIL-6Rα for 24, 48 and 72 hours. Protein lysates were 
collected from these cells and subjected to western blot analyses for detection of collagen and 
fibronectin. TGF-β was used as a positive control since it has been shown to be a potent inducer 
of extracellular matrix protein production and myofibroblast differentiation and to play a central 
role in pulmonary fibrosis(133, 140, 141).  
In control fibroblasts, TGF-β stimulation induced expression of collagen and fibronectin 
and increased expression of α-SMA and membrane IL-6Rα at all three time points (Figure 
5.12A-C). Stimulation of trans signaling via addition of IL-6 and sIL-6Rα resulted in increased 
collagen production visibly by 24 hours, with greater levels of protein seen at 48 hours; by 72 
hours, collagen levels had begun trending down to baseline. The trend in collagen levels was 
associated with fibronectin levels that were unchanged at 24 and 48 hours, though mildly 
decreased at 72 hours. There were no changes in α-SMA at 24 and 48 hours but a decrease in α-
SMA at 72 hours. Changes in expression of membrane IL-6Rα mirrored the changes in collagen 
production. Membrane IL-6Rα was mildly elevated by 24 hours, greatly enhanced by 48 hours, 
and was visibly decreased by 72 hours (Figure 5.12A-C).  
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Figure 5.12. Effect of IL-6 trans signaling on ECM protein production in control and IPF 
fibroblasts over time. Control and IPF fibroblasts were serum-starved for 24 hours and then 
stimulated with IL-6 and sIL-6Rα. Western blot analyses were performed for expression of 
collagen, fibronectin, α-SMA, and membrane IL-6Rα after 24, 48 and 72 hours in (A-C) normal 
fibroblasts and (D-F) IPF fibroblasts. Western blot pictures are representative of n=2. 
 
In IPF fibroblasts, TGF-β stimulation induced expression of collagen and fibronectin and 
increased expression of α-SMA and membrane IL-6Rα at all three time points, though to a lesser 
extent than in control fibroblasts (Figure 5.12D-F). Stimulation of trans signaling via addition of 
IL-6 and sIL-6Rα resulted in no difference at 24 hours and increased collagen production at 48 
and 72 hours. Fibronectin levels were mildly elevated at 24 hours and experienced greater 
increases at 48 and 72 hours. α-SMA was mildly increased at 24 and unchanged at 48 and 72 
hours. Membrane IL-6Rα was elevated at 24, 48 and 72 hours, in comparison to non-stimulated 
fibroblasts (Figure 5.12D-F).  
These findings suggest that IL-6 trans signaling promote production of collagen and 
fibronectin in control and IPF fibroblasts, perhaps through regulation of membrane IL-6Rα 
expression. Since expression of collagen and fibronectin appeared to be associated with changes 
in membrane IL-6Rα, we asked whether IL-6 classical signaling alone would alter collagen and 
fibronectin levels and to what extent in comparison to trans signaling. So, we repeated the 
stimulation experiment, but this time, fibroblasts were stimulated with TGF-β, IL-6 alone, or IL-
6 + sIL-6Rα. Stimulation occurred for 48 hours since the previous experiment indicated greatest 
changes in protein expression in 48-hour samples. 
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Figure 5.13. Differential effects of IL-6 classical and trans signaling on extracellular matrix 
protein production in control and IPF fibroblasts in vitro. (A) Control and (B) IPF 
fibroblasts were serum-starved for 24 hours and then stimulated with IL-6 alone or IL-6 and sIL-
6Rα for 48 hours. Western blot analyses were performed for expression of collagen, fibronectin, 
EDA-fibronectin, α-SMA, membrane IL-6Rα and phospho-STAT3. Western blot pictures are 
representative of n=2. 
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In control fibroblasts, IL-6 alone increased collagen expression slightly. IL-6 + sIL-6Rα 
induced a pronounced increase in collagen to levels comparable to or higher than those seen with 
TGF-β stimulation (Figure 5.13A). In IPF fibroblasts, both IL-6 alone and IL-6 + sIL-6Rα were 
able to induce collagen expression to levels comparable to those of TGF-β stimulation (Figure 
5.13B). In control fibroblasts, IL-6 alone increased fibronectin expression slightly. IL-6 + sIL-
6Rα induced a pronounced increase in fibronectin, to levels higher than those seen with TGF-β 
stimulation (Figure 5.13A). IL-6 stimulation in IPF fibroblasts led to an increase in fibronectin, 
while IL-6 + sIL-6Rα led to an increase that was even greater than that induced by TGF-β 
(Figure 5.13B). Recently, Muro et al demonstrated that IPF lung fibroblasts produce more of a 
specific isoform of cellular fibronectin, fibronectin containing extra type III domain A (EDA-
fibronectin), than normal fibroblasts(142). They also reported that mice lacking EDA-fibronectin 
were protected against development of pulmonary fibrosis after bleomycin challenge. Thus, we 
evaluated whether IL-6 trans signaling regulated expression of EDA-fibronectin. Results 
revealed variable expression of EDA-fibronectin in response to IL-6 alone or IL-6 + sIL-6Rα in 
control fibroblasts (Figure 5.13A). In IPF fibroblasts, however, IL-6 alone induced EDA-
fibronectin expression and IL-6 + sIL-6Rα increased expression even further (Figure 5.13B).  
IL-6 alone or IL-6 + sIL-6Rα did not change α-SMA and mIL-6Rα expression in control 
fibroblasts while inducing increased α-SMA and mIL-6Rα expression in IPF fibroblasts (Figure 
5.13A&B). In control fibroblasts, IL-6 alone did not promote phosphorylation of STAT3 while 
IL-6 + sIL-6Rα resulted in increased P-STAT3. In IPF fibroblasts, both IL-6 alone and IL-6 + 
sIL-6Rα stimulated increased activation of STAT3 (Figure 5.13A&B). These results suggest that 
both classical and trans signaling can regulate collagen and fibronectin production. Although IL-
6 trans signaling increases protein production in both normal and IPF fibroblasts, the effect on 
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collagen and fibronectin production is similar in normal fibroblasts, while in IPF fibroblasts, its 
effect on fibronectin production appear greater than on collagen production.  
 
5.14-5.15 – IL-6 trans signaling promoted proliferation & resistance to apoptosis in IPF 
fibroblasts in vitro. 
Having demonstrated the effect of trans signaling on extracellular matrix protein 
production, we next analyzed changes to proliferation and apoptosis subsequent to stimulation of 
trans signaling in these cells. Excessive proliferation and resistance to apoptosis are features of 
fibroblasts from IPF lungs that perpetuate their presence in the diseased lung and contribute to 
ongoing fibrotic changes(143). Moodley et al reported that IL-6 inhibited proliferation of 
fibroblasts isolated from normal lungs while promoting proliferation of IPF fibroblasts(144). 
They also demonstrated that IL-6 mediated enhanced Fas-induced apoptosis in normal 
fibroblasts while inhibiting apoptosis in IPF fibroblasts(145). However, evidence exists to 
suggest that there is much heterogeneity in fibroblast populations in IPF lungs and they respond 
differently to IL-6 signaling(119). Thus, we set out to determine the differential effects of IL-6 
classical and trans signaling on normal and IPF fibroblast proliferation and apoptosis in vitro.  
Baseline proliferation rates of IPF fibroblasts were already higher than those of normal 
fibroblasts (Figure 5.14A). Stimulation with IL-6 alone resulted in a significant increase in 
proliferation in IPF fibroblasts but not normal fibroblasts. The combination of IL-6 and soluble 
IL-6Rα significantly promoted proliferation in both normal and IPF fibroblasts. When 
proliferation rates were reported as a change from baseline rates, stimulation with IL-6 and sIL-
6Rα resulted in a significant 1.2-fold difference in normal fibroblasts (Figure 5.14B). In IPF 
fibroblasts, IL-6 stimulation alone was sufficient to induce a significant 1.4-fold increase in 
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proliferation, and IL-6 in combination with sIL-6Rα resulted in a 1.5-fold increase in 
proliferation. The difference in response to trans signaling may be due to baseline expression of 
membrane IL-6Rα in control versus IPF fibroblasts (Figure 5.14C).  
In terms of spontaneous apoptosis, IL-6 alone had no effect on normal fibroblasts while 
IL-6 + sIL-6Rα caused a slight decrease in apoptosis at a lower confluency (Thesis Figure 
5.15A) and increased apoptosis significantly at a higher confluency (Figure 5.15B). In IPF 
fibroblasts, IL-6 alone enhanced spontaneous apoptosis at low and high levels of confluency 
(Figure 5.15C&D). IL-6 + sIL-6Rα also enhanced apoptosis at low confluency but there was no 
significant increase at higher confluency of fibroblasts. In all, these experiments demonstrate a 
role for IL-6 trans signaling in proliferation and apoptosis of pulmonary fibroblasts.     
 
5.16 – Neutralization of IL-6 trans signaling in vitro inhibited production of collagen in 
control and IPF fibroblasts. 
To evaluate whether blockade of IL-6 trans signaling affects protein production in vitro, 
control and IPF fibroblasts were stimulated with IL-6 and sIL-6Rα for 48 hours in the presence 
or absence of recombinant gp130Fc. Protein lysates were prepared and subjected to western blot 
analyses for detection collagen expression. Results revealed inhibition of collagen production 
with addition of gp130Fc in both control and IPF fibroblasts (Figure 5.16A&B).   
 
5.17-5.18 – Neutralization of IL-6 trans signaling in vitro inhibited fibroblast proliferation 
and altered spontaneous apoptosis.  
To evaluate whether blockade of IL-6 trans signaling affects proliferative capacity of 
normal and IPF fibroblasts in vitro, proliferation rates were assessed in response to in vitro 
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neutralization of trans signaling via addition of recombinant gp130Fc. In normal fibroblasts, 
increasing concentrations of gp130Fc resulted in significant dose-dependent inhibition of 
proliferation, beginning at smaller doses (Figure 5.17A&B). In IPF fibroblasts, there was a trend 
for increasing inhibition of proliferation, with significant inhibition occurring at a higher dose of 
gp130Fc (Figure 5.17C&D). The difference in response to neutralization concentrations may be 
due to the higher responsiveness of IPF fibroblasts to stimulation by trans signaling in 
comparison to normal fibroblasts (Figure 5.14C).  
In terms of spontaneous apoptosis, in normal fibroblasts, IL-6 + sIL-6Rα caused a 
significant reduction in apoptosis, which was reversed with gp130Fc (Figure 5.18A). In IPF 
fibroblasts, IL-6 + sIL-6Rα enhanced spontaneous apoptosis, an effect that began to show 
evidence of reversing at the highest dose of gp130Fc (Figure 5.18B).  
In all, the findings from these in vitro experiments support a role for IL-6 trans signaling 
in enhancing fibroblast proliferation, activation and extracellular matrix protein production that 
could lead to the overpopulation of the lung parenchyma and excessive protein deposition 
observed in pulmonary fibrosis.  
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Figure 5.14. Effect of IL-6 trans signaling on proliferation rates in control and IPF 
fibroblasts in vitro. Control and IPF fibroblasts were serum-starved for 24 hours and then 
stimulated for 48 hours with IL-6 alone or IL-6 and sIL-6Rα. Proliferation rates were assessed in 
response to IL-6 and soluble IL-6Rα and expressed in raw data (A) and change from baseline 
proliferation (B). (C) Membrane IL-6Rα expression in control and IPF fibroblasts. All data 
presented as mean ± SEM, n≥8. *significant difference from media only cohort; #significant 
difference from IL-6 only group; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.  
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Figure 5.15. Effect of IL-6 trans signaling on spontaneous apoptosis in control and IPF 
fibroblasts in vitro. Control and IPF fibroblasts were serum-starved for 24 hours and then 
stimulated for 48 hours with IL-6 alone or IL-6 and sIL-6Rα. Spontaneous apoptosis at low and 
high confluency in (A&B) control fibroblasts and (C&D) IPF fibroblasts was assessed in 
response to IL-6 and soluble IL-6Rα and expressed in raw data. All data presented as mean ± 
SEM, n≥8. *significant difference from media only cohort; #significant difference from IL-6 only 
group; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.  
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Figure 5.16. Effect of neutralizing IL-6 trans signaling on collagen production in control 
and IPF fibroblasts in vitro. Control and IPF fibroblasts were serum-starved for 24 hours and 
then stimulated for 48 hours with IL-6 and sIL-6Rα in the presence of absence of recombinant 
gp130Fc. Western blot analyses of collagen expression in (A) normal fibroblasts and (B) IPF 
fibroblasts. 
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Figure 5.17. Effect of neutralizing IL-6 trans signaling on proliferation rates in control and 
IPF fibroblasts in vitro. Control and IPF fibroblasts were serum-starved for 24 hours and then 
stimulated for 48 hours with IL-6 alone or IL-6 and sIL-6Rα in the presence of absence of 
recombinant gp130Fc. (A&B) Changes to proliferation rate of normal fibroblasts in response to 
increasing concentrations of gp130Fc, expressed as raw data and changes with respect to 
baseline. (C&D) Changes to proliferation rate of IPF fibroblasts in response to increasing 
concentrations of gp130Fc, expressed as raw data and changes with respect to baseline All data 
presented as mean ± SEM, n≥6. *significant difference from media only cohort; #significant 
difference from IL-6 only group; %significant difference from IL-6+sIL-6Rα cohort; *= p<0.05, 
**= 0.001<p<0.01, ***= p<0.001.  
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Figure 5.18. Effect of neutralizing IL-6 trans signaling on spontaneous apoptosis in control 
and IPF fibroblasts in vitro. Control and IPF fibroblasts were serum-starved for 24 hours and 
then stimulated for 48 hours with IL-6 alone or IL-6 and sIL-6Rα in the presence of absence of 
recombinant gp130Fc. (A&B) Changes to spontaneous apoptosis of normal fibroblasts in 
response to increasing concentrations of gp130Fc, expressed as raw data and changes with 
respect to baseline. (C&D) Changes to spontaneous apoptosis of IPF fibroblasts in response to 
increasing concentrations of gp130Fc, expressed as raw data and changes with respect to 
baseline All data presented as mean ± SEM, n≥6 for control and n≥4 for IPF. *significant 
difference from media only cohort; #significant difference from IL-6 only group; %significant 
difference from IL-6+sIL-6Rα cohort; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.  
 134
5.19 – Recombinant gp130Fc reduced mIL-6Rα protein in whole lung and BAL cells.  
 In our in vitro mechanistic studies of control and IPF fibroblasts, we saw an association 
between increases and decreases in membrane IL-6Rα protein expression after stimulation of 
trans signaling in control and IPF fibroblasts and resulting changes in proliferation and protein 
production. This association suggested a cooperative effect of IL-6 trans and classical signaling 
in development of pulmonary fibrosis. Given this knowledge, we wanted to evaluate changes to 
mIL-6Rα after in vivo blockade of trans signaling to see if the same association is seen in vivo.  
Whole lung RNA and protein lysates were prepared from Day 33 bleomycin-exposed and 
gp130Fc-treated mice. Whole lung RNA was subjected to q-rtPCR analysis for transcript levels 
of mIL-6Rα. Protein lysates were subjected to western blot analysis of mIL-6Rα expression. 
Western blot analyses revealed elevated expression of membrane IL-6Rα protein in bleomycin-
exposed lungs (Figure 5.19A), consistent with the results of our initial characterization studies 
(Figure 3.4A). Gp130Fc treatment resulted in a reduction in protein expression. Protein lysates 
were also prepared from Day 33 BAL cells and western blot performed for evaluation of mIL-
6Rα. BAL cells from bleomycin-exposed lungs exhibited elevated mIL-6Rα protein expression 
(Figure 5.19B), once again consistent with our previous results (Figure 3.4B). Gp130Fc-treated 
lungs experienced a reduction in mIL-6Rα. Immunofluorescence staining of day 33 BAL cells 
revealed augmented expression of mIL-6Rα in bleomycin-exposed, fibrotic lungs (Figure 
5.19B). BAL cells from gp130Fc-treated mice displayed less expression of mIL-6Rα. These 
results, in combination with our in vitro results, indicate that in vivo neutralization of IL-6 trans 
signaling using gp130Fc had effected a reduction in classical signaling as well.  
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Figure 5.19. Changes in membrane IL-6R alpha following chronic bleomycin exposure in 
mice treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected 
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when 
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant 
gp130Fc was performed. Mice were sacrificed and samples collected on day 33. Western blot 
analysis of mIL-6Rα expression in (A) whole lung and (B) BAL cell pellet protein lysates. (C) 
Immunofluorescence detection of mIL-6Rα on macrophages isolated from bleomycin-exposed 
mice treated with saline or gp130Fc; membrane IL-6Rα (green), dapi (blue). Arrows point to 
positive cells. 
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DISCUSSION 
In support of a role for IL-6 trans signaling in pulmonary fibrosis, we have demonstrated 
ADAM17-mediated increases in soluble IL-6Rα in association with disease. To determine if 
there were therapeutic benefits to in vivo neutralization of sIL-6Rα and resulting antagonism of 
IL-6 trans signaling in disease, we utilized recombinant gp130Fc to neutralize sIL-6Rα and 
selectively block IL-6 trans signaling in our chronic bleomycin model and evaluated the effects 
on pulmonary inflammation and fibrosis.  
In the IPB model, bleomycin-exposed mice developed significant pulmonary 
inflammation. In mice challenged with bleomycin and treated with gp130Fc, there were marked 
reductions in pulmonary inflammation, as evident by a reduction in the number of inflamatory 
cells recovered in BAL fluid, including reductions in macrophages, lymphocytes, neutrophils and 
eosinophils. The reduction in pulmonary inflammation with gp130Fc treatment in our model is 
consistent with previous studies demonstrating that inhibition of IL-6 trans signaling resulted in 
improvement in chronic inflammatory conditions like colitis(76), arthritis(73), and colitis-
associated premalignant cancer(78). These results suggest that IL-6 trans signaling is responsible 
for the pro-inflammatory property of IL-6 in a model of pulmonary fibrosis. Though the role of 
inflammation in the pathogenesis of IPF is now controversial, there is still much interest in 
exploring specific cellular players in the lung and their roles in fibrosis. Of particular interest is 
the gp130Fc-mediated decrease in macrophages and lymphocytes that we saw in our study. This 
could point to mechanisms for reduced severity of disease with gp130Fc administration. Both 
macrophages and lymphocytes have been suggested to play roles in the development of 
pulmonary fibrosis (113-117, 146, 147), but their exact contribution to IPF has not been 
examined. Further evaluation of these cell types and their role in disease is needed.  
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Another point of interest is the gp130Fc-mediated reduction in IL-6-responsive mediators 
IL-17 and TIMP-1. Wilson et al previously reported increased IL-17A levels in bronchoalveolar 
lavage fluid from IPF patients and demonstrated an essential role for IL-17A in bleomycin and 
IL-1β-induced pulmonary fibrosis in mice(148). Conte et al demonstrated that a reduction in IL-
17-producing cells and IL-17 expression protected mice from bleomycin-induced pulmonary 
fibrosis(149). However, other studies suggest differently and the role of IL-17 in pulmonary 
diseases is controversial(150). Galati et al reported a significant reduction in Th17 cells and an 
increased TGF-α/IL-17 ratio in IPF patients(151). Interestingly, Ge et al demonstrated that lack 
of IL-17 receptor A (IL-17RA), which mediates IL-17A signaling, led to decreased numbers of 
tissue macrophages and attenuated inflammation and fibrosis in the kidneys(152). Nuovo et al 
demonstrated localization of IL-17 expression to regenerating epithelial cells and alveolar 
macrophages in IPF lungs(147). Our study demonstrated decreased macrophage numbers in 
association with decreased IL-17 in mice treated with gp130Fc treatment. This would suggest 
that IL-6 trans signaling may be regulating macrophage accumulation in the lung via IL-17 and 
needs further study. 
Our study revealed that TIMP-1 transcript was increased in bleomycin-exposed fibrotic 
lungs but decreased with gp130Fc treatment. This change in TIMP-1 is consistent with a 
previous study showing induction of TIMP-1 in human synovial fibroblasts after stimulation of 
IL-6 trans signaling, resulting in decreased collagenolytic activity(153). This suggests that 
blockade of IL-6 trans signaling by gp130Fc lifted the inhibitory effect of TIMP-1 and restored 
collagenolytic activity in the lung. Further study is needed to evaluate whether protein expression 
was reduced and whether it resulted in increased degradation of deposited collagen and 
resolution of fibrosis.  
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The compelling finding of this study was the novel observation that neutralization of IL-6 
trans signaling resulted in attenuation of pulmonary fibrosis in our chronic bleomycin model. 
The hallmark features of IPF include excessive fibroblast activation, accumulation of α-sma-
positive myofibroblasts and excessive production and deposition of matrix proteins, including 
collagen and fibronectin(2). Our study demonstrated that neutralization of IL-6 trans signaling 
resulted in a reduction in myofibroblast accumulation and extracellular matrix protein production 
and deposition in the lungs, which translated to a reduction in pulmonary fibrosis and 
improvement in pulmonary oxygenation. Previous studies have suggested a role for IL-6 trans 
signaling in liver fibrosis(154), renal fibrosis(82) and myocardial fibrosis(72), though none have 
demonstrated improvement in fibrosis with blockade of trans signaling in vivo using gp130Fc. 
This is the first study to examine the role of IL-6 trans signaling in pulmonary fibrosis and 
demonstrated a therapeutic benefit to antagonism of this pathway in vivo. 
In search of the underlying mechanism that would explain the improvement in fibrosis 
seen with gp130Fc treatment, we performed in vitro mechanistic studies that revealed the ability 
of IL-6 trans signaling to promote proliferation and collagen and fibronectin production in 
control and IPF fibroblasts, events crucial to disease progression. Findings from our in vitro 
studies of IL-6 trans signaling in fibroblasts are consistent with previous studies that have 
demonstrated that trans signaling can induce hepatocyte proliferation and intracellular 
signaling(154), promote collagen production in cardiac fibroblasts(72) and induce proliferation 
and extracellular matrix protein production in fibroblasts from hypertrophic scars(155). What 
may warrant further study is the downstream effects of IL-6 classical versus trans signaling in 
fibroblasts that may explain the differences in stimulation of fibronectin versus collagen 
production.  
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Figure 5.20. Proliferation rates in control fibroblasts in vitro. Control fibroblasts were serum-
starved for 24 hours and then stimulated IL-6 alone or IL-6 and sIL-6Rα. (A) Changes to 
proliferation rate after 24 hours of stimulation. (B) Changes to proliferation rate after 48 hours of 
stimulation with increasing concentrations of IL-6 alone or IL-6 and sIL-6Rα. All data presented 
as mean ± SEM, n≥4. *significant difference from media only cohort; #significant difference 
from IL-6 only group; %significant difference from IL-6+sIL-6Rα cohort; *= p<0.05, **= 
0.001<p<0.01, ***= p<0.001.  
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It must be noted, however, that Moodley et al examined the effect of IL-6 on fibroblast 
proliferation and concluded that IL-6 inhibits proliferation and enhanced Fas-induced apoptosis 
in normal fibroblasts but enhanced proliferation and increased resistance to apoptosis in IPF 
fibroblasts(144, 145) Differences between these findings may be related to the source of cells or 
conditions used. For example, the starvation and stimulation times were different between our 
studies. To confirm our results seen with 48 hours of stimulation, we evaluated proliferation in 
control fibroblasts after 24 hours of stimulation with IL-6 or IL-6 + sIL-6Rα. We did not show 
growth inhibition with IL-6 stimulation, even at 24 hours (Figure 5.20A). In the study by 
Moodley et al, changes in proliferation in response to IL-6 stimulation was compared to time 0 
fibroblasts. In our study, changes were reported in comparison to fibroblasts that have been 
cultured without stimulation for the same period of time as stimulated fibroblasts, i.e. fibroblasts 
cultured in media only for 24 0r 48 hours. Both studies agree that stimulation of normal 
fibroblasts with IL-6 ≤50ng/ml does not result in inhibition of proliferation. Moodley et al 
reported growth inhibition with IL-6 stimulation ≥100ng/ml, while in our hands, even higher 
concentrations of IL-6 were not anti-proliferative in normal fibroblasts (Figure 5.20B). It is 
unclear the reason for this difference in observations. However, Moodley et al did not examine 
the effect of trans signaling on fibroblast proliferation, whereas our study did.  
With regards to our apoptosis data, we did not examine Fas-induced apoptosis but rather 
only spontaneous apoptosis, so our results cannot be accurately compared to those of Moodley et 
al. We did not show enhanced apoptosis in normal fibroblasts stimulated with IL-6 alone, but we 
did see enhanced apoptosis in those stimulated with IL-6 + sIL-6Rα. In IPF fibroblasts, we saw 
enhanced apoptosis with stimulation of classical signaling and no change to apoptosis with 
stimulation of trans signaling. Thus, these results regarding spontaneous apoptosis, when 
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analyzed along with the proliferation data, suggest that classical signaling doesn’t affect 
proliferation or spontaneous apoptosis in normal fibroblasts. Trans signaling in normal 
fibroblasts, however, increases proliferation and exert different effects on apoptosis depending 
on the availability of space. Trans signaling may act to inhibit apoptosis when there is room for 
growth; however, when space is limited, trans signaling increases apoptosis of normal fibroblasts 
to control expansion. On the other hand, in IPF fibroblasts, IL-6 classical signaling alone can 
promote proliferation and increases apoptosis in low and high confluency states. Trans signaling 
in IPF fibroblasts, promotes apoptosis at lower confluency while inhibiting apoptosis at higher 
confluency, failing to control growth, leading to unregulated expansion. Further work is needed 
to evaluate differential effects of IL-6 trans signaling with regards to stimulus-induced apoptosis.  
The finding of improvement in pulmonary hypertension with recombinant gp130Fc 
treatment in our study was intriguing. As mentioned in chapter 1, PH is a recognized 
complication of the disease process in IPF. The presence of PH greatly increases mortality risk 
and decrease survival of IPF patients(2, 6, 11). Yet, there are no recommendation for therapy 
except in very advanced cases of PH associated with IPF. Hypoxemia (which can occur in lung 
disease) leads to PH and we were able to show that gp130Fc treatment caused an improvement in 
pulmonary hypertension. It’s possible that hypoxemia affects generation of sIL-6Rα, leading to 
PH. The improvement in PH could be due improvement in hypoxemia or a reduction in 
pulmonary fibrosis. It would be interesting and fruitful to explore the role of IL-6 trans signaling 
in pulmonary hypertension. This has not been studied and needs further exploration. 
Surprisingly, our analysis of changes to IL-6 classical signaling in response to 
neutralization of sIL-6Rα in vivo also generated some interesting theories. The decrease in 
membrane IL-6Rα mRNA in bleomycin-induced fibrotic lungs was consistent with published 
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results showing IL-6-mediated suppression of mIL-6Rα mRNA expression in a hepatoma cell 
line(156) or colitis-associated decreased mIL-6Rα mRNA(78). Yet, protein expression of 
membrane IL-6Rα was elevated in fibrotic lungs (in association with increased soluble receptor) 
and decreased with gp130Fc treatment, suggesting that the membrane receptor protein 
expression, and therefore IL-6 classical signaling, may be directly or indirectly regulated by 
trans signaling. Our in vitro studies appear to support this idea. Activation of pulmonary 
fibroblasts, via stimulation of trans signaling, can increase expression of membrane IL-6Rα 
(Figure 5.12). This would suggest a mechanism of action in fibrotic lungs, whereby IL-6 trans 
signaling may work to enhance classical signaling by increasing expression of the membrane 
receptor. The increased expression of the membrane receptor can either: 1) increase classical 
signaling if the membrane receptor is not cleaved or 2) increase trans signaling if the membrane 
receptor is cleaved to form the soluble receptor. In this way, there is potential for perpetuation of 
IL-6 signaling that leads to over-amplification of effects, resulting in progression of disease. We 
need to further study the effect of trans signaling on other pulmonary cell types as well as 
examine the changes to ADAM17 expression and production of sIL-6Rα from pulmonary 
fibroblasts after stimulation of IL-6 trans signaling in order to better understand the consequence 
of this pathway in the lung.  
The results of our in vitro studies raises questions about the existence of a cross-talk 
between TGF-β and IL-6 in pulmonary fibroblasts. We know TGF-β is increased in IPF and has 
been shown to be a pivotal player in disease(143). There is evidence of crosstalk between these 
two cytokines in other diseases. Yamamoto et al reported that TGF-β potentiates IL-6 induced 
STAT3 activation and resulting gene expression in hepatoma cells(157). Walia et al 
demonstrated TGF-β1 negatively regulated IL-6 signaling in intestinal epithelial cells(158). 
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Yamada et al provided evidence of a crosstalk betweent TGF-β1 and IL-6 in biliary tract cancer 
cells resulting in conferrence of malignant features, including epithelial-mesenchymal transition, 
increased invasiveness, and resistance to chemotherapy(159). More recently, O’Reilly et al 
revealed that IL-6 trans signaling, through phosphorylation of STAT3 and downstream 
activation of gremlin, leads to activation of TGF-β signaling and collagen production in dermal 
fibroblasts from systemic sclerosis patients(160). The intricacies of interaction of IL-6 and TGF-
β in IPF lungs, however, remains unclear.  
Elias et al has demonstrated that TGF-β induces IL-6 production in normal human 
pulmonary fibroblasts(161). Gallelli et al illustrated the role of membrane IL-6 receptor alpha in 
mediating TGF-β-induced proliferation of normal and fibrotic lung fibroblasts by showing 
decreased proliferation with the use of an antagonist against the receptor(162). In this study, we 
showed that TGF-β stimulation of control and IPF lung fibroblasts in vitro resulted in enhanced 
expression of mIL-6Rα protein in association with increased collagen and fibronectin production 
and increased myofibroblast differentiation (Figure 5.12). Our results are consistent with 
published results demonstrating TGF-β-mediated regulation of mIL-6Rα mRNA in a hepatoma 
cell line(156) and mIL-6Rα protein expression in biliary tract cancer cells(159). No previous 
study has reported changes to mIL-6Rα protein expression in response to TGF-β stimulation of 
lung fibroblasts though. The change in mIL-6Rα protein expression we have shown in response 
to TGF-β stimulation may represent mechanisms of positively regulating TGF-β activity since 
IL-6 has been reported to increase TGF-β1 signaling by regulating TGF-β receptor 
compartmentalization and turnover in human renal tubular epithelial cells (163). It could also be 
a means of counteracting the effects of TGF-β. Chen et al demonstrated that IL-6 protects 
hepatoma cells from TGF-β-induced apoptosis(164). Exactly how IL-6 and TGF-β interact – at 
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what time, in what cells – in order to exert their effects and whether this crosstalk perpetuates the 
actions of both these cytokines in fibrotic lungs needs further analysis to fully understand. 
Our in vivo and in vitro findings also led to questions regarding the role of IL-6 classical 
and trans signaling in macrophages and macrophage-fibroblast interactions. Murray et al 
demonstrated that TGF-β-mediated pulmonary fibrosis is dependent on macrophages of the M2 
phenotype(116). In our timecourse study, we have demonstrated an increase in macrophages in 
our chronic bleomycin model of pulmonary fibrosis (Figure 4.2C). In our in vivo neutralization 
study, we showed a reduction in these macrophages in gp130Fc-treated lungs associated with 
decreased pulmonary fibrosis (Figure 5.3B). These macrophages are known to be primarily M2 
in phenotype (Figure 2.4B) and we have reported increased mIL-6Rα protein expression on these 
cells as well as increased shedding of the membrane receptor from these cells to produce sIL-
6Rα (Figure 4.1 & 4.2). Thus we have supported an important role for them in disease, in 
agreement with Murray et al. We have also suggested a role for IL-6 trans signaling in 
recruitment and activation of M2 macrophages. Further study is needed to determine what the 
roles of IL-6 classical and trans signaling are in generation of these activated macrophages as 
well as in regulating their activities. 
We also know from the literature that TGF-β expression has been shown to be localized 
to epithelial cells and alveolar macrophages after bleomycin-induced pulmonary fibrosis(165, 
166). We know TGF-β transcript levels are elevated in normal alveolar macrophages and 
peripheral monocytes but only when the cells are activated do protein synthesis and TGF-β 
secretion occur(167). That knowledge, along with what we have seen in our studies, suggests a 
possible model of recruitment and activation of macrophages in the lungs in response to injury, 
which increases TGF-β secretion, which in turn can regulate mIL-6Rα expression in these 
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macrophages and other cells in the lung, including fibroblasts, to influence cellular activation, 
mediator production and induce collagen and fibronectin synthesis and secretion, all of which 
contributes to pulmonary fibrosis. It would also be interesting to determine if this proposed 
model is supported in the case of IPF patients. Of particular interest is the role of macrophage-
fibroblast interactions in development of fibrosis. Ma et al reported that co-cultures of 
macrophages and cardiac fibroblasts led to macrophage stimulation of IL-6 production in cardiac 
fibroblasts, resulting in activation of TGF-β1 and promotion of cardiac fibrosis(168). The same 
could be true in pulmonary fibrosis and needs to be studied. 
Overall, our in vivo and in vitro data suggest that IL-6 trans signaling mediates pro-
proliferative, pro-fibrotic effects in the lungs. We demonstrated the essential role of trans 
signaling in pulmonary fibrosis and the therapeutic benefits of its neutralization, providing a 
novel, potentially effective treatment modality for IPF. However, the contribution of IL-6 
classical signaling to disease cannot be denied as it appears that classical signaling in the lungs 
seem to be intimately connected with trans signaling. Our studies have provided a more detailed 
understand of IL-6 classical and trans signaling in IPF and our mouse model of pulmonary 
fibrosis, but there are many questions that remain unanswered and need further evaluation. 
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CHAPTER 6 
Interleukin-6 (IL-6)  
Classical and Trans Signaling in the 
Adenosine-deaminase (ADA)-Deficient 
Murine Model of Pulmonary Fibrosis 
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EXPERIMENTAL RATIONALE & KEY QUESTIONS 
Having demonstrated, in chapters 3-5, the involvement and role of both IL-6 classical and 
trans signaling in IPF and in our chronic bleomycin mouse model of pulmonary fibrosis, we 
proceeded to characterize these pathways in another mouse model, the adenosine-deaminase 
(ADA)-deficient model (Figure 1.4). In the ADA-deficient murine model of pulmonary fibrosis, 
genetic removal of the enzyme ADA results in adenosine-mediated pulmonary inflammation, 
emphysematous distal airspace enlargement and pulmonary fibrosis(28, 94, 95). Studying IL-6 
classical and trans signaling in this model will serve to confirm and enhance the results we 
obtained in the IPB model. At the same time, we will benefit from a second animal model that 
consists of the co-existence of pulmonary fibrosis and emphysema. 
Based on the analyses of recent retrospective studies, the prevalence of IPF patient with 
features of co-existing emphysema is about 28-55% depending on the population(17, 18). Over 
the past decade, there has been controversy about whether the presence of pulmonary fibrosis 
and emphysema represents a subgroup of IPF or a distinct clinical entity in itself. Cottin et al first 
coined the name Combined Pulmonary Fibrosis and Emphysema (CPFE) in 2005 when they 
formally described clinical characteristics comprising this syndrome. Those characteristics 
included findings of dyspnea on exertion, basal crackles, finger clubbing, upper lobe emphysema 
and lower lobe pulmonary fibrosis on CT, abnormal spirometry, severe gas exchange 
impairment, and high prevalence of pulmonary hypertension(18). What is clear though, is that 
the presence of both pulmonary fibrosis and emphysema carries a poorer prognosis than IPF 
alone and mortality is even worse if pulmonary hypertension is also present(6, 17, 18). Thus, 
better comprehension of pulmonary fibrosis with co-existing emphysema is of interest to us, and 
the ADA-deficient mouse model provides a medium to explore these manifestations. 
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Figure 6.0. Adenosine level and disease progression in adenosine-mediated pulmonary 
fibrosis. ADA-deficient (ADA-/-) mice were identified at birth and maintained on ADA enzyme 
replacement therapy until postnatal day 25. Therapy was then discontinued and disease allowed 
to develop. BAL fluid samples were collected at various timepoints during the course of disease 
progression. (A) Measurement of adenosine levels was performed in BAL fluid samples from 
ADA-/- mice and their ADA-competent (ADA+/-) littermates. (B) Soluble collagen was quantified 
in BAL fluid samples using Sircol assay. Results from A&B obtained by Ernestina Melicoff, 
MD. All data presented as mean ± SEM, n≥4. *significant difference from ADA+/- cohort; *= 
p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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In the ADA-deficient model (Figure 1.4), ADA-deficient (ADA-/-) mice are identified at 
birth and maintained on ADA enzyme replacement therapy from postnatal day 1 to 25 to allow 
for normal pulmonary development. Discontinuation of therapy then allows for progressive 
accumulation of endogenous adenosine in the lungs (Figure 6.0A), leading to chronic injury and 
inflammation, enlargement of distal airways and development of pulmonary fibrosis, as indicated 
by increasing presence of collagen in the lungs (Figure 6.0B). Elevations in adenosine have been 
linked to development of disease in this model and reversal of disease was seen with therapy to 
lower adenosine levels, thus demonstrating the influence of adenosine in lung disease(28, 95, 
96). The ADA-deficient model has been used extensively by our lab as well as others to study 
processes involved in adenosine-mediated lung injury(28-30, 97-102, 169).  
Adenosine is a signaling nucleoside generated in response to lung injury. Through 
activation of its G-protein-coupled receptors (A1AR, A2AAR, A2BAR and A3AR), adenosine 
exerts various effects on inflammation, repair and remodeling processes, and fibrosis, producing 
either tissue-protective or tissue-destructive results(25, 27, 170). Adenosine has been shown, in 
humans and mouse models, to be elevated in and contribute to chronic lung disorders, including 
asthma, COPD, and pulmonary fibrosis. Recent publications have reported, specifically, that it is 
the activation of the A2B receptor by adenosine that mediates production of pro-fibrotic 
molecules, like interleukin-6, leading to chronic lung diseases(25, 28-31, 91). Adenosine 
regulates production and release of IL-6 from various cell types, including from lung epithelial 
cells(32), macrophages(33), smooth muscle cells(34) and fibroblasts(35). More recently, Pedroza 
et al demonstrated the role of IL-6 in mediating pulmonary fibrosis in this model(29). To further 
clarify the roles of IL-6 classical versus trans signaling in this model, we set out to characterize 
the pathways and answer the following questions: 
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6.1 Is soluble IL-6Rα increased in adenosine-mediated pulmonary fibrosis? What 
happens as disease progresses? 
6.2 Is membrane IL-6Rα increased in pulmonary fibrosis? What happens to levels as 
pulmonary fibrosis develops and progresses? 
6.3 Is ADAM17 elevated in adenosine-mediated pulmonary fibrosis? What happens to 
expression throughout the model? 
6.4-6.7 Does in vivo neutralization of IL-6 trans signaling attenuate pulmonary 
inflammation? What about pulmonary fibrosis? 
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RESULTS 
6.1 – Soluble IL-6R alpha is elevated in adenosine-mediated pulmonary fibrosis.  
As an initial assessment of whether sIL-6Rα is elevated in adenosine-mediated lung 
disease, we examined its levels in the lungs of day 42 ADA-deficient (ADA-/-) mice and their 
ADA-competent (ADA+/-) littermates. BAL fluid samples were collected and analyzed for 
presence of the soluble receptor in the bronchoalveolar compartment of the lung. ELISA 
quantification revealed a significant, more than 2-fold elevation in sIL-6Rα in ADA-/- samples in 
comparison to their ADA+/- littermates (Figure 6.1A). Secondary confirmation was performed 
using western blot analysis of these samples. It confirmed the presence of sIL-6Rα in ADA-/- 
samples (Figure 6.1B). Knowing soluble receptor levels were elevated in established adenosine-
mediated lung disease, we next set out to evaluate changes to expression of sIL-6Rα during 
disease onset and progression in ADA-deficient lungs.  
Lung protein lysates were prepared and BAL fluid samples were collected from the lungs 
of ADA+/- and ADA-/- mice at various stages of development between postnatal day 26 and 44 
(on postnatal days 26, 30, 34, 38, and 42). Western blot analysis of lung protein lysates 
demonstrated increasing appearance of sIL-6Rα as adenosine accumulates and injury progresses 
in these lungs (Figure 6.1C). ELISA measurement and western blot analysis of sIL-6Rα in BAL 
fluid samples confirmed this temporal increase in sIL-6Rα in ADA-/- lungs (Figure 6.1D&E). 
There was a visible increase in soluble receptor by day 38. By day 42, there was a significantly 
elevated level of sIL-6Rα in ADA-/- lungs in comparison to ADA+/- lungs. These findings 
demonstrate an association between increases in soluble IL-6Rα and adenosine-mediated lung 
disease and suggest a role for IL-6 trans signaling in disease onset and progression. 
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Figure 6.1. Soluble IL-6R alpha expression in an adenosine-mediated mouse model of 
pulmonary fibrosis. Soluble IL-6Rα expression was assessed in mice with pulmonary fibrosis. 
(A & B) ELISA measurement and western blot analysis of sIL-6Rα in BAL fluid from postnatal 
day 41-42 ADA+/- and ADA-/- mice. (C) Western blot analysis of sIL-6Rα in ADA-/- lung lysates 
at various timepoints between postnatal day 26 and 44. (C) ELISA quantification of sIL-6Rα in 
BAL fluid samples from ADA+/- and ADA-/- mice at various timepoints between postnatal days 
26 and 42. (D) Western blot confirmation of sIL-6Rα in BAL fluid samples from ADA-/- mice 
throughout progression of disease in model. All data presented as mean ± SEM, n≥4. *significant 
difference from ADA+/- cohort; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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6.2 – Membrane IL-6R alpha is elevated in adenosine-mediated pulmonary fibrosis. 
It was noted from our findings in human IPF samples and the IPB model that IL-6 
classical signaling also has a role in pulmonary fibrosis. There is evidence to indicate that 
increased IL-6 trans signaling may promote a feedback loop that enhances mIL-6Rα expression 
and enhanced mIL-6Rα expression can either increase classical signaling and/or provides more 
supply for production of soluble receptor. Membrane IL-6Rα was elevated in bleomycin-induced 
pulmonary fibrosis and neutralization of trans signaling in vivo reduced mIL-6Rα expression in 
association with reduction of fibrosis (Figure 5.19B&C). Trans signaling promoted recruitment 
of inflammatory cells to the lung (Figure 5.3), cells that possessed enhanced membrane IL-6Rα 
expression (Figure 3.4B&3.5B, 4.1E). These cells can then be stimulated to shed their receptors 
to produce the soluble receptor (Figure 4.5). Stimulation of trans signaling in fibroblasts resulted 
in increased mIL-6Rα, associated with increased proliferation and extracellular matrix protein 
production (Figure 5.12&5.14). These results support the hypothesis that, in the lungs, classical 
signaling and trans signaling interact to over-amplify the effects of IL-6, leading to fibrosis.  
We wondered if the same pattern would hold in the ADA-deficient model, so we began 
evaluating expression of mIL-6Rα in ADA-/- mice. BAL fluid samples were collected from 
postnatal day 41-42 ADA+/- and ADA-/- mice. Western blot analysis of mIL-6Rα revealed 
increased mIL-6Rα in ADA-/- samples (Figure 6.2A). BAL cells were isolated and also examined 
for expression of mIL-6Rα. Immunofluorescence staining with membrane IL-6Rα (green) and 
DAPI (blue) demonstrated enhanced expression of mIL-6Rα in ADA-/- samples (Figure 6.2B). 
Furthermore, to determine if mIL-6Rα levels change over time, lung protein lysates were 
prepared and BAL fluid samples were collected from the lungs of ADA-/- mice at various stages 
of development between postnatal day 26 and 44 (on postnatal days 26, 30, 34, 38, and 42). 
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Western blot analysis of lung lysates showed no difference in mIL-6Rα expression over time 
(Figure 6.2C). Western blot analysis of mIL-6Rα expression in BAL fluid samples over time 
demonstrated a temporal increase (Figure 6.2D) resembling the pattern of increase in sIL-6Rα, 
adenosine and collagen. These findings suggest that there is an increase in mIL-6Rα expression 
in the bronchoalveolar compartment of the lungs, but perhaps not in the whole lung. 
 
6.3 - ADAM17 is increased in adenosine-mediated pulmonary fibrosis.  
Having demonstrated elevations in soluble IL-6Rα in ADA-deficient mice with 
pulmonary fibrosis, we next assessed the underlying mechanism of sIL-6Rα production in their 
lungs. From our studies in the IPB model, we know the protease ADAM17 to play a pivotal role 
in shedding membrane IL-6Rα from activated macrophages to produce the soluble receptor 
(Figure 4.5). Thus, we explored the possibility of ADAM 17 cleaving membrane IL-6Rα to 
produce the soluble receptor in ADA-deficient lungs.  
BAL fluid was collected from postnatal day 41-42 ADA+/- and ADA-/- mice and analyzed 
for presence of ADAM17 in the airways and airspaces of the lung. Western blot analysis 
detected increases in immature and mature forms of ADAM17 in ADA-/- samples (Figure 6.3A). 
We further localized the increase in ADAM17. Immunostaining of sections from postnatal day 
41-42 lungs revealed the most prominent increase of ADAM17 in alveolar macrophages of 
ADA-deficient lungs (Figure 6.3B). These macrophages are the same ones that, when stained for 
membrane IL-6Rα, expressed higher levels of the receptor than in the control (Figure 6.2B).   
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Figure 6.2. Membrane IL-6R alpha expression in a mouse model of adenosine-mediated 
pulmonary fibrosis. Membrane IL-6Rα expression was assessed in mice with pulmonary 
fibrosis. (A) Western blot analysis of mIL-6Rα in BAL fluid from ADA+/- and ADA-/- mice, 
postnatal day 41-44. (B) BAL cells were collected and immunofluorescence staining performed 
for detection of membrane IL-6Rα (green) and DAPI (blue). Arrows denote positive cells. 
Images are representative of n≥4 animals from each group. Scale bars: 50µm, 100x oil 
immersion. (C) Western blot analysis of mIL-6Rα in ADA-/- lung lysates at various timepoints 
between postnatal day 26 and 44. (D) Western blot confirmation of mIL-6Rα expression in BAL 
fluid samples from ADA-/- mice throughout progression of disease in model.  
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Figure 6.3. ADAM17 expression in a mouse model of adenosine-mediated pulmonary 
fibrosis. Expression of the protease ADAM17 was evaluated in mice with pulmonary fibrosis. 
(A) Western blot analysis of immature (130 kDa) and mature (89 kDa) forms of ADAM17 in 
bronchoalveolar lavage fluid from postnatal day 41-42 ADA+/- and ADA-/- mice. (B) 
Immunostaining for ADAM17 (brown) in the lungs of postnatal day 41-42 ADA+/-  and ADA-/- 
lungs. Arrows denote positive cells. Images are representative of n≥4 animals from each group. 
Scale bars: 50µm, 100x oil immersion. Western blot analysis of ADAM17 in (C) lung protein 
lysates and (D) BAL fluid as disease develops and progresses in an adenosine-mediated model.  
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Further characterization of ADAM17 expression during onset and development of 
fibrosis was achieved via preparation of lung protein lysates and collection of BAL fluid from 
ADA-/- lungs at various stages of development between postnatal day 26 and 44 (on postnatal 
days 26, 30, 34, 38, and 42). Western blot analysis of lung lysates revealed no difference in 
ADAM17 expression, though there may be a slight reduction on days 42 and 44 in the mature 
form and an increase in a potential isoform found at a lower molecular weight (Figure 6.3C). 
Western blot analysis of mIL-6Rα in BAL fluid samples, on the other hand, indicated a temporal 
increase in ADAM17 expression that mirrored the increase in sIL-6Rα in this model (Figure 
6.1C&E). Collectively, these findings demonstrate an association between increases in ADAM17 
and increases in soluble IL-6Rα in the bronchoalveolar compartment of ADA-deficient lungs, 
suggesting a role for the protease in generating the soluble receptor in ADA-deficient lungs. 
 
6.4 – In vivo neutralization of IL-6 trans signaling in the ADA-deficient model.  
We have characterized increases in membrane and soluble IL-6Rα in ADA-deficient, 
fibrotic mouse lungs and suggested a role for ADAM17 in generation of the soluble receptor in 
these lungs. We saw similar patterns of expression of soluble IL-6Rα in the IPB model and were 
able to demonstrate therapeutic benefits of neutralizing sIL-6Rα in vivo in that model. We 
wanted to see if the same benefits would apply when we neutralize sIL-6Rα in ADA-/- mice.  
In vivo neutralization of sIL-6Rα was performed in the ADA-deficient model using 
mouse recombinant gp130Fc, shown in our studies and published literature to be an effective 
inhibitor of IL-6 trans signaling(73, 74, 76, 78). The treatment protocol was as illustrated in 
Figure 6.4A. Treatment with gp130Fc occurred from postnatal day 30 to 41. Mice were 
sacrificed on postnatal day 42 and pulmonary phenotypes were assessed for pulmonary 
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inflammation and fibrosis. The dosage and schedule for administration of recombinant gp130Fc 
are adapted from previous studies that have shown effectiveness of soluble gp130 at blocking IL-
6 trans signaling in vivo,(76-80, 103) including our attempts to neutralize trans signaling in the 
IPB model. The decision of when to begin treatment with gp130Fc was based on previous work 
by Pedroza et al, who used the ADA-deficient model to study the role of IL-6 in adenosine-
mediated injury(29). They initiated pharmacologic blockade of IL-6 signaling on postnatal day 
26 and demonstrated attenuation of fibrosis. Also, data from our characterization studies in this 
model informed us that soluble IL-6Rα was already present in the lungs as early as postnatal day 
26 in ADA-/- mice even though significant changes in collagen levels did not occur until between 
day 34 and 38 (Figure 6.1C & 6.0B). This suggests that fibrosis became much more robust and 
trans signaling takes a more prominent role in the disease process between days 34 and 38. Thus, 
we attempted to antagonize trans signaling in a preventative manner by initiating recombinant 
gp130Fc therapy on day 30. 
To determine whether our neutralization protocol was sufficient to reduce levels of the 
soluble receptor and inhibit trans signaling, Day 42 BAL fluid samples were collected and 
subjected to ELISA analysis of sIL-6Rα. ADA-/- mice exhibited an elevation in sIL-6Rα in BAL 
fluid (Figure 6.4B), though not significant and not to the levels observed in our characterization 
studies. Treatment with gp130Fc led to a trend for lower levels of sIL-6Rα in BAL fluid but not 
significantly different. This suggests us that the administration of recombinant gp130Fc in this 
experiment was unable to significantly alter levels of soluble IL-6Rα and antagonize IL-6 trans 
signaling in the lung microenvironment.  
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Figure 6.4. Protocol for in vivo neutralization of soluble IL-6Rα using mouse recombinant 
gp130Fc in a mouse model of adenosine-mediated pulmonary fibrosis. (A) Experimental 
setup for in vivo neutralization of sIL-6Rα in the adenosine deaminase (ADA)-deficient murine 
model of pulmonary fibrosis. ADA-/- mice were identified at birth and maintained on PEG-ADA 
enzyme replacement therapy until postnatal day 25. Therapy is then discontinued and 
endogenous adenosine allowed to accumulate in the lungs. Beginning on postnatal day 30 and 
continuing until day 41, daily treatment with vehicle (saline) or recombinant gp130Fc was given. 
Mice were sacrificed and samples collected for analysis on postnatal day 42. (A) ELISA 
measurement of sIL-6Rα levels in BAL fluid from day 42 lungs. All data presented as mean ± 
SEM, n=2 for ADA+/- + PBS, n≥4 for other cohorts. *significant difference from ADA+/- cohort 
given PBS; #significant difference from ADA-/- mice given PBS. *= p<0.05, **= 0.001<p<0.01, 
***= p<0.001. 
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6.5 – Effects of treatment with recombinant gp130Fc on pulmonary inflammation.   
Despite not being able to show a significant reduction in sIL-6R alpha in our 
neutralization study, we proceeded to evaluate changes to pulmonary phenotype. The 
histopathology of ADA-/- lungs included pulmonary inflammation, emphysematous distal airway 
enlargement and pulmonary fibrosis.  
To assess changes in pulmonary phenotype, we first examined the effects of recombinant 
gp130Fc administration on pulmonary inflammation. Using a hemocytometer, total cell counts 
were performed on BAL fluid samples from day 42 ADA-/- mice. Analysis of BAL fluid samples 
revealed a significant elevation in total BAL cells in ADA-/- lungs, consistent with the presence 
of inflammation (Figure 6.5A). Though there was a trend for decrease, there was no significant 
reduction in total BAL cells in ADA-/- mice treated with gp130Fc (Figure 6.5A). Surprisingly, 
cellular differential analysis revealed a significant reduction in BAL macrophages in ADA-/- 
mice treated with gp130Fc (Figure 6.5B). No significant trends could be concluded from 
examination of the other cell types in BAL fluid (Figure 6.5C&D).  
 
6.6 – Effect of recombinant gp130Fc on collagen protein expression in the lungs. 
We next attempted to evaluate pulmonary fibrosis in gp130Fc-treated and untreated 
ADA-/- mice. We assessed collagen production in the lungs by measuring soluble collagen 
protein in BAL fluid using Sircol assay. ADA-/- lungs exhibited significantly higher levels of 
soluble collagen in BAL fluid, indicative of fibrosis (Figure 6.6A), though not to the extent 
expected based on previous descriptive studies (Figure 6.0B). Gp130Fc administration did not 
result in a significant reduction in collagen protein though there was a trend for decrease. These 
results were confirmed in second manner by evaluation of collagen deposition in the lungs. Lung 
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sections from day 42 ADA+/- and ADA-/- mice, placebo and treated groups, were prepared and 
stained using Masson’s trichrome protocol to visualize collagen deposition (blue). Untreated 
ADA-/- lungs had evidence of emphysematous distal airway enlargement and mild pulmonary 
fibrosis (Figure 6.6B). Gp130Fc-treated ADA-/- lungs appeared mildly improved, though there 
was not enough fibrosis in either cohorts to accurately draw conclusions about changes. 
 
6.7 – Effect of recombinant gp130Fc on pulmonary fibrosis and myofibroblast accumulation.  
We next attempted to quantify extent of pulmonary fibrosis in gp130Fc-treated and 
untreated ADA-/- mice. Ashcroft scoring was performed on Masson’s trichrome-stained sections. 
Untreated ADA-/- lungs had evidence of mild pulmonary fibrosis, with Ashcroft scores of around 
3 (Figure 6.7A). There was a trend for decrease in scores in gp130Fc-treated lungs, though it was 
not significant. Lung sections were also stained with α-SMA for detection of myofibroblasts. 
Neither ADA-/- treated nor untreated lungs displayed very much SMA staining (Figure 6.7B). In 
combination with the collagen data, these results support the idea that the collected ADA-/- + 
PBS samples in this experiment were not representative of what is typically expected of diseased 
lungs and no valid comparisons can be made between treated and untreated mice. 
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Figure 6.5. Pulmonary inflammation after recombinant gp130Fc treatment in a mouse 
model of adenosine-mediated pulmonary injury. ADA-/- mice were identified at birth and 
maintained on PEG-ADA enzyme replacement therapy until postnatal day 25. Therapy is then 
discontinued. Beginning on postnatal day 30 and continuing until day 41, daily treatment with 
vehicle (saline) or recombinant gp130Fc was given. Mice were sacrificed and samples collected 
for analysis on postnatal day 42. (A-D) Total BAL cells count and differentials, including 
macrophages, lymphocytes, eosinophils and others were determined in day 42 samples. All data 
presented as mean ± SEM, n=2 for ADA+/- groups, n≥3 for ADA-/- cohorts. *significant 
difference from ADA+/- cohort given PBS; #significant difference from ADA-/- mice given PBS. 
*= p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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Figure 6.6. Collagen production and deposition following treatment with recombinant 
gp130Fc in a mouse model of adenosine-mediated pulmonary injury. ADA-/- mice were 
identified at birth and maintained on PEG-ADA enzyme replacement therapy until postnatal day 
25. Therapy is then discontinued. Beginning on postnatal day 30 and continuing until day 41, 
daily treatment with vehicle (saline) or recombinant gp130Fc was given. Mice were sacrificed 
and samples collected for analysis on postnatal day 42. (A) Lung sections from day 42 ADA+/- 
and ADA-/- mice, placebo and treatment groups, were immunostained using Masson’s trichrome 
protocol for detection of collagen deposition (blue). (B) Sircol measurement of soluble collagen 
in BAL fluid samples from Day 42.  All data presented as mean ± SEM, n=2 for ADA+/- groups, 
n≥4 for ADA-/- cohorts. *significant difference from ADA+/- cohort given PBS; #significant 
difference from ADA-/- mice given PBS. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. 
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Figure 6.7. Pulmonary fibrosis following treatment with recombinant gp130Fc in a mouse 
model of adenosine-mediated pulmonary injury. ADA-/- mice were identified at birth and 
maintained on PEG-ADA enzyme replacement therapy until postnatal day 25. Therapy is then 
discontinued. Beginning on postnatal day 30 and continuing until day 41, daily treatment with 
vehicle (saline) or recombinant gp130Fc was given. Mice were sacrificed and samples collected 
for analysis on postnatal day 42. (A) Ashcroft scoring was performed on Day 42 from ADA+/- 
and ADA-/- mice, placebo and treated groups. (B) Day 42 lung sections were immunostained 
with alpha-smooth muscle actin for detection of myofibroblasts (red). All data presented as mean 
± SEM, n=2 for ADA+/- groups, n≥4 for ADA-/- cohorts. *significant difference from ADA+/- 
cohort given PBS; #significant difference from ADA-/- mice given PBS. *= p<0.05, **= 
0.001<p<0.01, ***= p<0.001. 
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DISCUSSION 
With the encouraging results found in the IPB mouse model, we approached the study of 
IL-6 classical and trans signaling in the ADA-deficient model with the hopes of secondary 
validation of our findings and the potential of exploring the role of these pathways in combined 
pulmonary fibrosis and emphysema states. We were able to characterize increases in soluble IL-
6Rα, membrane IL-6Rα and ADAM17 expression in adenosine-induced pulmonary disease that 
were similar in most respects to the patterns seen in bleomycin-induced pulmonary fibrosis. Our 
characterization studies suggested: 1) a role for IL-6 classical and trans signaling in adenosine-
mediated disease, and 2) ADAM17 in shedding IL-6Rα from alveolar macrophages. Our initial 
attempt to neutralize soluble IL-6Rα in vivo in the ADA-deficient model, however, failed to 
achieve significant reduction in sIL-6Rα in the lungs. Further optimization of the neutralization 
protocol is needed in order to more accurately determine the significance of IL-6 trans signaling 
in this model and decipher its part in the pathogenesis of adenosine-mediated pulmonary disease.  
Our characterization experiments were able to support a role for IL-6 trans signaling in 
the ADA-deficient model. We saw that soluble IL-6Rα was elevated in both bronchoalveolar and 
parenchymal compartments of ADA-deficient lungs. This elevation was seen in established 
pulmonary disease, which includes pulmonary inflammation and pulmonary fibrosis. We also 
demonstrated that soluble IL-6Rα increased in ADA-deficient lungs in association with 
increasing disease, as indicated by increasing adenosine and collagen content. This pattern of 
increase in sIL-6Rα is in agreement with the pattern seen in the IPB model and suggests trans 
signaling could be involved in adenosine-mediated pulmonary injury in this model. This would 
not be surprising since adenosine regulates IL-6 expression and release in various pulmonary 
sources(32-35). It would be interesting to assess whether adenosine also regulates expression of 
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IL-6Rα. Also, more work is necessary to understand the trans signaling-mediated activation of 
intracellular pathways in the ADA-deficient model.  
In contrast to the overall increase in membrane IL-6Rα expression in whole lung in the 
IPB model, we determined that membrane IL-6Rα is elevated only in the bronchoalveolar 
compartment of ADA-deficient lungs. This increase was further localized to the alveolar 
macrophages, similar to the observation made in the IPB model. This observation suggests that 
alveolar macrophages may represent the source of soluble IL-6Rα generation in this model as 
well. When we examined ADAM17 expression in the model, we saw increased levels over time 
in the bronchoalveolar compartment of ADA-deficient lungs, in association with increasing sIL-
6Rα. The increase was localized to alveolar macrophages. In comparison to the pattern seen in 
the IPB model, the more specific localization of membrane IL-6Rα and ADAM17 to the alveolar 
macrophages in ADA-deficient lungs further implicate the protease and these cells in generation 
of sIL-6Rα. Macrophage stimulation experiments similar to those conducted in the IPB model 
needs to be performed to further assess the role of ADAM17 in producing sIL-6Rα. 
As for our attempt at in vivo neutralization of sIL-6Rα in the ADA-deficient model, we 
were unable to demonstrate a significant reduction in sIL-6Rα in the cohort treated with mouse 
recombinant gp130Fc. As such, we were unable to draw solid conclusions regarding pulmonary 
inflammation and fibrosis since we are unsure whether or not antagonism of IL-6 trans signaling 
was successful. There could be several possibilities as to the reason for our failure to demonstrate 
a significant difference in sIL-6Rα levels with gp130Fc treatment. Failure could be due to 
inadequate dosing, treatment frequency and/or duration of therapy. Our attempt at neutralization 
in ADA-deficient mice was based on what was effective in the IPB model. However, every 
model is different, and the metabolism of recombinant gp130Fc in ADA-deficient could be 
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entirely different than that of bleomycin-exposed mice. Perhaps the same dose of recombinant 
gp130Fc is metabolized too quickly in the ADA-/- lungs or is being shuttled to other sites of 
inflammation and disease since we know ADA-/- mice to have metabolic disturbances in many 
organs, including spleen, liver and kidney(94, 95). Treatment failure could also be due to timing 
of therapy initiation or the duration of therapy. Perhaps gp130Fc treatment needs to be started 
earlier in the model.  
Another valid possibility could be that we did not examine the quantity and quality of 
mice necessary to observe a difference with treatment. One of the difficulties of the ADA-
deficient model is in timing of sample collection. Several ADA-/- mice treated with PBS were 
lost to collection due to death occurring before day 42. They were excluded from the study. 
Thus, the most severely ill mice were eliminated from the analysis. The ones that survived to day 
42 did not appear to be sufficiently ill, given the low sIL-6Rα and soluble collagen levels 
measured in BAL fluid. Neither the levels of sIL-6Rα nor soluble collagen in BAL fluid samples 
from our untreated ADA-/- cohort were consistent with what was observed in our previous 
descriptive study (Figure 6.0B). This suggests that we weren’t capturing the mice representative 
of the severity of disease seen in our characterization studies. As such, perhaps because we did 
not have adequate positive controls (i.e. sick ADA-/- + PBS mice), we were unable to assess 
changes with treatment with gp130Fc. Surprisingly, our analysis of BAL cells yielded a 
significant reduction in macrophages in gp130Fc-treated ADA-/- mice. However, in the face of 
unaltered levels of sIL-6Rα, we are uncertain what conclusion can be drawn from these results.  
Overall, our experiments in the ADA-deficient model validated elevations in soluble sIL-
6Rα in onset and progression of adenosine-mediated pulmonary disease. We confirmed 
elevations in mIL-6Rα and ADAM17 in alveolar macrophages of ADA-deficient lungs. Our 
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studies in this model have provided preliminary data to support further need for analysis of IL-6 
classical and trans signaling as well as the role of ADAM17 in adenosine-mediated lung injury. 
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CHAPTER 7 
Summary & Conclusions  
and  
Future Directions 
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SUMMARY OF RESULTS 
The published literature suggests an important role for IL-6 trans signaling in diseased 
states, yet trans signaling has not been examined in IPF, a deadly form of pulmonary fibrosis and 
the most common interstitial lung disease(1). This project was intended to 1) characterize IL-6 
classical and trans signaling in fibrotic lungs, 2) examine protease-mediated generation of 
soluble IL-6 receptor alpha, and 3) evaluate the therapeutic benefit of blocking IL-6 trans 
signaling in pulmonary fibrosis.  
Characterization of IL-6 classical and trans signaling in IPF lungs revealed elevations of 
soluble IL-6Rα in parenchyma and bronchoalveolar compartments. Membrane IL-6Rα is 
augmented in M2 macrophages in IPF lungs. M2 macrophages, fibroblasts and myofibroblasts 
from IPF lungs are capable of responding to classical and trans signaling, while type II 
pneumocytes are only responsive to trans signaling. Enhanced activation of STAT3 was seen in 
IPF lungs in a number of different cell types. These results supported a role for IL-6 trans 
signaling in amplifying the effects of IL-6 in IPF lungs.  
Evaluation of IL-6 trans signaling in a chronic bleomycin mouse model, the 
Intraperitoneal Bleomycin (IPB) model, revealed elevations in both membrane and soluble IL-
6Rα levels in association with fibrosis initiation and progression. The soluble receptor was 
generated via protease-mediated cleavage of membrane IL-6Rα from M2 macrophages and the 
protease ADAM17 was responsible. Neutralization of IL-6 trans signaling in vivo resulted in 
attenuation of pulmonary inflammation and fibrosis in the model, which translated to 
improvement in pulmonary hypertension and hypoxia. In vitro mechanistic studies revealed that 
IL-6 trans signaling promoted fibroblast proliferation and production of extracellular matrix 
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proteins. In all, these results revealed an essential role for IL-6 trans signaling in development of 
disease in a mouse model.  
Attempts to validate our findings in a second model, the Adenosine Deaminase (ADA)-
deficient model, resulted in confirmation that IL-6 trans signaling was augmented in association 
with disease in ADA-deficient mice. Membrane IL-6Rα and ADAM17 were elevated in 
activated M2 alveolar macrophages, same as in the IPB model. An initial attempt to antagonize 
IL-6 trans signaling in this model failed to significantly reduce levels of the soluble receptor. 
Further optimization of neutralization protocol is needed. Results obtained in this second model 
were able to validate some findings from IPF and the IPB model.  
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Figure 7.0. Working model of IL-6 trans signaling in pulmonary fibrosis. In fibrotic lungs, 
elevated ADAM17 expression in M2 macrophages leads to cleavage of membrane IL-6Rα to 
produce soluble IL-6Rα. Soluble IL-6Rα binds IL-6, which is released by a number of cells, 
including alveolar macrophages, in response to adenosine stimulation (work done by Yang Zhou, 
PhD). The IL-6/sIL-6Rα complex can then activate various cells in the lung in a paracrine 
manner or further activate M2 macrophages in an autocrine manner. (A&B) Stimulation of IL-6 
trans signaling in fibroblasts results in (1) increased extracellular matrix protein production and 
(2) increased proliferation. (C) Stimulation of trans signaling in type II pneumocytes has been 
shown to induce EMT (results obtained by Mesias Pedroza, PhD). (D) Stimulation of IL-6 trans 
signaling in M2 macrophages has not been examined yet. The resulting effects are unknown.  
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WORKING MODEL  
Given what is known from published literature, the work done previously in our lab, as 
well as data obtained from studies in this project, we propose the following working model for 
IL-6 trans signaling in pulmonary fibrosis (Figure 7.0). As pulmonary fibrosis develops and 
progresses, there is increasing recruitment and accumulation of macrophages in the lung. In 
response to stimulatory signals present in the lung, these macrophages adopt the M2 phenotype 
and express augmented levels of membrane IL-6Rα. Activation of ADAM17 in M2 macrophages 
allows them to shed their membrane receptor to generate soluble IL-6Rα. Because of this, sIL-
6Rα accumulates in the lung as disease progresses. Soluble IL-6Rα acts by first binding IL-6, 
which is released from a number of cells in fibrotic lungs, including alveolar macrophages 
(under stimulation by adenosine). The complex of IL-6/sIL-6Rα can then activate IL-6 trans 
signaling, amplifying the effects of IL-6. These effects include increasing recruitment of 
inflammatory cells, including more macrophages. IL-6/sIL-6Rα can activate IL-6 trans signaling 
in fibroblasts and myofibroblasts, promoting their proliferation and synthetic capabilities, 
resulting in expansion of these cells and increased production and deposition of extracellular 
matrix proteins like collagen and fibronectin in the parenchyma. Over time, this process results 
in progressive fibrosis, alterations of pulmonary architecture and impairment of gas exchange, 
manifested as hypoxia and respiratory dysfunction, ultimately leading to respiratory failure and 
death.  
 
CONCLUSIONS 
In this project, we have emphasized the significance of IL-6 trans signaling by showing 
elevations in soluble IL-6Rα in IPF lungs. We demonstrated a temporal increase in sIL-6Rα 
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during onset and progression of pulmonary fibrosis in two separate murine models, suggesting 
IL-6 trans signaling is involved in disease pathogenesis. We characterized IL-6 classical 
signaling and demonstrated a role for ADAM17 in generating soluble IL-6Rα by shedding the 
membrane receptor from mouse M2 macrophages. Neutralization of sIL-6Rα and resulting 
antagonism of IL-6 trans signaling attenuated bleomycin-induced pulmonary inflammation and 
fibrosis in a mouse model. In vitro studies using human normal and IPF fibroblasts suggested 
activation of IL-6 trans signaling results in effects that are relevant to the progression of lung 
fibrosis. These findings are consistent with the hypothesis that IL-6 trans signaling is essential in 
mediating pro-inflammatory and pro-fibrotic effects in the lungs. Further studies are necessary to 
validate these observations in additional human IPF tissues and samples. However, this study 
presents, to our knowledge, the first in vivo preclinical evidence that blockade of IL-6 trans 
signaling may be of therapeutic value to the management of IPF.  
 
FUTURE DIRECTIONS 
Though we have made some progress in understanding some of the events that govern the 
initiation and progression of pulmonary fibrosis, much remains unclear. Our findings in this 
project, along with what is known from the published literature, have directed our thought 
process to generate the following questions that will drive our future studies and our search for 
more answers to this complex condition.  
 
 
 
  
 175
7.1 – Validate preliminary human findings & mouse model findings in more IPF samples 
This thesis has yielded some intriguing findings regarding soluble IL-6Rα and trans 
signaling in pulmonary fibrosis. To provide even more preclinical data to support targeting this 
pathway in humans, we would like to validate our mouse findings in more human samples. I am 
most interested in the following questions.  
1) Can we replicate the data showing that sIL-6Rα is increased specifically in a fibrotic 
lobe and not a non-fibrotic lobe (Figure 3.1A)? We would need to obtain more BAL fluid 
samples from different lobes of each patient and assess enough patients to see if the pattern 
holds. If we can show that this pattern of increased sIL-6Rα only occurs in fibrotic areas of the 
lungs, then it would support the idea of using sIL-6Rα as a biomarker of fibrosis in IPF.  
2) Can we confirm in IPF samples the finding in both IPB and ADA-deficient models 
showing a temporal increase in sIL-6Rα with increasing severity of fibrosis (Figures 3.3 and 
6.1)? We would need samples from patients at different stages of the disease, as representatives 
of varying (or increasing) severity of disease. There are a few issues with that plan. Ideally, we 
would recruit newly diagnosed IPF patients and follow them with periodic BALs and tissue 
collection. However, there are no known therapeutic justifications for subjecting patients to 
invasive procedures for periodic BALs and tissue collection. The other problem is that IPF is 
such a heterogeneous disease, with different phenotypes of IPF. How would initial classification 
of patients be done? What factors would be important? Imaging findings? Pulmonary function? 
Genotype? Duration of symptoms? As mentioned in chapter 1, rapidly progressing forms of IPF 
present with similar lung volumes, capacities and findings as stable or slowly progressing IPF. 
We would need to follow those patients to make sure they were classified correctly based on how 
they progress. That would take tremendous time and effort for follow-ups. However, if we are 
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able to gather enough samples representative of the spectrum of IPF disease and stratify them 
appropriately, it would provide valuable information about the disease process. If we can show 
the pattern of sIL-6Rα expression replicates in IPF, it would support the use of sIL-6Rα as a 
prognostic marker and indicator of disease severity/stage.  
3) Can we validate the finding in the IPB model showing a temporal increase in M2 
macrophages and ADAM17 in association with increasing sIL-6Rα (Figure 4.2)? Can we 
stimulate shedding from M2 macrophages from IPF lungs? Doing so would provide the rationale 
to block ADAM17 activity specifically in macrophages to prevent generation of sIL-6Rα in IPF 
lungs.  
4) What is the expression of membrane IL-6Rα in IPF lungs? We need to determine if the 
preliminary results in IPF samples regarding expression of the membrane receptor is true (Figure 
3.4A). We would like to evaluate mIL-6Rα expression in more IPF lung lysate samples and 
using a more specific antibody for the membrane receptor. Doing so would allow us to determine 
how much of the mouse model findings with regards to mIL-6Rα could apply to the human 
disease and direct our future efforts.   
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Figure 7.1. Activation of STAT3 in IPF patients with and without pulmonary hypertension. 
(A) Immunostaining for phospho-STAT3 and α-SMA around vessels in lung sections from IPF 
patients. Scale bars: 50µm, 100x oil immersion. (B) Western blot analysis of sIL-6Rα and P-
STAT3 in lung lysates from explanted IPF samples from patients with and without co-existing 
pulmonary hypertension.  
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7.2 – Over-express soluble IL-6Rα to induce pulmonary fibrosis in wildtype mice  
We were able to show that neutralization of IL-6 trans signaling using gp130Fc was 
therapeutic in our IPB model. To further support the role of sIL-6Rα in disease, we could over-
express the IL-6/sIL-6R complex in wildtype mice to see if we can induce pulmonary fibrosis. 
The use of Hyper IL-6(44), a fusion protein consisting of IL-6 and sIL-6Rα, would come in 
handy for this purpose.  
 
7.3 – Explore the role of IL-6 trans signaling in pulmonary hypertension associated with 
pulmonary fibrosis  
As mentioned in chapter one, the presence of pulmonary hypertension worsens prognosis 
and survival. In this thesis, we showed that mice with bleomycin-induced pulmonary fibrosis 
also exhibit pulmonary hypertension. In vivo antagonism of IL-6 trans signaling with gp130Fc 
resulted in improvement in pulmonary hypertension (Figure 5.10). This could represent an 
effective therapy for fibrosis-associated PH.  
Ammit et al reported stimulation of IL-6 trans signaling in airway smooth muscle cells in 
asthmatics promotes eotaxin and VEGF release, which may contribute to inflammation locally 
and vessel expansion(85). This could have significance in the vascular changes leading to 
development of PH. Karmouty-Quintana et al recently demonstrated the role of the adenosine 2B 
receptor (A2BAR) in pulmonary hypertension associated with interstitial lung diseases (ILD)(91, 
171). They provided evidence that receptor activation of vascular cells promoted IL-6 release.  
Given what we have shown in our in vivo neutralization study as well as results from 
analysis of P-STAT3 in IPF lungs, there is reason to suggest involvement of IL-6 signaling in PH 
secondary to ILDs. Evaluation of the vessels in IPF lung sections (PH status unknown) revealed 
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increased activation of STAT3 in alpha-SMA positive cells (Figure 7.1A), suggesting enhanced 
IL-6 signaling may play a role in vascular and perivascular cells. To further assess whether trans 
signaling might be involved in PH associated with IPF, IPF lung lysates samples were separated 
by presence or absence of confirmed PH in medical history and evaluated by western blot for 
expression of P-STAT3 and sIL-6Rα. Western blot revealed increased phospho-STAT3 in IPF 
patients with PH (Figure 7.1B). Soluble IL-6Rα was present in every sample but did not show a 
clear pattern of increase of decrease. Further analysis is needed to evaluate whether there is a 
difference in sIL-6Rα or membrane IL-6Rα among IPF patients with and without PH. If not due 
to IL-6 signaling, then something else must explain the difference in P-STAT3 expression among 
IPF patients with and without PH. Other than IL-6, STAT3 is known to be activated in response 
to other IL-6 family cytokines, including interleukin 11, leukemia inhibitory factor (LIF), 
oncostatin M (OSM), cardiotrophin 1 (CT-1) cardiotrophin-like cytokine (CLC), among others. 
Whatever the case, these findings need further exploration.  
What was interesting in our studies was the analysis of sIL-6Rα and P-STAT3 expression 
in explanted samples from COPD patients, who can have pulmonary fibrosis and develop PH as 
a complication of their disease process. COPD patients without pulmonary hypertension 
expressed sIL-6Rα in 7/7 samples (Figure 7.2). COPD patients with PH did not express sIL-6Rα 
in 5/7 samples. Expression of P-STAT3 was variable, with 4/7 COPD with PH samples showing 
greater activation of STAT3 than COPD without PH. If these patterns hold up with analysis of 
more samples, the presence of sIL-6Rα in COPD lungs may indicate a protective effect from PH 
or that those COPD lungs have fibrosis and the other ones do no. It could also mean that IL-6 
trans signaling has no role in development of PH in COPD. 
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Figure 7.2. Activation of STAT3 in COPD with and without pulmonary hypertension. (A) 
Immunostaining for phospho-STAT3 and α-SMA around vessels in lung sections from IPF 
patients. Scale bars: 50µm, 100x oil immersion. (B) Western blot analysis of phospho-STAT3 in 
lung lysates from explanted IPF samples from patients with and without co-existing pulmonary 
hypertension.  
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7.4 – Optimize protocol for neutralization of IL-6 trans signaling in ADA-deficient model 
As mentioned in the introduction and chapter 6, combined pulmonary fibrosis and 
emphysema represents a clinical presentation that confers bad prognosis. There are no available 
recommendations regarding therapy at this time due to a lack of knowledge of how these 
combined features developed. The ADA-deficient model provides what could be considered a 
potential model for this condition of combined fibrosis and emphysema since ADA activity has 
been shown to be significantly reduced in COPD (which consists of emphysema & chronic 
bronchitis) and IPF lungs and ADA-deficient mice are known to exhibit these two features of 
chronic lung disease secondary to chronically elevated adenosine(30, 31).  
Though our first attempt at neutralizing sIL-6Rα in the ADA-deficient model did not 
yield significant reductions in receptor levels, we would like to make another attempt at 
neutralizing sIL-6Rα in this model and exploring the impact of IL-6 trans signaling in the 
disease process. We may just need to increase the dosage of gp130Fc and/or start therapy earlier 
to see if we can effect significant changes. The other option is to over-express IL-6/sIL-6R by 
injecting Hyper IL-6 in our ADA-deficient mice and see if that would worsen severity of disease 
or hasten disease progression. 
 
7.5 – Evaluate role of membrane IL-6R alpha and IL-6 classical trans signaling in regulation 
and function of M2 macrophages 
 Characterization studies in this thesis were able to determine that membrane IL-6Rα 
expression is increased in M2 macrophages from IPF lungs (Figure 3.4B), bleomycin-induced 
fibrotic mouse lungs (Figure 4.1E), and adenosine-mediated fibrotic mouse lungs (Figure 6.2B). 
We provided evidence that M2 macrophages from bleomycin-induced fibrotic mouse lungs shed 
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their membrane IL-6Rα to generate soluble IL-6Rα in those lungs (Figure 4.5). We have shown 
that antagonism of IL-6 trans signaling in bleomycin-induced pulmonary fibrosis led to a 
reduction in the number of macrophages in the lungs (Figure 5.3B).  
These findings support an essential role for activated macrophages in the development of 
pulmonary fibrosis in our chronic bleomycin mouse model. Analysis of IPF human samples 
provided some validation. A search of the literature base also supports a role for these cells in 
IPF(115). We need to explore the functions of M2 macrophages in fibrotic lungs, beyond serving 
as the source of IL-6R shedding. Our thesis findings have sparked the following questions.  
Is the reduction in total BAL macrophages with gp130Fc treatment a reduction in M2 
macrophages? We suspect that is the case since the type of macrophage that is increased in IPF 
and fibrotic mouse lungs are M2 in phenotype. However, we need to confirm that by either 
performing immunofluorescence staining of BAL cells from gp130Fc-treated mice for CD206, a 
marker of M2 macrophages or by western blot analysis probing for expression of arginase 1, 
another M2 marker.  
 Is enhanced expression of membrane IL-6Rα an indication of M2 phenotype? The human 
and mouse data seem to suggest so. What role does IL-6 classical signaling have in M2 
macrophage function? Does it regulate release of mediators? What happens to the cells after the 
membrane receptor is cleaved off? Do the cells retain their M2 phenotype?  
What regulates expression of membrane IL-6Rα in these macrophages? Since adenosine 
can stimulate production of IL-6 from these cells(31), does it also stimulate expression of the 
membrane receptor? Is the A2B receptor involved in the process since this receptor is also 
elevated in M2 macrophages(31)? 
 
 183
7.6 – Explore the effect of IL-6 trans signaling on M2 macrophage activity 
 We have shown that antagonism of IL-6 trans signaling in bleomycin-induced pulmonary 
fibrosis led to a reduction in the number of macrophages in the lungs (Figure 5.3B). We still 
need to confirm that this is a decrease in M2 macrophages, though the suspicion is high that it is. 
As such, it would suggest that IL-6 trans signaling may have important effects in this cell. The 
effects of stimulating IL-6 trans signaling in M2 alveolar macrophages have not been examined.  
I am particularly interested in whether stimulation of IL-6 trans signaling would induce 
production/release of fibronectin from these cells. Rennard et al reported that alveolar 
macrophages from IPF patients secreted more fibronectin than those from normal lungs and that 
fibronectin has a chemoattractant effect on fibroblasts. Does IL-6 trans signaling regulate TGF-
β, IL-6 or other pro-fibrotic mediator production and release from these macrophages? 
 
7.7 – Evaluate adenosine-mediated activation of ADAM17 in macrophages and evaluate 
ADAM17 neutralization specifically in macrophages on development of pulmonary fibrosis 
 ADAM17 is activated by PMA and bacterial pathogens. The process of ADAM17-
mediated shedding of IL-6Rα is dependent on PKC activation(58). We know adenosine can 
activate PKC. We know A2B receptor expression is enhanced in activated alveolar 
macrophages(31). This begs the question of whether adenosine is involved in the regulation of 
ADAM17 activation in activated macrophages in order to cause shedding of IL-6Rα. Further 
study is necessary to elucidate the mechanism of shedding in alveolar macrophages. Further 
analysis is needed to support the hypothesis that adenosine activation of its A2BAR in M2 
macrophage leads to enhanced activation of ADAM17 in these cells, resulting in shedding of IL-
6Rα. 
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 Since the our results seem to indicate an essential role for ADAM17 in generating soluble 
IL-6Rα in fibrotic lungs, the next reasonable step would be to attempt neutralization of 
ADAM17 to see if there is any therapeutic benefit. However, because ADAM17 cleaves 
numerous different substrates in the body, many of which are physiologically necessary, global 
blockade of ADAM17 is not appropriate. In fact, ADAM17-deficiency in mice is embryonically 
lethal. Thus, since we demonstrate that the scene of the crime in fibrotic lungs is the activated 
alveolar macrophage, we wonder if it would be possible to neutralize ADAM17 specifically in 
macrophages to prevent shedding of IL-6Rα and determine effects on development of pulmonary 
fibrosis in the IPB model.   
 
7.8 – Explore the effect of trans signaling on senescence of airway epithelial cells 
We have demonstrated effects of stimulating IL-6 trans signaling in fibroblasts and 
myofibroblasts that are pertinent to pulmonary fibrosis. We have not examined the effects in 
airway epithelial cells (AEC). Given the current theory regarding IPF development, a theory that 
is epithelium-centered, with the thought that injury responses in alveolar airway epithelial cells is 
central to the initiation of a series of events that culminate in fibrosis, it would seem that we 
should also examine the role of IL-6 trans signaling in AECs. This pathway may be even more 
important in AECs than in other pulmonary cell types since we did not see expression of 
membrane IL-6Rα in AECs (Figure 3.4D), which suggests that these cells are not capable of 
classical signaling and only susceptible to trans signaling.  
Pedroza et al (unpublished data) demonstrated that stimulation of IL-6 trans signaling in 
AEC induces epithelial to mesenchymal transition (EMT). We are interested in further exploring 
effects of trans signaling in AEC, particularly proliferation, senescence and apoptosis, since the 
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current view in the field is that there is premature senescence and excessive apoptosis of AECs in 
response to alveolar injury that is at the source of pulmonary fibrosis. It would be fascinating to 
see if IL-6 trans signaling has any effect on these processes.  
 
7.9 – Clarify whether there is any change in M1 macrophages as disease develops and 
progresses.  
 Though our focus in this thesis has been on the increase in M2 macrophages as fibrosis 
progressed in our mouse model, we can’t help but wonder if changes to M1 macrophages also 
contribute to the pathogenesis of IPF. M1 and M2 macrophages appear to play different roles in 
renal fibrosis(172). Can the same be true in pulmonary fibrosis? We would need to characterize 
and monitor changes to M1 markers in the IPB model over the course of the model to answer that 
question. 
 
7.10 – Evaluate the increase in lymphocytes during disease onset and progression in IPB as 
another source of shedding or release of mediators 
 In our characterization studies, we showed a temporal increase in lymphocytes in 
bleomycin-induced fibrotic mouse lungs (Figure 7.3). We should determine if lymphocytes shed 
their membrane receptor to generate soluble receptor. We could also explore whether activation 
of IL-6 classical signaling in these cells alter their phenotype or activities. 
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Figure 7.3. Lymphocyte accumulation in bleomycin-induced pulmonary fibrosis. Number of 
lymphocytes in BAL fluid samples from PBS-injected and bleomycin-exposed mice at various 
points throughout the model. Data presented as mean ± SEM, n≥4. *significant difference from 
PBS-treated cohort. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. Data obtained by Tina 
Melicoff, MD, Tingting Weng, PhD and Harry Karmouty-Quintana, PhD.  
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7.11 – Evaluate the role of IL-6 trans signaling and ozone exposure on exacerbation of 
fibrosis in IPF patients  
  We are interested in how ozone exposures affect IPF because ozone is known to play an 
important role in chronic lung disorders like asthma and chronic obstructive pulmonary disease 
(COPD)(173) and ambient ozone has been reported to increase IL-6 production in the lungs(174, 
175). However, nothing is known about the impact of ozone on pulmonary fibrosis, so much 
work is required in this area. I will utilize mouse models and human samples to examine the 
hypothesis that IL-6 trans signaling contributes to pulmonary fibrosis and ozone exposure 
exacerbates pulmonary fibrosis. First, I will characterize IL-6 classical and trans signaling 
components during the development of pulmonary fibrosis. Then I will assess the effect of block 
IL-6 trans signaling on fibrosis. Lastly, I will determine the effect of ozone exposure on the 
onset and progression of pulmonary fibrosis. We hope to achieve novel findings with this project 
that will translate into innovative therapeutics for the disease. 
 
FINAL WORDS 
As mentioned from the beginning, there is an urgent need to develop effective therapies 
for IPF. In this thesis, we have emphasized the significance of IL-6 trans signaling during the 
development and progression of pulmonary fibrosis and achieved novel findings that contribute 
to the understanding of the pathogenesis of IPF. Though the effect of recombinant gp130Fc in 
mice with pulmonary fibrosis was only partial, it was still significant enough to indicate this may 
be effective in slowing or perhaps even halting progression of disease in IPF patients. Our 
findings support the use of recombinant gp130Fc, and perhaps ADAM17 inhibition specifically 
in alveolar macrophages, for treatment of IPF patients. However, there is a need to further 
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validate our mouse findings in more human samples and a need to evaluate the safety profile and 
effects of long-term use of gp130Fc in humans. Much work remains to better understand the 
complex interactions of the pulmonary micro-environment in order to develop even better 
therapies against this deadly disease.  
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